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         Abstract 
Campylobacter jejuni is a foodborne pathogen recognised as the leading cause of human 
bacterial gastroenteritis. Undercooked poultry products and contaminated water are 
considered as the most important sources of infection. Antimicrobial therapy is 
warranted only for immunocompromised patients and, although most people recover 
from this disease, others may develop rare neurodegenerative disorders such as 
Guillain-Barre Syndrome (GBS). The latter affects the nerves of the body leading to 
paralysis and requires extensive medical treatment. The wide use of antibiotics in 
medicine and in animal husbandry has led to an increased incidence of antibiotic 
resistance in Campylobacter over the last decade. Investigation of the molecular 
mechanisms of antibiotic resistance is considered important to control the spreading of 
resistant bacteria.  
CmeABC RND-type multidrug efflux (MDR) pump and the tetO gene found on pTet 
plasmids mediate tetracycline resistance in Campylobacter. CmeABC MDR pump 
consists of three components: an outer membrane protein CmeA, an inner membrane 
drug transporter CmeB and a periplasmic protein CmeC.  
Even though C. jejuni strains G1 and 11168H do not contain the pTet plasmid, the 
former was shown to be more resistant to tetracycline (Tet).  Comparison of the genome 
of the G1 strain with that of the reference strain, 11168H, revealed a remarkable 
difference between the nucleotide sequences of their cmeB genes. In addition, it was 
observed that the transfer of the pTet plasmid from C. jejuni 81-176 to the G1 strain 
increased the level of Tet resistance above that of the former strain carrying this 
plasmid. This finding suggests that CmeB of strain G1 has a higher capacity to excrete 
this drug than its analogue in C. jejuni strains 81-176 and 11168H and thus, the former 
strain could be considered as an efflux pump variant with increased resistance to 
antibiotics. In this study we demonstrate that contribution of MDR pumps to antibiotic 
resistance might be dependent on the sequence variation of CmeB.   
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Although antibiotic resistance is the main function of MDR pumps, these pumps may 
have other physiological roles, such as in virulence. An important mechanism of 
bacterial pathogenesis is the survival of Campylobacter inside environmental hosts. As 
a host of pathogenic microorganisms, the protozoan Acanthamoeba is a good model for 
the investigation of bacterial survival in the environment and the molecular mechanisms 
of pathogenicity. The endosymbiotic relationship between this eukaryotic organism and 
microbial pathogens may contribute to persistence and spreading of the latter in the 
environment, which has significant implications for human health. 
Although some studies suggest that Acanthamoeba supports Campylobacter survival in 
the environment, the type of interaction between these microorganisms needs to be 
elucidated. Also, the bacterial factors involved in this interaction remain unknown. 
Using a modified gentamicin protection assay it was found that C. jejuni 81-176 is able 
to survive and multiply inside this eukaryotic host. Thus, since these microorganisms 
can co-exist in the same environments (e.g. in poultry farms) the risk of infection with 
this foodborne pathogen is elevated.  It is also reported that the CmeABC MDR pump is 
beneficial for the intracellular survival and multiplication of C. jejuni within A. 
polyphaga. 
 However, this MDR pump was found to be dispensable for C. jejuni biofilm formation, 
motility and oxidative stress. Moreover, it was observed that capsule production is also 
required for the interaction between C. jejuni and with amoebae. Due to their role in 
antibiotic resistance and virulence of C. jejuni, MDR pumps could be considered as 
good targets for the development of antibacterial drugs against this pathogen.  
During the course of this study, a new chimeric C. jejuni strain was created due to 
horizontal gene transfer between two different strains, 81-176 and G1, which were 
growing together. This finding emphasises how easily Campylobacter can exchange its 
genetic material and thus adapt to the surrounding environment.  
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CHAPTER 1: Introduction 
 
1.1 The Campylobacter genus 
Campylobacter was originally described as a member of the genus Vibrio as they were 
both curved cells with a microaerobic nature (Veron, 1973). In 1913, a microorganism 
responsible for abortion of pregnant ewes was discovered and designated as Vibrio fetus. 
However, the classification of this organism was deemed unsatisfactory due to the large 
difference in the G+C content of the DNA between this organism and that characteristic 
of Vibrio species (Veron, 1973).  Therefore in 1973, Sebald and Veron proposed a new 
genus, Campylobacter, comprising Gram-negative and curved bacteria (0.2 to 0.8μm 
wide and 0.5 to 5μm long). These microorganisms are motile by means of a single polar 
flagellum, non-spore forming, microaerophillic (5-10% O2 and 3-5% CO2), with optimal 
growth between 30°C and 42°C. As opposed to the genus Vibrio that contains DNA with 
G+C content between 40 and 53%, Campylobacter G+C content varies between 26 and 
36% (Wassenaar & Newell, 2006). These organisms are found ubiquitously in the 
environment and can colonise the intestine of wild birds (Dasti et al., 2010). 
Campylobacter comprises 17 species with valid published names (Zhou et al., 2013) (Fig. 
1.1). Campylobacter can colonise a diverse range of hosts, from farm livestock to humans 
and can adapt to various host environments (Zhou et al., 2013). Some members of this 
genus, such as C. coli, C. upsaliensis and C. lari, can cause human disease, but the most 
common is C. jejuni which is the leading cause of human gastroenteritis worldwide. 
Whilst some species, for instance e.g. C. coli, cause severe animal diseases, others are 
non-pathogenic (Zhou et al., 2013). 
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Figure 1.1. Phylogenetic tree of the family Campylobacteraceae. Fourteen distinct 
Campylobacter species and their closest neighbours, based on the 16S rRNA gene 
sequence similarity, are present in this tree. Arcobacter and Sulfurospirillum are Gram 
negative spiral-shaped bacteria and belonging to the Family Campylobacteraceae. 
Burkholderia cepacia was used as an outgroup organism (Wassenaar & Newell, 2006). 
 
1.2. Overview of Campylobacter jejuni 
C. jejuni is one of the most important food-borne pathogens in the world and, as 
mentioned above, is the leading bacterial cause of human gastroenteritis (Zhou et al., 
2013; Havelaar et al., 2015). Most commonly, the disease is associated with 
consumption of undercooked poultry and contaminated water (Young et al., 2007). As a 
natural host and important food source of humans, the chicken is a good model for the 
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investigation of Campylobacter mechanisms of infection. In vitro, human intestinal 
epithelial cell lines are those most commonly used to examine pathogenic processes. C. 
jejuni is highly fastidious and sensitive to unfavourable growth conditions such as 
adverse pH or temperature (Altekruse et al., 1999). For its protection, when in stress 
conditions, C. jejuni is able to enter a dormant, but viable non-culturable state after 
transformation from a rod or spiral cell shape into a spherical or coccoid form (Fig. 1.2) 
(Ikeda & Karlyshev, 2012).  
 The first full genome sequence of C. jejuni (strain NCTC 11168) was published in 
2000 (Parkhill et al., 2000). C. jejuni has a small genome (1.6 megabases) and displays 
extensive genetic variation. Campylobacter is naturally competent, meaning that it can 
take up DNA from the environment, leading to recombination between the genomes of 
the different species and the generation of even more genetic diversity among them 
(Young et al., 2007). Horizontal transfer may occur during host colonisation or in vitro 
growth, with both plasmids and chromosomal DNA, and may lead to the spread of new 
bacterial characteristics, such as antibiotic resistance, even in the absence of selective 
pressure (Young et al., 2007). To date, at least 117 Campylobacter complete genomes 
have been sequenced, enhancing the study of this pathogenic organism (NCBI, 2017). 
Availability of the whole genome sequences of several Campylobacter strains may 
allow great opportunities to develop improved preventive measures and novel treatment 
strategies.  
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1.3. Clinical features of Campylobacter jejuni infection 
               Campylobacteriosis is a zoonotic disease caused mostly by C. jejuni and C. coli that 
can be transmitted directly or indirectly between animals and humans (CDC, 2014). 
Several environmental reservoirs can lead to human infection by C. jejuni (Fig. 1.3). In 
developed countries, contaminated animal products are the primary source of human 
infection, most commonly, after the consumption of undercooked chicken or 
unpasteurised milk (Young et al., 2007). C. jejuni can also infect humans directly 
through drinking water, where Campylobacter can associate with protozoans, such as 
freshwater amoebae, and form biofilms (Fig. 1.3) (Young et al., 2007).  
               Campylobacter infections are generally mild, but can be fatal among very young 
children, the elderly, or immunosuppressed individuals (EFSA, 2014). The most 
common clinical symptoms of Campylobacter infections include diarrhoea (frequently 
bloody), abdominal cramps, fever and vomiting with an infective dose being as low as 
500-800 bacteria (Young et al., 2007). The symptoms typically last between three to six 
days, and non-immunocompromised individuals infected with Campylobacter generally 
recover without any specific treatment (WHO, 2016). For these individuals, 
antimicrobial therapy is not required, and all that is normally required is electrolyte 
Figure 1.2. Scanning electron microscopy of C. jejuni cells (1 µm) (A) spiral shape (Xie 
et al. 2011) and (B) coccoid form (NG et al., 1985). 
A B 
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replacement and anti-dehydration therapy such as drinking extra fluids (CDC, 2014; 
WHO, 2016). Antimicrobial treatment (macrolides are the most effective antibiotics) is 
recommended for the individuals presenting invasive cases of this disease (when 
bacteria invade the intestinal mucosa and damage the tissues) and for those with 
immune systems severely weakened (WHO, 2016). Campylobacteriosis can be 
prevented by cooking all avian products thoroughly, avoiding cross-contamination in 
the kitchen and good hand hygiene control by washing hands with soap before 
preparation of food. Measures to reduce the prevalence of Campylobacter in poultry 
include enhanced biosecurity and reduction in antibiotic use in animals (CDC, 2014; 
WHO, 2016). However, in a minority of individuals infected with Campylobacter, 
serious illness may develop. This includes reactive arthritis and neurological disorders, 
such as Guillan-Barré Syndrome (GBS), a condition of the peripheral nervous system 
that can lead to paralysis and requires intensive medical care (Bolton, 2015). It is 
estimated that 1 in 5,000 campylobacterioisis individuals develop GBS (about 112 GBS 
cases annually in the United Kingdom are associated with Campylobacter infection) 
(Tam & O'Brien, 2016). In addition, complications such as bacteraemia, hepatitis, 
pancreatitis and miscarriage have been reported with various degrees of frequency 
(WHO, 2016). 
               A vaccine to protect against Campylobacter jejuni was recently approved for human 
clinical trials by the U.S. Food and Drug Administration (FDA) (Zuraw, 2014). This 
vaccine is a conjugate containing polysaccharides from C. jejuni capsule joined to a 
carrier protein which will enhance immunogenicity, as carbohydrate antigens cannot 
directly activate naïve T cells. This is because most capsular polysaccharides are 
thymus-independent (TI) antigens meaning that helper T cells are needed to generate 
robust, long-lived antibody responses (Guerry et al., 2012). This vaccine strategy 
effectively converts a TI antigen into a thymus dependent (TD) antigen, allowing 
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boosting of the immune response, IgG antibody class switching, and the generation of 
memory cells possessing antibody with higher avidity for CPS (Guerry et al., 2012). In 
summary, by conjugating CPS to carrier proteins it is possible to induce a T-dependent 
immune response against these antigens. This vaccine is currently in Phase I trials 
where it is being tested for safety and immunogenicity (Riddle & Guerry, 2016). 
 
 
 
 
 
 
 
 
 
 
 
 
1.3.1. Epidemiology 
There is evidence to suggest an increase in the global incidence of campylobacteriosis 
in the past decade (Havelaar et al., 2015; Kaakoush et al., 2015). In 2015, 
Campylobacter continued to be the most commonly reported gastrointestinal bacterial 
pathogen in humans in the European Union (EU) and has been so since 2005 (Fig. 1.4). 
Figure 1.3. The sources and outcomes of C. jejuni infection. Several environmental 
reservoirs can lead to human infection by this bacterium, such as contaminated water 
and chicken products. C. jejuni can enter the water and associate with freshwater 
protozoa prolonging the risk of infection. C. jejuni can invade the gut epithelial layer 
resulting in inflammation and diarrhoea (Young et al., 2007).  
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The number of reported confirmed cases of human campylobacteriosis in Europe in 
2014 was 229,213 with a hospitalisation rate of 31.2% and a 0.03% case-fatality rate 
(59 reported deaths), costing approximately 2.4 billion euros a year to public health 
systems and through loss of productivity (EFSA, 2016a).  In 2015 a total of 4,362 food-
borne outbreaks were reported and Campylobacter caused 8.9% of the outbreaks 
(EFSA, 2016a). Broiler meat was the main food vehicle implicated in the reported 
Campylobacter outbreaks (EFSA, 2016a). In the United States (US) campylobacteriosis 
is estimated to affect 1.3 million persons every year, occurring especially during the 
summer with an average of 76 deaths a year (CDC, 2014). Overall, in the US it is 
estimated that costs to the health service and to patients from Campylobacter infections 
is $69.6 million annually (Havelaar et al., 2015). 
 
 
 
Figure 1.4. Reported numbers and notification rates of confirmed human 
zoonoses cases in the EU, 2015. In 2015, Campylobacter continued to be the most 
commonly reported gastrointestinal bacterial pathogen in humans in the European 
Union (EU). The number of reported confirmed cases of human campylobacteriosis 
was 229,213 with an EU notification rate of 65.5 per 100,000 population, a 5.8% 
decrease compared with the rate in 2014 (EFSA, 2016a). 
 
 
 8 
1.4. Campylobacter jejuni pathogenesis 
Despite the significant health burden caused by C. jejuni, our current understanding of 
disease pathogenesis is still developing. Sequencing of the genome of many different C. 
jejuni strains in the recent years has started to accelerate research in Campylobacter 
genetics, pathogenesis and host immunity in response to infection (Backert & Hofreuter, 
2013). 
To establish infection in humans and animal hosts, C. jejuni must bypass the mechanical 
and immunological barriers of the gastrointestinal (GI) tract (Young et al., 2007). C. 
jejuni is able to penetrate the mucus layer of the GI epithelium to further interact with 
the underlying epithelial cells (Young et al., 2007). High motility of this pathogen was 
shown to be crucial for the infection process (Morooka et al., 1985). The establishment 
of infection of epithelial cells by C. jejuni can be divided into three distinct processes: 
(i) adherence to the enterocytes, (ii) invasion into the intestinal epithelium cells and (iii) 
survival inside a defined intracellular compartment (Fig. 1.5) (Backert & Hofreuter, 
2013). There is considerable evidence that C. jejuni can disrupt the tight junctions of 
epithelial cells which thus allows the bacterium to move to the basolateral surface and 
either re-invade these cells or be taken up by macrophages (Poly & Guerry, 2008). The 
main focus in the field of C. jejuni research has been to identify the bacterial factors 
mediating the efficient interaction with cultured epithelial cells, but these studies depend 
on the bacterial strain, cell line choices, and variation in the experimental procedures 
(Backert & Hofreuter, 2013).  
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1.4.1. Virulence factors  
The pathogenicity of C. jejuni depends on its capability to interact with and, 
subsequently, invade host cells (Lugert et al., 2015). Each of these steps in the 
pathogenesis of C. jejuni infection depends upon the expression of a combination of 
several virulence factors such as capsular polysaccharide, flagellar apparatus, cytolethal 
distending toxin and post-translational glycosylation (Zilbauer et al., 2008; Bolton, 
2015).  
Motility of C. jejuni is known to be a crucial factor for invasion and intestinal 
colonisation by this pathogen (Yao et al., 1994). C. jejuni motility is mediated by a 
powerful flagellar apparatus, which enables this bacterium to move with high velocity 
inside a particular microenvironment and to be able to reach potential target cells 
(Lugert et al., 2015). The flagellum comprises a hook-basal body (composed by several 
proteins such as FlhA, FliR, FliY, MotA/B) and an extracellular filament structure 
(composed by the proteins FlaA and FlaB) (Bolton, 2015). Some studies suggest that 
this apparatus also functions as a type III secretion system, transporting virulence 
Figure 1.5. Hypothetical model of C. jejuni mechanism of infection. This pathogen 
can interact with, invade into, transmigrate across and survive within polarised 
intestinal epithelial cells (Backert & Hofreuter, 2013). 
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factors into the host cell (Konkel et al., 2004). Campylobacter uses chemotaxis, a 
mechanism by which motile bacteria sense and move towards more favourable 
conditions, to locate colonisation sites in the avian gut (Chang & Miller, 2006). Proteins 
associated with Campylobacter chemotaxis include CheA/B/R, transducer-like proteins, 
the response regulator controlling flagellar rotation CheY and the AL-2 biosynthesis 
enzyme LuxS (Hamer et al., 2010; Hermans et al., 2011). 
The adherence of C. jejuni to the intestinal epithelial cells is essential for host 
colonisation and is mediated by several components on the bacterial surface named 
adhesins (Lugert et al., 2015). An important adhesin that mediates C. jejuni adherence 
to fibronectin is the outer membrane protein CadF (Konkel et al., 1997). Other 
important adhesins include the Campylobacter adhesion protein CapA, the N-linked 
glycosylated lipoprotein JlpA, the fibronectin-like protein FlpA, the periplasmic protein 
with chaperone and protease activity HtrA, the periplasmic binding protein PEB1, the 
N-oligosaccharyltransferase PglB and the putative global posttranscriptional regulator 
CsrA (Pei & Blaser, 1993; Jin et al., 2001; Szymanski et al., 2002; Ashgar et al., 2007; 
Fields & Thompson, 2008; Flanagan et al., 2009; Baek et al., 2011). Besides these, 
several other adhesins have also been reported (Rubinchik et al., 2014). A virulence 
plasmid termed pVir encodes genes that are involved in DNA uptake and transport of 
proteins by a putative type VI secretion system. Two of those genes, comB3 and virB11, 
were reported to also be required for C. jejuni adherence to intestinal cells (Bacon et al., 
2000).  
Further to adhesion, the invasion process of C. jejuni is considered to be the most 
important stage that causes damage to the host cells (Lugert et al., 2015). Many proteins 
have been associated with the process of invasion. These include the flagella secreted 
Campylobacter invasion antigens CiaB, CiaC and CiaI; the invasion associated protein 
IamA; a lipoprotein involved in iron acquisition CeuE, a small acidic protein FspA and 
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the outer membrane CadF (Park & Richardson, 1995; Carvalho et al., 2001; Monteville 
et al., 2003; Konkel et al., 2004; Poly et al., 2007; Christensen et al., 2009; Buelow et 
al., 2011). The chaperone HtrA and the antimicrobial peptide resistance protein VirK 
were also shown to be required for C. jejuni invasion (Novik et al., 2009; Baek et al., 
2011). Secretion of the cytolethal-distending toxin (CDT) by C. jejuni is highly 
important for its invasion to host cells (Asakura et al., 2008). CDT is a tripartite toxin 
composed of three subunits encoded by the ctdA, cdtB and cdtC genes that are all 
required for the toxin to be functionally active (Asakura et al., 2008). CDT causes 
eukaryotic cells to arrest in the G2/M phase of their cell cycle, preventing them from 
entering into mitosis and, therefore, leading to cell death (Asakura et al., 2008). The 
Campylobacter glycome composed of carbohydrate structures, such as 
lipooligosaccharides (LOS) and polyssacharide capsule (CPS) and by N-linked protein 
glycosylation systems was shown to be required for adhesion and invasion of this 
pathogen (Karlyshev et al., 2005a; Louwen et al., 2008). More specifically, the galE 
gene, which encodes a UDP-glucose 4-epimerase and is involved in LOS synthesis, was 
shown to be required for adherence and invasion of epithelial cells (Fry et al., 2000).  A 
capsular polysaccharide transport protein KpsM, a capsule biosynthesis protein KpsE 
and an N-linked general protein glycosylation pathway were also shown to reduce not 
only host cell invasion, but also chicken colonisation (Bacon et al., 2000; Karlysehv et 
al., 2004; Bachtiar et al., 2007). The CPS varies in sugar composition and linkage, 
leading to capsular structure diversity among different C. jejuni strains (Bacon et al., 
2001). In addition due to variation in sugar composition, the CPS can be modified with 
ethanolamine, glycerol, and O-methyl phosphoramidate (MeOPN), and this 
modification may be advantageous at some points during the C. jejuni lifestyle and 
disadvantageous at others, proving to be a key determinant in virulence (Guerry et al., 
2012; Maue et al., 2013).  
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Among the factors known to be required for intracellular survival of Campylobacter 
within host cells, are superoxide dismutase SodB; aspartate ammonia lyase AspA; 
fumarate reductase flavoprotein FrdA; iron transporter FeoB; Campylobacter invasion 
antigen CiaI; guanosine-3-pyrophosphohydrolase SpoT; polyphosphate kinase Ppk1; 
heptosyltransferase WaaF (required for LOS formation); sensor kinase CprS; and a 
virulence protein VirK (Gaynor et al., 2005; Naikare et al., 2006; Candon et al., 2007; 
Novik et al.,  2009; Svensson et al. 2009; Naito et al., 2010; Novik et al., 2010; Buelow 
et al., 2011; Liu et al., 2012). Intracellular survival of C. jejuni within macrophages has 
been confirmed in different studies (Kiehlbauch et al., 1985; Day et al., 2000; Hickey et 
al., 2005).  
 C. jejuni possesses a rigorous stress control response which enables it to adapt to 
different oxygen conditions, heat shock, reduced pH and nutrient starvation (Bolton, 
2015). Campylobacter may encounter some of these conditions during food processing 
or storage, and resistance to these is important for its survival, transmission and 
infection in humans. SpoT is responsible for the stringent control of the C. jejuni stress 
survival response (Gaynor et al., 2005). Campylobacter oxidative stress regulator CosR 
and the metalloregulatory proteins Fur and PerR are also essential to control the 
oxidative stress response (Belzer et al., 2011; Hwang et al., 2011). Proteins that are 
required for oxygen stress include the catalase KatA (that converts hydrogen peroxide to 
water and oxygen when the former is too high in the cell cytoplasm); the alkyl 
hydroperoxide reductase AhpC; the thiol peroxidase Tpx; cytochrome c peroxidases; 
the iron-binding protein Dps; the antioxidant superoxide dismutase SodB that confers 
protection against the superoxide anion; the iron-induced ferredoxin FdxA and DnaJ 
which is involved in the heat shock response (Konkel et al., 1998; Baillon et al., 1999; 
van Vliet et al., 2001; Ishikawa et al., 2003; Atack et al., 2008; Bingham-Ramos & 
Hendrixson, 2008; Atack & Kelly, 2009; Palyada et al., 2009).  
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1.5. Antibiotic resistance in Campylobacter jejuni  
Antimicrobial resistance (AMR) has increasingly become a problem in recent years 
since not only has the discovery of novel antibiotics slowed drastically, but, at the same 
time, antibiotic use is rising, causing microbes to evolve and resist these drugs (O´Neill, 
2014). Antimicrobial resistance currently claim at least 50,000 lives each year across 
Europe and the US alone, where in other areas of the world a similar scenario was 
observed (O´Neill, 2014). The major cause for this increasing AMR is the heavy use of 
antimicrobial drugs in humans and animals when most of the time they are unnecessary, 
or not properly used (O´Neill, 2014).  
 When clinical therapy is warranted for Campylobacter infections, macrolides, 
(erythromycin) and fluoroquinolones (FQ) (ciprofloxacin) are the most frequently used 
antimicrobials and, although in practice not often used, tetracyclines have been 
suggested as an alternative choice of treatment (Wieczorek & Osek, 2013). However, 
Campylobacter is becoming increasingly resistant to these antibiotics, especially to FQ 
and tetracycline (Tet). Campylobacter isolates very commonly show resistance to these 
antibiotics in many countries (Luangtongkum et al. 2009; Bolinger & Katheriou, 2017). 
For this reason, macrolides are still the most effective antibiotics against Campylobacter 
infections whilst FQ are losing effectiveness against this pathogen (Bolinger & 
Katheriou, 2017).  
Antibiotics have been widely used in food-producing animals, contributing to the 
emergence of antibiotic-resistant bacteria in many poultry products that are further 
consumed by humans. The latter can develop resistance to antibiotics with 
consequences to human health. Because antibiotics enable animals to grow faster and to 
gain weight more efficiently, their use in growth promotion became a common practice 
in animal rearing (Markus & van Lankveld, 2014). Concerns about increasing antibiotic 
resistance and transfer of antibiotic resistance genes from animal pathogens to human 
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pathogens, led to the withdrawal of antibiotics as growth promoters in the EU since 
January 2006 (Castanon, 2007). The major goal of the European ban on antibiotic 
growth promoters is to reduce antibiotic resistance traits in the microbial flora of farm 
animals (Castanon, 2007). Although European countries banned the use of tetracycline 
in animals in 1972, this antibiotic is still used in the USA and Canada as a growth 
promoter in animal feeds and tetracyclines are still licensed for therapeutic use in 
poultry in the UK (Wieczorek & Osek, 2013; Markus & van Lankveld, 2014). In fact, 
according to Piddock et al. (2008) chlortetracycline was the most commonly used 
therapeutic antibiotic in poultry production). 
Monitoring AMR to ciprofloxacin, erythromycin and tetracycline in Campylobacter 
became mandatory in the major food-producing animals. There is evidence that 
antimicrobial resistance in Campylobacter isolated from chicken meat is widespread 
and increasing and that Campylobacter isolates resistant to tetracycline are highly 
prevalent in many countries (Piddock et al., 2008; EFSA, 2016b), including the UK 
(Wimalarathna et al., 2013). The widespread antimicrobial resistance in the 
Campylobacter population probably results from horizontal gene transfer, where 
bacteria can acquire genetic material, including antimicrobial resistance genes, from 
relatively distant lineages (Wimalarathna et al., 2013). The frequently high level of Tet 
resistance in Campylobacter is most likely due to the presence of the tetracycline 
resistance gene tetO, carried by a transferable plasmid pTet, which facilitates 
tetracycline resistance transmission (Wieczorek & Osek, 2013).  
 The Campylobacter multidrug resistance virulence factors will be discussed in detail in 
Section 1.6.2 of the introduction.   
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1.6. Antibiotic resistance mechanisms 
There are several mechanisms of antibiotic resistance in Gram-negative bacteria, where 
synergy between antibiotic efflux and a second mechanism (e.g. antibiotic resistance 
genes) is well established (Iovine, 2013).  In general, antibiotic resistance mechanisms 
include modification of the antibiotic target or its expression; antibiotic failure in 
reaching its target; antibiotic efflux out of the cell and modification or inactivation of 
the antibiotic (Iovine, 2013). These distinct mechanisms provide resistance against 
different classes of antibiotics, such as aminoglycosides, β-lactams, fluoroquinolones, 
macrolides and tetracyclines.   
 
1.6.1. RND multidrug efflux pumps 
Multidrug resistance efflux (MDR) pumps are widely distributed in bacterial species 
and constitute an important class of resistance determinants. These pumps allow for 
drug extrusion out of the cells and have been increasingly associated with clinically 
relevant AMR and are consequently a major threat to the public health (Sun et al., 
2014). Although there are several types of multidrug efflux pumps, members of the 
resistance-nodulation-division (RND) multidrug efflux pump superfamily are the most 
clinically relevant (Blair et al., 2014).  
 The RND systems are highly conserved and are found in different bacterial species. 
These systems are found as a tripartite system always comprising an inner membrane 
transporter, an outer membrane protein channel and a periplasmic adaptor protein (Blair 
et al., 2014). Importantly, each of these three component proteins is essential for drug 
efflux, and the absence of even one component makes the entire complex totally non-
functional (Nikaido & Takatsuka, 2009). RND proteins form a continuous channel 
across the Gram-negative cell envelope ensuring that the drug target is effluxed across 
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the periplasm and the outer membrane directly into the external medium using a proton-
gradient as an energy source (Dinesh & Kumar, 2013). Efflux systems lower the 
intracellular antibiotic concentration, allowing bacteria to survive at higher antibiotic 
concentrations. In addition, overexpression of these systems may cause clinically 
relevant levels of AMR in Gram-negative pathogens (Blair et al., 2014). RND pumps 
are also known to interact synergistically with other resistance mechanisms. For 
instance, they are able to increase the outer membrane permeability barrier and thus, 
increase the levels of antibiotic resistance (Li et al., 2015).  
Examples of RND efflux pumps that are able to confer resistance to a broad range of 
antimicrobial compounds which are found in Gram-negative pathogens are: AcrAB-
TolC in Escherichia coli, Klebsiella pneumoniae and Salmonella enterica, MexAB-
OprM in Pseudomonas aeruginosa, AdeABC in Acinetobacter baumannii, MtrCDE in 
Neisseria gonorrhoeae, BpeAB-OprB in Burkholderia pseudomallei, VexAB-TolC in 
Vibrio cholerae and CmeABC in Campylobacter jejuni (Blair et al., 2014).  
Resistance to several types of antimicrobial compounds by these efflux pumps clearly 
indicate great challenges in antibiotic development against Gram-negative bacteria. 
Nonetheless, if these systems can be antagonised by an efflux pump inhibitor (EPI) this 
could offer a good opportunity for adjuvant therapy to combat infections by these 
pathogens (Li et al., 2015). An ideal EPI would enhance the activity of multiple 
antibiotics and be relatively stable and non-toxic to the eukaryotic cells (Blair et al., 
2014). Phenylarginine β-naphthylamide (PaβN) was the first identified as an EPI since it 
inhibits the conformational change required for the inner membrane transport to 
function. However, this compound is not clinically useful as it is toxic to eukaryotic 
cells (Blair et al., 2014). Another range of compounds shown to increase the 
intracellular accumulation of several antibiotics are the naphthylpiperazines (NMP), but, 
unfortunately, these compounds are also too toxic for clinical use as they posess 
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serotonin agonist properties (Sun et al., 2014). Although several types of compounds, 
such as quinolone derivatives, have been investigated as potential EPIs, none have been 
used in clinics (Sun et al., 2014). 
 
1.6.2. The Campylobacter CmeABC multidrug efflux pump 
 Although genome sequencing predicts 14 efflux pumps in Campylobacter (e.g. 
CmeDEF, CmeG, Acr3), the best studied is the CmeABC (Campylobacter multidrug 
efflux) and this is described as the major efflux pump causing AMR (Iovine, 2013). 
CmeABC belongs to the family of RND pumps and includes an outer membrane protein 
CmeC, an inner membrane drug transporter CmeB and a periplasmic protein CmeA that 
bridges CmeB and CmeC (Iovine, 2013).  It has been widely reported that CmeABC 
works synergistically with other resistance mechanisms to confer high-level antibiotic 
resistance (see Section 1.7). This MDR pump has been reported to be required for 
resistance in different C. jejuni strains to a broad range of structurally unrelated 
antimicrobial agents. Examples are the different categories of antibiotics (tetracycline, 
ampicillin, nalidixic acid, chloramphenicol, gentamicin, erythromycin, etc.); bile salts 
(cholic acid, taurocholic acid, etc.); surfactants (sodium dodecyl sulphate, benzalkonium 
chloride); disinfectants and antiseptics (chlorhexidine, cetylpyridinium chloride); metals 
(cobalt, zinc, copper) and other compounds such as triclosan, protamine and ethidium 
bromide (Lin et al., 2002; Pumbwe & Piddock, 2002; Mavri & Mozina, 2012). Bile 
salts are present in the small intestine for digestion of fats and are able to kill bacteria by 
destroying the lipid bilayer of their cell membrane (Gunn, 2000). The CmeABC MDR 
pump was shown to be essential for Campylobacter growth in bile-containing media, 
and consequently for colonisation of the chickens’ intestinal tract by mediating 
resistance to bile salts (Lin et al., 2003).  
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CmeR (encoded by cmeR) is the transcriptional repressor of the three genes cmeA, cmeB 
and cmeC (Lin et al., 2005). The cmeR gene is located upstream of cmeA and encodes a 
protein with a sequence and structure similar to TetR (Gu et al., 2007), a known 
transcriptional repressor that regulates the expression of the tetracycline resistance 
determinant encoded by the tetA gene (Cuthbertson & Nodwell, 2013). Additionally, it 
was shown that CmeR directly regulates the cmeABC promoter region via specific 
binding to this promoter region (Lin et al., 2005). As inactivation of cmeR leads to 
overexpression of the cmeABC pump, it was observed that mutation in this regulator 
results in higher resistance to different antibiotics (Lin et al., 2005). Importantly, in 
addition to controlling the expression of CmeABC MDR pump, CmeR also modulates 
expression of different genes with diverse physiological functions and is required for 
optimal colonisation of chickens (Guo et al., 2008). The Campylobacter CosR response 
regulator that modulates oxidative stress response was also shown to repress cmeABC 
expression (Grinnage-Pulley et al., 2016). In Campylobacter, CmeR and CosR act as 
moderators to maintain balanced production of cmeABC and facilitate its adaptation to 
environmental changes (Lin et al., 2005; Grinnage-Pulley et al., 2016). Different point 
mutations in the cmeR resulted in an altered expression of the cmeABC MDR pump 
(Cagliero et al., 2007; Perez-Boto et al., 2015).  
A second efflux system, CmeDEF, which has different substrate-binding properties, 
and, thus, is functionally distinct from CmeABC, has been identified in Campylobacter 
(Pumbwe et al., 2005). In this system, the inner membrane transporter CmeF that has 
homology with CmeB is linked to an outer membrane CmeD by a putative membrane 
protein CmeE (Pumbwe et al., 2005). Although little is known about this secondary 
efflux system, it is described as being expressed at low level and acts interactively with 
CmeABC in conferring resistance to antimicrobials and toxic compounds (Akiba et al., 
2006). Inactivation of CmeF leads to increased susceptibility to several antibiotics and 
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CmeABC and CmeDEF are involved in maintaining cell viability since at least one of 
these efflux pumps is required for optimal growth of Campylobacter, showing a 
physiological role for these MDR pumps (Akiba et al., 2006). A new putative efflux 
transporter, CmeG, has recently been reported (Jeon et al., 2011). CmeG was shown to 
be required for optimal growth in vitro, antibiotic resistance, and also for oxidative 
stress resistance by mediating resistance to hydrogen peroxide (Jeon et al., 2011).  
Because CmeABC is a good target for the development of intervention strategies to 
combat antibiotic resistance in Campylobacter, inhibition of this MDR pump by an EPI 
has been considered a novel approach to enhance drug accumulation inside the bacterial 
cell and thus, increase bacterial susceptibility to antibiotics (Kaatz, 2002). The EPI, 
Phe-Arg β-naphthyl-amide dihydrochloride, was shown to be effective at inhibiting the 
function of CmeABC pump (Martinez & Lin, 2006). However, several key aspects (e.g. 
toxicity, in vivo stability, production costs) should be addressed before EPIs can be used 
clinically and accepted in the medical community (Zeng et al., 2010). A more realistic 
and promising approach currently being investigated to potentiate the activity of clinical 
antibiotics against C. jejuni infection is a CmeC vaccine as this was shown to be 
important for colonisation and is dramatically induced and immunogenic in vivo (Zeng 
et al., 2010). However, the CmeC vaccination regimen should be optimised to enhance 
CmeC-specific mucosal immune response for protection against C. jejuni infection 
(Zeng et al., 2010). 
It became clear that the CmeABC MDR pump plays an important role in mediating 
AMR in Campylobacter, but the contribution of other efflux transporters remains to be 
elucidated. In addition, other natural functions of these efflux transporters in 
Campylobacter physiology await further investigation.  
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1.7. Other antibiotic resistance mechanisms in Campylobacter  
Besides the CmeABC efflux pump, there are other major resistance mechanisms in 
Campylobacter (Fig. 1.6).  Quinolones exert their antibacterial effect by preventing 
synthesis of the bacterial DNA causing cell death (Wieczorek & Osek, 2013). 
Fluoroquinolone resistance in Campylobacter is mainly mediated by point mutations in 
the quinolone resistance-determining region of the DNA Gyrase (gyrA), with the 
mutation They-86-Ile being the most common and the one responsible for ciprofloxacin 
resistance (Alfredson & Korolik, 2007; Iovine, 2013).  Briefly, FQ form a stable 
complex with the intracellular enzymatic target DNA gyrase (encoded by gyrA), 
trapping it onto DNA and thus, leading to a decrease in DNA replication and 
transcription, and ultimately cell death (Iovine, 2013). The C. jejuni mfd (mutation 
frequency decline) gene encodes a transcription-repair coupling factor involved in 
DNA-repair and it has been reported that mutations in this gene also contribute to the 
development of FQ resistance in this pathogen (Han et al., 2008). Another mechanism 
of FQ resistance is efflux, reducing the intracellular concentration of FQ. Additionally, 
the CmeABC pump works synergistically with GyrA mutations in causing high-level 
FQ resistance (Luo et al., 2003; Ge et al., 2005; Yan et al., 2006).  
Macrolides are antibiotics, mostly produced by Streptomyces, which interrupt protein 
synthesis in the bacterial ribosome by targeting the 50S subunit and inhibiting RNA-
dependent protein synthesis (Wieczorek & Osek, 2013). Macrolide resistance in 
Campylobacter is the result of modification of the ribosome target-binding site by 
mutation of the 23S rRNA gene (Wieczorek & Osek, 2013). Efflux through CmeABC is 
also described as a macrolide resistance mechanism and so is its synergy with 23S 
rRNA mutations, the latter conferring high-level of resistance (Lin et al., 2007; Gibreel 
et al., 2007). Additionally, a third mechanism of macrolide resistance involves altered 
membrane permeability mediated by expression of the major outer membrane porin 
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(MOMP). This porin creates transmembrane pores and allows diffusion of hydrophilic 
molecules, limiting the entry of most antibiotics with a high molecular weight (Iovine, 
2013).  
Aminoglycosides, such as gentamicin and kanamycin, are a class of antibiotics that 
inhibits bacterial protein synthesis (Iovine, 2013). Aminoglycoside resistance in 
Campylobacter is mediated by the aminoglycoside resistance gene aphA-3, a gene that 
encodes for a phosphotransferase, the latter modifying aminoglycoside antibiotics 
(Iovine, 2013). These enzymes bind to the decoding region in the A-site of the bacterial 
ribosomal 30S subunit, resulting in aberrant proteins by interfering with accurate 
proofreading (Wieczorek & Osek, 2013). Additionally, kanamycin resistance has been 
also linked to a Campylobacter plasmid that encodes tetracycline resistance, as it carries 
a kanamycin-phosphotransferase gene, aph-7 (Taylor & Courvalin, 1988).  
The β-lactams, such as penicillins, are a category of antibiotics that contain a β-lactam 
ring in their structure (Wieczorek & Osek, 2013). In Campylobacter, three mechanisms 
mediate resistance to these antibiotics: inactivation by the enzymes β-lactamases, such 
as the OXA-61, efflux out of the cell and decrease of the membrane permeability of 
most anionic antibiotics (Alfredson & Korolik, 2005; Iovine, 2013).   
Tetracycline works by inhibiting bacterial protein synthesis. In Campylobacter, tetO 
encodes for TetO, a protein that mediates tetracycline resistance (Wieczorek & Osek, 
2013). Once inside the cell, tetracycline reversibly binds to the 30S subunit of 
ribosomes and prevents the attachment of the charged aminoacyl-tRNA to the ribosomal 
site A thus, inhibiting protein synthesis (Dasti et al., 2007). The tetO gene is more 
frequently carried on transmissible plasmids; however, it can also be chromosome-
encoded (Dasti et al., 2007). Besides efflux through CmeABC, this was also reported to 
work synergistically with TetO, conferring a high-level of Tet resistance (Gibreel et al., 
2007).  
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Although mutations play a major role in the development of AR in Campylobacter, this 
pathogen can also acquire antibiotic-resistance determinants via horizontal gene transfer 
(HGT) (Luangtongkum et al., 2009). In Campylobacter, HGT is mainly mediated by 
natural transformation or conjugation, where the former is a major mechanism for the 
transfer of chromosomally encoded resistance and the latter plays a role in the transfer 
of plasmid-mediated resistance (Luangtongkum et al., 2009). Transfer of DNA, 
especially antibiotic-resistance determinants, has been widely reported in 
Campylobacter and has been shown both in vitro in bacterial cultures (Wilson et al., 
2003; Jeon et al., 2008) and in vivo in the chicken intestine (de Boer et al., 2002; Avrain 
et al., 2004). It is highly likely that the transfer of the pTet plasmid in the intestinal tract 
of chickens is possible because it has been reported that this contributes to the spread of 
Tet resistance in this pathogen (Avrain et al., 2004).  
As Campylobacter is naturally competent, there is considerable ground for the 
emergence of resistant mutants (Parkhill et al., 2000). Additionally, as this pathogen is a 
commensal of animal species, antimicrobial treatment in poultry farms may create an 
ideal opportunity for Campylobacter to evolve additional resistance mechanisms 
(Iovine, 2013). As macrolides are the drug of choice in the treatment of 
campylobacteriosis, further understanding of macrolide resistance mechanisms in 
Campylobacter is required to avoid the spread of this antibiotic resistance category, 
which is of great clinical concern in public health. Modern approaches such as genomics 
and proteomics are expected to provide new insights into the molecular mechanisms 
and help in our understanding of the development of AMR in Campylobacter 
(Wieczorek & Osek, 2013).  
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1.8. Other physiological functions of multidrug efflux pumps  
Recently, several studies have identified different physiological roles for MDRs, 
indicating that they are not only involved in antibiotic resistance. This is because efflux 
pumps not only export antibiotics, but also host-derived antimicrobial agents, allowing 
the bacteria to adapt and survive in their ecological niches. Other functions of MDR 
efflux pumps include cell communication, stress response, fitness, biofilm formation, 
detoxification of intracellular metabolites and colonisation of both animal and plant 
hosts (Piddock, 2006; Poole, 2008; Martinez et al., 2009; Alvarez-Ortega et al., 2013; 
Dinesh & Kumar, 2013; Sun et al., 2014; Li et al., 2015; Blanco et al., 2016).    
Figure 1.6.  Major antibiotic resistance mechanisms in Campylobacter. The ribosome, 
shown in blue at the left, is the site of binding of the TetO protein (shown in brown) to the 
A site (shown in dark purple) confering tetracycline resistance. Point mutations in 23S 
rRNA (shown in black and indicated by red stars) confers resistance to macrolides. 
MOMP (shown in green) limits the entry of most antibiotics that are negatively charged or 
with a molecular weight larger than 360 kDa; The Thr-86-Ile substitution in DNA gyrase 
(shown in light purple) confers resistance to this antibiotic class. The MDR CmeABC 
(shown as stacked blue squares) contributes to resistance to several antibiotics and works 
synergistically with other resistance mechanisms, often leading to high-level resistance. 
Aminoglycoside-modifying enzymes (AME; shown as the multi-colored star burst) are 
the main means of aminoglycoside resistance. Finally, β-lactamases (shown as the orange 
star burst) contribute to β-lactam resistance (Iovine, 2013). 
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As previously mentioned, AcrAB-TolC and MexAB-OprM are homologs of 
Campylobacter CmeABC. Since MDR pumps are able to pump toxic bile salts out of 
the cells, they are able to promote the bacterial adaptation to the animal’s intestinal tract 
(Sun et al., 2014). Although CmeABC was reported to be required for chicken 
colonisation by mediating resistance to the bile salts (Lin et al., 2003), several 
homologs of this efflux pump have been reported to be crucial for other pathogens to 
colonise and invade other host cells. For instance, the Pseudomonas aeruginosa 
MexAB-OprM, the Klebsiella pneumoniae AcrAB pump, the Salmonella AcrAB-TolC, 
the Vibrio cholerae efflux pump VexB, the Burkholderia pseudomallei BpeAB-OprB 
efflux pump, the Neisseria gonorrhoeae MtrCDE efflux system and the Francisella 
tularensis AcrAB were shown to be required for mice colonisation and in some cases 
for epithelial cell invasion and survival in macrophages (Hirakata et al., 2002; Jerse et 
al., 2003; Chan & Chua, 2005; Buckley et al., 2006; Nishino et al., 2006; Bina et al., 
2008; Webber et al., 2009; Padilla et al., 2010). It was also reported that the 
Pseudomonas MexAB-OprM system contributes to the colonisation of tomato plants 
(Vargas et al., 2011). 
In Salmonella enterica and Burkholderia cenocepacia, these efflux systems were 
demonstrated to be required for bacterial motility (Webber et al., 2009; Bazzini et al., 
2011). Bacterial quorum sensing through efflux of auto inducers by this MDR was 
shown for Burkholderia paseudomallei and cenocepacia and for Pseudomonas 
aeruginosa (Evans et al., 1998; Chan & Chua, 2005; Bazzini et al., 2011).  In the 
literature, there are some studies reporting on whether RND efflux pumps are required 
for biofilm formation, although MDR pumps have been reported to be required for 
biofilm formation (Kvist et al., 2008; Matsumura et al., 2011; Baugh et al., 2012). 
However, a recent publication reported to the contrary (Schlisselberg et al., 2015), thus 
suggesting further investigation regarding this topic is required.  
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In summary, it is clear that MDR pumps influence bacterial pathogenesis and may act as 
virulence determinants.  
 
1.9. The Acanthamoebae genus  
Protozoa are defined as a group of unicellular eukaryotic organisms that lack cell walls. 
A large group within the protozoa are the amoebae, which are ubiquitously distributed 
in the environment (Khan, 2006). Acanthamoeba is a genus of amoebae that was first 
described by Volkonsky in 1930 (Volkonsky, 1931). Acanthamoebae are opportunistic 
protists that are characterised by the presence of protoplasmic spine-like structures on 
its surface (known as acanthopodia), double wall cysts and an irregular outer layer 
(Khan 2006; Siddiqui & Khan, 2012a). They contain one or more contractile vacuoles 
(required for osmotic regulation), digestive vacuoles, lysosomes and several glycogen-
containing vacuoles (Siddiqui & Khan, 2012a). Acanthamoebae move through the actin 
cytoskeleton that forms the cytoplasmic protrusions and it is relatively fast, with a 
motility rate of approximately 0.8μm/second (Siddiqui & Khan, 2012a). Food uptake in 
these organisms occurs by pinocytosis (engulfing of liquids/small particles by 
invagination of the plasma membrane) and/or by phagocytosis (engulfing large particles 
forming an internal compartment) (Khan, 2006).  
Acanthamoebae are free-living amoebae (FLA) that are distributed worldwide and are 
the most prevalent protozoa found in the environment (Sandstrom et al., 2011). They 
have the ability to survive in diverse environments and have been isolated from public 
water supplies (swimming-pools, lakes, seawater, rivers), bottled water, ventilation 
ducts, air-conditioning units, sewage, soil, vegetables, surgical instruments, hospital 
units, mammalian cell culture and contact lenses (Sandstrom et al., 2011). 
Acanthamoebae are highly resistant organisms as they have the capacity to survive 
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under adverse conditions, such as extreme pH, high osmotic pressure, high temperature 
and food deprivation (Tosetti et al., 2014).  
These eukaryotic organisms undergo two stages during their life cycle: an active 
trophozoite phase and a resistant cyst stage (Fig. 1.7). Throphozoites are normally 25-
40μm in diameter and possess a large number of mitochondria (that generate the energy 
required for the metabolic activities. They exhibit acanthopodia on their surface that 
allow movement, feed on organic particles, or microbes, and are able to divide asexually 
via binary fission (parent cell mitotically divides into two daughter cells). When 
exposed to harsh conditions, Acanthamoebae adopt a reversible and dormant double-
walled cyst stage with minimal metabolic activity and that are normally 13-20μm in 
diameter (Marciano-Cabral & Cabral, 2003). This process where the throphozoite 
encloses itself within a resistant shell is known as encystment (Khan, 2006; Siddiqui & 
Khan, 2012a). The outer walls of the cyst consist of proteins and polysaccharides, while 
the inner wall possesses cellulose (Khan, 2006). Cysts may be airborne, helping in the 
spread of Acanthamoebae in the environment and they remain viable for several years 
protecting, transmitting and maintaining the pathogenicity of this organism (Siddiqui & 
Khan, 2012a).  When under favourable conditions, the excystment process is induced 
(throphozoites emerge from the cysts leaving behind the outer shell) and they are able to 
reproduce and complete the cycle (Siddiqui & Khan, 2012a).  
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There are over than 20 unique species of Acanthamoebae, the most common being A. 
polyphaga and A. castellanni (Maycock & Jayaswal, 2016). Initially, they were 
classified based on the cyst size and shape; however, this classification has proved 
unreliable because cyst morphology may change depending on culture conditions 
(Marciano-Cabral & Cabral, 2003). Classification of Acanthamoebae species is now 
based on the sequence analysis of 18S ribosomal RNA coding DNA (18S rDNA) 
(Marciano-Cabral & Cabral, 2003; Kong, 2009). Comparison of 18S rDNA sequences 
allowed distinction of three morphological groups of Acanthamoebae and divided them 
into 15 unique sequence types (T1-T15 genotypes) (Kong, 2009; Maycock & Jayaswal, 
2016), each genotype exhibits 5% or more sequence divergence between different 
genotypes (Siddiqui & Khan, 2012a). A. polyphaga and A. castellanii belong to group 
III (small cysts less than 18μm with polygonal or stellate endocysts and irregular or 
wrinkled ectocysts) and the genotype T4 (Kong, 2009). There is a strong resemblance 
among these species with the major differences being related with their length while 
moving and in their cyst structure (Page, 1967). A. castellanii has a median locomotion 
length of approximately 26.2μm, whilst A. polyphaga has a length of approximately 
20.7μm. A. castellanii usually moves faster than A. polyphaga, but both species have 
Figure 1.7. The life cycle of Acanthamoebae spp. Under optimal environmental 
conditions, Acanthamoeba remains in the active throphozoite form (A), while, under 
harsh conditions, it changes to a resistant double-walled cyst form (B).  
A B 
  Unfavourable conditions 
  Favourable conditions 
40x 40x 
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only one contractile vacuole. The cysts from A. polyphaga are usually smaller (12.6μm 
median length) than the cysts from A. castellanii (17.1μm median length) (Page, 1967). 
Lastly, both species are capable of causing the same diseases, which will be described in 
more detail in Section 1.10.  
 
1.10. Acanthamoebae pathogenesis and clinical features  
The majority of human infections due to Acanthamoebae have been associated with the 
isolates from the genotype T4, most likely associated with their greater virulence and 
properties that enhance their transmissibility (Siddiqui & Khan, 2012a). Eight species of 
Acanthamoebae have been reported to cause human infection (Maycock & Jayaswal, 
2016). Acanthamoebae cause two well-known diseases that are a major concern to 
human health: Acanthamoebae keratitis (AK) and Acanthamoebae granulomatous 
encephalitis (AGE) (Siddiqui & Khan, 2012a). Although the trophozoites are the 
infective forms, both cysts and trophozoites may gain entry into the human body (Fig. 
1.8) (CDC, 2012).  
AK is a potentially sight-threatening infection of the ocular surface that may lead to 
blindness and it is caused by different species of Acanthamoebae, the most common of 
which are A. castellanii and A. polyphaga (Maycock & Jayaswal, 2016). Although AK 
may occur in non-contact lens wearers, this disease is most common in individuals who 
use contact lenses (CL) that were exposed to contaminated water (Maycock & Jayaswal, 
2016). AK has been increasing in prevalence in recent years, with reporting rates of 1 to 
33 cases per million CL wearers (Maycock & Jayaswal, 2016). The main reasons why 
AK occurs are due to extensive time or re-use of CL, inappropriate cleaning of CL, lack 
of personal hygiene and exposure of the CL to contaminated water (e.g. swimming-
pools) (Khan, 2006; Maycock & Jayaswal, 2016). The sequence of events of AK 
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involves adhesion of Acanthamoeba to the corneal epithelial cells through cell surface 
proteins, such as the mannose binding protein MBP, followed by invasion with 
secretion of toxins, resulting in stromal degradation and deep penetration into the 
cornea, contributing to eye damage (Maycock & Jayaswal, 2016). Symptoms include 
considerable production of tears, photophobia, inflammation and redness of the eye, 
stromal opacity, stromal abscess formation with vision-threatening consequences and 
excruciating pain (Khan, 2006). AK is a difficult infection to treat, requiring early 
diagnosis and an aggressive treatment (Khan, 2006). Although amoebic trophozoites are 
sensitive to a large number of available antibiotics (e.g. metronidazol), the cysts may 
lead to a prolonged or resistant infection, as most of the treatment is ineffective. The 
most effective cysticidal antiamoebics are diamines and biguanines (Maycock & 
Jayaswal, 2016).   
AGE is a rare central nervous system (CNS) infection that occurs mainly in 
immunocompromised patients and almost always leads to death (Siddiqui & Khan, 
2012a). Acanthamoebae enter the human host by inhalation through the lower 
respiratory tract or through skin lesions, leading to invasion of the blood vessels 
followed by spread from the lungs or skin and cross of the blood-brain-barrier further 
entering in the CNS and resulting in neuronal damage and brain dysfunction (Marciano-
Cabral & Cabral, 2003). The symptoms include headache, fever, stiff neck, aphasia, 
lethargy, vomiting, behavioural changes, increased intra-cranial pressure, seizures and 
coma (Siddiqui & Khan, 2012a). These symptoms are due to necrotising lesions with 
severe encephalitis (Khan, 2006). There is no recommended treatment and the majority 
of cases are diagnosed post-mortem (Siddiqui & Khan, 2012a). The current treatment 
regimen for AGE involves a mixture of drugs to provide additive/synergistic effects and 
even so the mortality remains more than 90% (Siddiqui & Khan, 2012a). However, the 
existing drugs have limitations due to a high degree of toxicity associated with 
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deleterious side effects (Kulsoom et al., 2014). Combinations of drugs are being tested 
and have been shown to have effective amoebicidal effects. These include (i) 
prochlorperazine plus loperamide; (ii) prochlorperazine plus apomorphine; and (iii) 
procyclidine plus loperamide (Kulsoom et al., 2014).  
Other common infections due to Acanthamoebae include cutaneous infections, which 
are characterised by nodules and skin ulcerations. In healthy individuals, this is self-
limiting, but, in immunocompromised individuals, it may lead to severe and/or fatal 
consequences since Acanthamoebae may gain entry into the blood stream and spread to 
different tissues (Khan, 2006). Treatment includes different antifungal drugs, such 
asitraconazol (Khan, 2006).  
 
Figure 1.8. The life cycle of Acanthamoebae spp. in humans. Acanthamoeba presents 
two stages, cysts (1) and trophozoites (2), in its life cycle. The trophozoites replicate by 
mitosis (3).  The trophozoites and cysts enter into the body (4) through various means. 
Entry can occur through the eye (5), the nasal passages to the lower respiratory tract (6), 
or ulcerated or broken skin (7). When Acanthamoeba spp. enters the eye it can cause 
severe AK (8). When it enters the respiratory system or through the skin, it can invade 
the CNS causing AGE (9), disseminated disease (10), or skin lesions (11) in individuals 
with compromised immune system (CDC, 2012). 
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1.11. Acanthamoebae interaction with microbial species  
Historically, amoebae were known to consume microbes and to regulate bacterial 
populations in the environment, contributing to the functioning of ecosystems (Siddiqui 
& Khan, 2012a). Nowadays, an increasing number of microorganisms, such as bacteria 
and viruses, have been shown to benefit from the interaction with these free-living 
pathogens, as they play a role as a reservoir, allowing them to escape predation and 
potentially enabling them to survive or multiply inside their host (Thomas et al., 2010). 
Since they are highly resistant to physical and chemical stresses and may serve bacteria 
as their hosts, amoebae enable pathogenic bacteria to survive under conditions that 
would normally kill them (Thomas et al., 2010). Acanthamoebae can also act as “Trojan 
horses” for bacteria by facilitating their transmission and providing protection against 
the human immune system (Siddiqui & Khan, 2012a). Pathogenic microorganisms 
residing inside amoebae become more resistant to disinfectants, making it difficult to 
eradicate them from public water supplies (Winiecka-Krusnell & Linder, 2001). 
Moreover, interaction with Acanthamoebae can increase bacterial virulence and their 
resistance to antibiotics (Cirillo et al., 1994; Barker & Brown, 1995; Cirillo et al., 1997; 
Cirillo et al., 1999). 
Different types of interaction between bacteria and protozoa have been described, with 
possible outcomes including intracellular survival, with or without multiplication, 
(leading to amoebic lysis in case of bacterial multiplication) or intracellular lysis of 
bacteria, followed by their digestion by amoebae (Thomas et al., 2010). The outcome of 
amoebal-bacteria interactions is dependent on the virulence properties of the amoebae 
and the bacteria, or the environmental conditions they encounter (Khan & Siddiqui, 
2014). Because 22% of the Acanthamoeba isolates contain endosymbiont pathogenic 
microorganisms (Guimaraes et al., 2016), these associations are thus of great concern to 
human, animal and ecosystem health, especially since Acanthamoeba can co-exist in the 
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same environments as bacteria, e.g. in the water of industrial poultry houses, despite the 
stringent biosecurity measures (Bare et al., 2009; Vaerewijck et al., 2014).  
Amoebae are able to harbour a wide variety of microorganisms, share remarkable 
similarities with macrophages (in cellular structure, molecular motility, biochemical 
physiology, ability to capture their prey by phagocytosis, and in the way they interact 
with microbial pathogens), and are easy to handle experimentally (Sandstrom et al., 
2011; Ruqaiyyah & Naveed, 2011; Siddiqui & Khan 2012b; Tosetti et al., 2014; 
Guimaraes et al., 2016). Thus, this eukaryotic organism is an attractive and simple 
model of infection to study host-pathogen interactions in vitro, allowing the discovery 
of new bacterial virulence factors, which may assist in the development of new 
antibacterial therapeutic agents. In addition, through their capacity to resist digestion by 
amoebae, potential intracellular bacterial species are also likely to resist digestion by 
macrophages and thus represent new pathogenic species (Greub & Raoult, 2004). 
 
1.11.1. Interaction with viruses, fungi and parasitic protozoa 
The number of viruses known to survive and reside inside Acanthamoebae is increasing 
(Aherfi et al., 2016; Colson et al., 2017). For instance the human pathogenic enterovirus 
Coxsackie virus b3 (small RNA virus) was shown to survive intracellularly (IC) in A. 
castelannii and that the latter plays the role of a host and as a vehicle of transmission of 
this virus to humans (Mattana et al., 2006). The human pathogens adenoviruses, 
polioviruses and echoviruses were also shown to survive within Acanthamoeba and be 
transmitted by this host (Danes & Cerva, 1981; Scheid & Schwarzenberger, 2012). 
Recently identified genera of giant viruses (nucleocytoplasmic large DNA virus) that 
infect amoebae are Mimiviruses (mimicking microbes) and Marseilleviruses. These 
genera of viruses are able to survive and multiply within amoebae and the latter is 
considered to be its natural host (La Scola et al., 2003; Colson et al., 2013). As giant 
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viruses were discovered using amoebal co-cultures, these have become the method of 
choice to hunt for these microorganisms (Colson et al., 2017). Mimivirus isolations also 
led to the discovery of a new type of virus, named virophages that cannot replicate alone 
in Acanthamoeba spp., but replicates in the presence of a mimiviral host (La Scola et 
al., 2008). To date, there are very little data available in regards to human infection by 
giant viruses, but Mimiviruses were associated with pneumonia and Marseille viruses 
were associated with adenitis and lymphoma, posing a great clinical concern (Colson et 
al., 2017). 
Different types of fungi have also been reported to survive and multiply inside 
Acanthamoebae (Thomas et al., 2010). For instance, Cryptococcus neoformans, a soil 
fungus that causes life-threatening meningitis in immunocompromised patients, has 
been shown to multiply within A. castellanii leading to its lysis (Steenbergen et al., 
2001). Other pathogenic fungi Blastomyces dermatitidis, Sporothrix schenckii, and 
Histoplasma capsulatum are also able to multiply within A. castellanii leading to its 
lysis (Steenbergen et al., 2004).  
The obligate intracellular parasitic alveolate Toxoplasma gondii, that causes the disease 
toxoplasmosis, was shown to survive within A. castellanii and to be transmitted by this 
host in water environments (Winiecka-Krusnell et al., 2009).  
 
1.11.2. Interaction with bacteria 
After Legionella pneumophila was found to be able to survive and grow within 
amoebae (Rowbotham, 1980), an increasing interest in studying the interaction between 
pathogenic bacteria and amoebae was raised (Thomas et al., 2010). Although 
Legionella are the most established pathogenic bacteria that are able to survive and 
multiply intracellularly within Acanthamoebae, many other pathogens have been 
identified as able to grow within this host (Thomas et al., 2010). An extensive review of 
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the literature listed 102 bacterial species capable of interacting with FLA, where the 
majority of the studies have used A. polyphaga and A. castellanii as a host (Thomas et 
al., 2010). In addition, it has also been reported that amoebae can harbour two different 
bacterial species and co-exist within separate IC compartments (Heinz et al., 2007). 
Table 1.1 presents a non-exhaustive list of some Acanthamoebae-bacteria interactions 
described. Importantly, it has been reported that some pathogenic bacteria are capable of 
survival and persistence within amoebic cysts, thus, enabling foodborne pathogens to 
survive physical and chemical cleaning and disinfection methods in food-related 
environments, increasing the risk of infection (Thomas et al., 2010; Lambrecht et al., 
2015).  
Several bacterial factors, especially in Legionella pneumophila, have been reported as 
crucial for the interaction with amoebae. Examples are the flagellin structural protein 
FliC and the secretion system apparatus protein SsaU that are required for invasion and 
survival of Burkholderia pseudomallei and Salmonella typhimurium within 
Acanthamoeba, respectively (Inglis et al., 2003; Bleasdale et al., 2009). The 
Escherichia coli and Klebsiella pneumoniae outer membrane protein OmpA was shown 
be required for survival of these pathogens within amoebae (Alsam et al., 2006; March 
et al., 2013).  The transcriptional regulators PhoB, PhoP and ToxR were shown to have 
secondary roles in the survival of E. coli, S. typhimurium and Vibrio cholerae within 
Acanthamoebae, respectively (Bleasdale et al., 2009; Chekabab et al., 2012; Valeru et 
al., 2012). The type III system from E. coli and Pseudomonas aeruginosa was also 
shown to be involved in this interaction (Abd et al., 2008; Siddiqui et al. 2011). Capsule 
form E. coli, the intracellular protease Lon and the ribosome-binding GTPase TypA 
from P. aeruginosa are required for survival of both these pathogens within amoebae 
(Jung et al., 2007; Breidenstein et al., 2012; Neidig et al., 2013). Flagellin FlaA, 3-
dehydroquinated synthase AroB, ferrous iron transport FeoB, ankyrin AnkB, the outer 
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membrane efflux TolC, two-component regulator system signal sensor kinase PmrB, 
protease ClpP and the outer membrane OmpA are a few examples of L. pneumophila 
bacterial factors shown to be required for the interaction of this pathogen with amoebae 
(Dietrich et al., 2001; Polesky et al., 2001; Robey & Cianciotto, 2002; Al-Khodor et al., 
2008; Ferhat et al., 2009; Al-Khodor et al., 2009; Li et al. 2010; Goodwin et al., 2016).  
Despite great advances in the exploration of bacteria-amoebae interactions, other 
bacterial determinants involved in this interaction remain to be elucidated.  
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ICS, intracellular survival; ICM, intracellular multiplication; ICCS, intracellular cyst survival; 
*contradictory results; If ICM is not referred to this means it was not studied. 
 
 
 
Table 1.1. Interactions described for different bacteria and Acanthamoebae 
species 
Bacterial species Interaction with 
Acanthamoebae 
References 
Acinetobacter baumannii ICS; ICM; ICCS Cateau et al., 2011 
Aeromonas hydrophila 
ICS; ICCS (not able 
to multiply IC) 
Rahman et al., 2008; Anacarso et al., 2012; 
Yousuf et al., 2013  
 
Burkholderia cepacia ICS; ICM
*
 Lamothe et al., 2004; Landers et al., 2000 
Burkholderia pseudomallei ICS Inglis et al., 2000; 2003 
Citrobacter freundii ICS King et al., 1988 
Coxiella burnetii ICS La Scola & Raoult, 2001 
Enterococcus faecalis ICS; ICM Anacarso et al., 2012 
Enterobacter aerogenes ICS; ICCS Yousuf, et al., 2013) 
Escherichia coli ICS; ICCS: ICM 
Alsam et al., 2006; Jung et al., 2007; Siddiqui et 
al., 2011; Matin & Jung, 2011; Chekabab et al., 
2012; Lambrecht et al., 2015 
Francisella tularensis ICS; ICM; ICCS Abd et al., 2003; El-Etr et al., 2009 
Helicobacter pylori ICS Winiecka-Krusnell et al., 2002 
Klebsiella pneumoniae ICS King et al., 1988 
Legionella pneumophila ICS; ICM; ICCS 
Thomas et al., 2010; Tosetti et al.,2014; 
Gunderson et al., 2015;  Goodwin et al., 2016; 
Mengue et al., 2016  
Listeria monocytogenes 
Not able to ICS
*
 and 
ICM
*
 
Akya et al., 2009a; 2009b; Akya et al., 2010;  
Anacarso et al., 2012; Doyscher et al., 2013; 
Fieseler et al., 2014  
Mycobacterium avium ICS; ICM; ICSS 
Cirillo et al., 1997; Steinert et al., 1998; Miltner 
& Bermudez, 2000; Mura et al., 2006; Chan et 
al., 2015 
Mycobacterium smegmatis ICS; ICCS 
Taylor et al., 2003; Sharbati-Tehrani et al., 2005; 
Lamrabet et al., 2012 
Mycobacterium 
bovis/marinum/tuberculosis 
ICS; ICCS 
Kennedy et al., 2012; Medie et al., 2011 
Pasteurella multocida ICS; ICM Hundt & Ruffolo, 2005 
Pseudomonas aeruginosa ICS; ICCS Maschio et al., 2015; Siddiqui et al., 2015) 
Salmonella 
typhimurium/enterica 
ICS; ICM; ICCS 
Gaze et al., 2003; Tezcan-Merdol et al., 2004; 
Bleasdale et al., 2009; Douesnard-Malo & Daigle, 
2011; Lambrecht et al., 2015  
Shigella dysenteriae/sonnei ICS; ICM Jeong et al., 2007; Saeed et al., 2009 
Staphylococcus aureus ICS; ICM; ICCS Anacarso et al., 2012; Cardas et al., 2012 
Streptococcus pneumoniae ICS; ICM Evstigneeva et al., 2009) 
Vibrio cholerae ICS; ICM;ICCS 
Abd et al., 2007; Abd et al., 2009; Sandstrom et 
al., 2010; van der Henst et al., 2016) 
Yersinia 
pestis/enterocolitica/pseudo
tuberculosis 
ICS; ICM: ICCS 
King et al., 1988; Anacarso et al., 2012; 
Lambrecht et al., 2015; Santos-Montanez et al., 
2015 
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1.11.2.1. Interaction with Campylobacter jejuni 
The results from some publications describing the interaction between Acanthamoeba 
and C. jejuni are contradictory. Whilst some of them suggest the ability of C. jejuni to 
survive and/or multiply within amoebae (Axelsson-Olsson et al., 2005; Snelling et al., 
2005; Olsson et al., 2007; Snelling et al., 2008; Axelsson-Olsson et al., 2010a; 2010b; 
Griekspoor et al., 2013; Olofsson et al., 2013) others support only an extracellular mode 
of survival (Bare et al., 2010; Bui et al., 2012a; 2012b; Dirks & Quinlan, 2014). These 
conflicting results may be explained by variation in experimental strains and conditions 
(Backert & Hofreuter, 2013). For instance, invasiveness of C. jejuni is both bacterial 
strain (due to variability of the structures of lipooligosaccharides and capsular 
polysaccharides) and host cell line dependent (Poly et al., 2007; Backert & Hofreuter, 
2013). The bacterial multiplicity of infection (MOI) is another factor that may influence 
the efficiency of infection (Backert & Hofreuter, 2013). The absence or presence of 
gentamicin to kill the extracellular bacteria is also a crucial factor for the outcome of the 
Acanthamoebae infection by bacteria (Backert & Hofreuter, 2013).  Recently, a critical 
analysis of these data was carried out by the author and colleagues, which discussed 
possible reasons for the conflicting results. In this review, the Campylobacter factors, 
which may be involved in the interaction of this pathogen with amoebae and other host 
cells were explored (Vieira et al., 2015). Although Campylobacter-Acanthamoebae 
interactions are described in detail in the review written by Vieira et al., 2015 that is 
attached to the Appendix section, a brief description of the studies about this interaction 
is given below.   
The survival of C. jejuni within both A. polyphaga and A. castellanii species was 
demonstrated in some studies, but, despite the fact that they did not use gentamicin to kill 
extracellular bacteria, the experimental data were supported by the use of microscopy 
where C. jejuni cells could be seen inside amoebae (Snelling et al., 2005; Axelsson-
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Olsson et al., 2005; Griekspoor et al., 2013; Olofsson et al., 2013). Massive invasion of 
A. polyphaga by C. jejuni was reported, a process shown to be dependent on bacterial 
viability, and that the bacteria may escape degradation by avoiding localisation in 
amoebae lysosomal vacuoles and instead, reside within non-digestive vacuoles (Olofsson 
et al., 2013). Unfortunately, some of the studies that reported IC survival not only did not 
use a gentamicin stage, but, also, did not provide any supporting visual evidence (Olsson 
et al., 2007; Axelsson-Olsson et al., 2010a). Importantly, amoebae were shown to protect 
C. jejuni against harsh environmental conditions, such as low pH, a condition 
encountered in the human or chicken stomach, which may possibly help C. jejuni survival 
and passage through the gastrointestinal tract (Axelsson-Olsson et al., 2010b). In 
addition, C. jejuni within A. castellanii was able to colonise broilers and was resistant to 
chlorination of the drinking water of chickens (King et al. 1988; Snelling et al., 2008). 
This is important as C. jejuni and protozoa co-exist in the broilers drinking water and 
thus, increase the risk of infection of this host (Snelling et al., 2008). Although one study 
reported on the extracellular (EC) mode of survival only, it was observed that C. jejuni 
cells started to lose their viability inside A. castellanii after five hours (Bare et al., 2010). 
However, even if Campylobacter was able to reside within amoeba for a short time 
period, this may be of epidemiological importance as this could still represent a sufficient 
period of time for this eukaryotic organism to be a source of transmission of this 
pathogen. 
The first reports that used gentamicin in their experiments to elucidate this interaction 
observed a decrease in the viability of C. jejuni inside A. castellanii after a few hours and 
that multiplication of this foodborne pathogen occurs EC only (Bui et al., 2012a; Bui et 
al., 2012b; Dirks & Quinlan, 2014).  
In general, it is clear that Campylobacter survival is increased in the presence of 
Acanthamoebae, but that there is a disagreement on whether it occurs intra- or 
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extracellularly. The enhanced survival of C. jejuni in the presence of Acanthamoeba was 
due to the uptake of oxygen by amoebae, creating the necessary microaerobic conditions 
necessary to support C. jejuni growth (Bui et al., 2012b). The type of interaction between 
C. jejuni and A. polyphaga and the molecular mechanisms (e.g. bacterial factors) 
involved in this interaction still need to be elucidated.  
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1.12. Aims and objectives 
The association between foodborne pathogens and protozoa leads to serious 
consequences in food safety, increasing the risk of infection (Vaerewijck et al., 2014). It 
is suggested, therefore, that the deciphering of the molecular mechanisms of 
Campylobacter-amoebae interaction will assist in a better understanding of 
Campylobacter lifestyle aiding in the development of novel intervention strategies.  
The main aim of this study was to explore the type of interaction between C. jejuni and A. 
polyphaga and to identify the bacterial factors involved in this interaction. A second aim 
of this study was to study antibiotic resistance mechanisms in C. jejuni.   
 Therefore the objectives of this study were to  (i) elucidate the type of interaction 
between Campylobacter jejuni and Acanthamoeba polyphaga; (ii) investigate if the 
CmeB multidrug efflux transporter and capsule production were involved in the 
interaction between A. polyphaga and C. jejuni; (iii) investigate if CmeB was involved in 
biofilm formation, motility and oxidative stress; and (iv) investigate the contribution of 
amino acid sequence variation of the cmeB to tetracycline resistance of C. jejuni.   
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CHAPTER 2: Material and Methods 
 
2.1. General methods 
2.1.1. Bacterial strains and plasmids  
Four main strains of C. jejuni were used in this study: 81-176 a highly virulent strain 
isolated from a girl infected in a raw milk outbreak (Hofreuter et al., 2006); 11168H, a 
hyper motile variant of the reference strain NTCT11168 (Karlyshev et al., 2002); G1, a 
strain isolated from a Guillan-Barré syndrome patient (Gregson et al., 1997) and X, a 
strain isolated from a patient with enteritis (Karlyshev & Wren, 2001). A chimeric C. 
jejuni strain B7 was created naturally by growing C. jejuni 81-176 and G1 strains 
together. C. jejuni 81-176-pCPE107/28/GFP strain was kindly provided by Dr. Patricia 
Guerry from the Naval Medical Research Centre. The plasmids used in this study are 
listed in Table 2.1.  
 
Table 2.1. Plasmids used for the generation of C. jejuni mutant and derivative 
strains 
Plasmids Description Source/Reference 
pGEM-T easy 
Cloning vector to construct C. jejuni 
mutants 
Promega 
pJMK30 
Source of kanr cassette to construct C. 
jejuni mutants 
(van Vliet et al., 1998) 
pRRC 
Vector with a fragment of rRNA gene 
cluster and a camr cassette used as a 
control to check efficiency of competent 
cells 
(Karlyshev & Wren, 2005) 
pRED1 
pRRC vector with egfp gene used for 
complementation of C. jejuni mutants via 
insertion of a camr cassette into rRNA 
gene cluster  
(Karlyshev & Wren, 2005) 
pCPE107/28/GFP 
GFP plasmid kindly provided by Dr. 
Guerry  
(Ewing et al., 2009) 
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2.1.2. Bacterial media and growth conditions 
Laboratory stocks were stored at -80°C in Mueller-Hinton (MH, Fluka) supplemented 
with 15% glycerol, prepared originally from two day culture. Campylobacter jejuni 
strains were recovered from -80°C by incubation in microaerobic conditions (5% O2, 
10% CO2 in N2) within a controlled atmosphere incubator (Don Whitley) on Columbia 
Blood Agar (CBA, Oxoid) supplemented with 5% defibrinated horse blood and 
Campylobacter selective supplement (Oxoid) at 37°C for 24 hours. 
E. coli cultures were grown at 37°C on Luria Bertani (LB) media (Oxoid). Stocks of E. 
coli were stored at -80°C in LB broth with 15% glycerol.  
When necessary, the media were supplemented with the appropriate antibiotics, 
ampicillin (100μg/ml), kanamycin (50μg/ml), tetracycline (10μg/ml) or chloramphenicol 
(10μg/ml).  
For liquid cultures, C. jejuni was suspended in Brain Heart Infusion (BHI, Oxoid) broth 
and adjusted to an OD600nm of 1. The bacterial suspension was diluted 100-fold in BHI 
broth in sterile conical flasks and incubated with shaking (200 rpm) at 37°C 
microaerobically for two days. One ml samples of each bacterial culture were taken at 
each time-point (0, 6, 24, 30 and 48h) and the OD600nm was measured.  
All culture media made in the laboratory were autoclaved at 121°C for 15 minutes prior 
to use.  
 
2.1.3. Cell morphology and motility  
For Gram staining, C. jejuni samples grown on CBA agar for 24h hours at 37°C were 
heated and fixed onto glass slides and stained using crystal violet (CV), iodine, 90% 
ethanol and carbol fuchsin. Slides were visualised using light microscopy with 100x oil 
immersion objective lens to check the morphology of the bacterial cells (Nikon Eclipse 
80i).  
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Motility of C. jejuni was determined as previously described with a few modifications 
(Baldvinsson et al., 2014). C. jejuni bacteria were grown on CBA blood agar plates at 
37°C for 24 hours, suspended in BHI broth and adjusted to an OD600nm of 0.5, after which 
1μl aliquots of the bacterial suspension were spotted onto 0.4% BHI soft-agar plates. The 
low density of the agar allows the bacteria to move within the agar, forming a halo of 
growth around the point of inoculation. Plates were incubated for three days at 37°C in 
microaerobic conditions. 
 
2.2. Molecular and cloning techniques 
2.2.1. DNA isolation 
Plasmid DNA was isolated using the Qiagen plasmid purification Kit (Qiagen) and 
chromosomal DNA were isolated by the Gentra Puregene Yeast/Bacteria Kit (Qiagen). 
The kits were used according to the manufacturer’s protocol. 
DNA samples were purified using two different methods: the QIAquick PCR purification 
Kit (Qiagen) used to clean DNA samples after restriction digestion and PCR products, 
and the QIAquick Gel Extraction Kit (Qiagen) used for the isolation of specific fragments 
of DNA derived from restriction digested reactions. The 1% (w/v) agarose gel segment 
with the fragment of interest was cut using a scalpel and a long wavelength UV source. 
 
2.2.2. Polymerase chain reaction (PCR) and agarose gel electrophoresis 
Each of the PCR reactions contained the following constituents: GoTaq Hot Start G2 
Green Master Mix (Promega); appropriate reverse and forward primers (10μM); 
nuclease-free water and the DNA sample. For the High Fidelity PCRs, used to amplify 
highly accurate DNA fragments, the following constituents were used: Q5 reaction 
buffer; Q5 DNA polymerase; appropriate primers; dNTPs (10mM); nuclease-free water 
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and the DNA sample. DNA samples were either bacterial genomic DNA or bacterial 
lysates. Bacteria lysates were obtained by suspending bacteria in 10μl of lysis buffer 
(1mg/ml lysozyme; 10mM EDTA; 0.02% Triton and 10mM Tris pH 8.0), followed by 
heating at 95ºC for 10 sec. Lysates were then diluted in 50μl of Tris-EDTA (TE). The 
cycler conditions were performed in accordance to the manufacturer’s protocol. Thermal 
cycler conditions for the DNA polymerases used are listed in Tables 2.2 and 2.3. Primers 
used to check identity of the C. jejuni strains are listed in Table 2.4. 
To visualise PCR products, plasmids and DNA fragments, the samples were run on 1% 
(w/v) agarose gels, containing 1g of agarose (Sigma), 100ml 1x Tris-Borate EDTA 
Buffer (TBE) (Fisher) and 0.1μg/μl ethidium bromide (Fisher) for visualisation. Samples 
were directly loaded into the gel when amplified with Go Taq G2 Green Master Mix or 
supplemented with bromophenol blue based loading buffer (NEB) when amplified with 
Q5 Reaction PCR mix. Quick-Load 2-Log DNA Ladder (NEB) was used as a standard to 
estimate the DNA fragment sizes. Gel electrophoresis was conducted in a horizontal gel 
tank (Fisher) containing 1x TBE buffer. The gel was run at 150V for one hour and 
visualised with the trans illuminator setting in the G:Box (Syngene) using GeneSnap 
software (Syngene). 
 
 
 Table 2.2. Thermal cycler conditions for GoTaq Hot Start G2 DNA Polymerase  
             PCR step Temperature (ºC)          Duration of step Number of cycles 
 Initial denaturation 95ºC 2 min 1 
Denaturation 95ºC 30 sec 
25 Annealing 55ºC 30 sec 
Extension 72ºC 1 min per kb 
Final extension 72ºC 5 min 1 
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Table 2.3. Thermal cycler conditions for Q5 High-Fidelity DNA Polymerase   
               PCR step Te         Temperature (ºC) Dur   Duration of step Nu     Number of cycles 
   Initial denaturation 98ºC 30 sec 1 
Denaturation 98ºC 10 sec 
35 Annealing 60ºC 30 sec 
Extension 72ºC 30 sec per kb 
Final extension 72ºC 2 min 1 
 
Table 2.4. Primers used for identification of C. jejuni strains 
       Gene Name    Primer Name Primer sequence (5’ to 3’) 
dmhA DmhA_for ATGAAAAAAACAGCGTTAATTACAGGATTTACAG 
 DmhA_rev GAATTCTGCCTCTCTTAATTTCATTTCTCCAATG 
tag Tag_for GCTCTTGAAAACATGAGAAGATATCAAGAAGCGG 
 Tag_rev AAGATTTTTATCCTTTAGAATATCTTCAGATAAC 
cj1435 Cj1435_for GCCTTATTTGATTTTTGTGAAACTTTAAC 
 Cj1435_rev GAGCTAATTTGTAAAGTTTTCTTTCTTGC 
moaA MoaA_for GACTAGCGAATTGAAAAGAAATATAACTTCATTTAC 
 MoaA_rev CTAATAATTTATATGGCTGAGAACATTGAAATTTC 
tet(O) pTet_for GGCGTTTTGTTTATGTGCG 
 pTet_rev ATGGACAACCCGACAGAAGC 
virB11 pVir_for GAACAGGAAGTGGAAAAACTAGC 
 pVir_rev TTCCGCATTGGGCTATATG 
luxS 
LuxS-81-176 GAAAACACCTAAGGGTGATGATATTAGT 
 LuxS-G1 TAAGGGTGATGATATTAGCGTG 
LuxS-Rev GTAAATCAAGTATAGGTAAGTTCATTTTTG 
 
2.2.3. Restriction digestion and other enzymatic reactions 
The restriction mixtures were prepared according to the manufacturer’s protocol, which 
included an appropriate NEB buffer at 1x concentration, a respective restriction enzyme, 
a DNA sample and nuclease-free water. The digestion reactions were incubated for one 
hour and the temperature was dependent on the type of restriction enzyme used.  
Antarctic phosphatase (NEB) was used for dephosphorylating vectors after restriction 
digestion, by the removal of the 5’ phosphate from DNA to prevent re-circularisation, 
which creates background during cloning. Antarctic phosphatese buffer at 1x 
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concentration and Antarctic phosphatase enzyme were added to the digestion reaction and 
incubated at 37ºC for 30 minutes.  
T4 DNA Ligase (Promega) was used to ligate the fragment of interest to a vector in order 
to create a recombinant vector. The ligation reaction contained T4 DNA ligase buffer 
(1X), T4 DNA ligase, nuclease-free water and a DNA sample and was incubated at 4ºC 
overnight.  
T4 DNA polymerase (NEB) catalyses the synthesis of DNA in the 5’ – 3’ direction and 
removes 3’ overhangs to form blunt ends with dNTPs. The T4 polymerase, T4 DNA 
polymerase buffer (NEB) and dNTPs were added to the DNA sample and incubated for 
30 minutes at 37ºC.  
CloneChecker kit (Invitrogen) was used to rapidly analyse and screen recombinant 
bacterial cultures for target plasmids, according to the manufacturer’s protocol.   
 
2.2.4. Transformation of E. coli and C. jejuni cells 
         NEB Express Competent E. coli (High Efficiency) (NEB) and E. coli XL1 Blue Super 
competent cells (Stratagene) were used according to the manufacturer’s protocol. For 
transformation, 50μl aliquots of E. coli competent cells were inoculated with 5μl of the 
ligation mixture, followed by heat shock at 42ºC. Recovery of the cells in Super Optimal 
Broth (SOC, Fisher) was performed for one hour at 37ºC with shaking.  E. coli 
transformation mixtures were plated in LB agar supplemented with an appropriate 
antibiotic.  
To prepare C. jejuni competent cells, bacteria were grown as a lawn on CBA blood agar 
overnight at 37ºC under microaerobic conditions. The cells were harvested in 1ml of MH 
broth and pelleted by centrifugation at 10000xg for five minutes at 4ºC. The pellet was 
suspended in 1ml of cold wash buffer (272mM sucrose, 15% glycerol) and centrifuged in 
the same conditions. This procedure was repeated three times before cells were 
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suspended in 500μl of wash buffer. The competent cells were immediately stored at -
80ºC in 50μl aliquots. 
For electroporation, 2μg of DNA was added to 50μl competent cells and then transferred 
to 0.2cm electroporation cuvettes (Thermo Scientific). Electroporation was conducted at 
2.5kV, 200Ω and 25μF, using a BioRad MicroPulser electroporation apparatus (BioRad). 
After electroporation, cells were flushed with 100μl of SOC, spread onto a CBA blood 
agar plate and incubated overnight at 37ºC in microaerobic conditions for recovery. The 
following day, cells were plated onto a CBA blood agar plate with the respective 
selective antibiotic for three days at 37ºC microaerobic conditions.  
 
2.2.5. Generation of kpsM mutants  
The genomic DNA of C. jejuni strain 11168H/kpsM::kanr (Karlyshev et al., 2000), 
available in the laboratory -80ºC collection, was isolated using the Gentra Puregene 
Yeast/Bacteria Kit and electroporated into C. jejuni 81-176 or G1. The electroporation 
mixture was plated onto CBA agar supplemented with kanamycin (50μg/mL) and allelic 
replacement of the clonal isolates was confirmed by PCR using gene-specific primers 
(Table 2.5).  
 
Table 2.5. Primers used for confirmation of C. jejuni kpsM mutants   
Primer name Sequence (5’ – 3’) 
ak55-Fw CCCCATCAAACCTATGCTAC 
ak59-Rev GCCTATAAACCTGTAAAGCCTATAC 
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2.2.6. Generation of cmeB mutants 
Inactivation of the C. jejuni 81-176 gene cmeB was achieved by an insertional 
mutagenesis approach (Karlyshev & Wren, 2001) where cmeB was disrupted by insertion 
of a kanamycin resistance cassette (kanr). Primers CmeB-Fw and CmeB-Rev (Table 2.6) 
were used to amplify the 3kb fragments containing the cmeB gene from C. jejuni strains 
81-176, 11168H and G1 chromosomal DNA. GoTaq Hot Start G2 DNA Polymerase 
Master Mix (one cycle) was used for the creation of A’ overhands in the HF Q5 PCR 
products, which were then purified with the PCR purification Kit and subsequently 
cloned into pGEM-T Easy vector (Promega). The ligation mixture was transformed into 
NEB Express E. coli and recombinant plasmids were selected using the CloneChecker kit 
The kanamycin cassette was isolated from vector pJMK30 by digestion with SmaI 
enzyme (1.5 kb), followed by gel extraction of the 1.5 kb fragment containing the kanr 
cassette. To create blunt ends the plasmid pGEM-T Easy/cmeB was digested with SmaI 
and then it was ligated with the kanr fragment using T4 DNA ligase. After transformation 
of E. coli with the ligation mixture, the pGEM-T Easy/cmeB::kanr plasmid containing the 
insert of interest in the correct orientation was isolated. The pGEM-T Easy/cmeB::kanr 
recombinant plasmid was transformed into C. jejuni via electroporation and transformants 
were selected on CBA agar supplemented with kanamycin (50μg/mL). The C. jejuni 
cmeB::kanr mutants were confirmed by PCR analysis.  
 
Table 2.6. Primers used for generation of C. jejuni cmeB mutants  
Primer name Sequence (5’ – 3’) 
CmeB-Fw AAGGAGATATACCATGTTTTCTAAATTTTTTATAGAAAGACCTATTTTTG 
CmeB-Rev TCATTCATGAATCTTACCTCTTTTTTTATCTAGC 
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2.2.7. Complementation of the cmeB mutants  
Initially complementation of cmeB mutant strain was attempted by an insertional system 
for gene delivery and expression in Campylobacter jejuni (Karlyshev & Wren, 2005). 
Briefly, this consists of a pRRC vector containing a camr cassette that has complementary 
flanking regions with three rRNA gene clusters, allowing the insertion of the construct 
into the chromosome by homologous recombination, where the gene of interest would be 
under the control of camr (Karlyshev & Wren, 2005). The cmeB fragment was amplified 
by a high fidelity PCR using the complementation primers (Table 2.7, 1) and digested 
with XbaI enzyme for further ligation to the pRRC plasmid. The vector was also digested 
with XbaI and dephosphorylated after digestion. The ligation mixture was then 
transformed into E. coli and CloneChecker using ClaI enzyme was conducted to check 
the orientation of the cmeB fragment into the pRRC plasmid, for further extraction and 
purification of the recombinant plasmid and transformation into C. jejuni cmeB mutant. 
Due to failure in cloning the cmeB fragment into pRRC in the correct orientation, the 
pRED1 plasmid (pRRC containing an egfp gene) was used for selection of the clones 
lacking fluorescence, following a replacement of the egfp gene (Karlyshev & Wren, 
2005). The cmeB fragment was amplified by a high fidelity polymerase using the new 
complementation primers (Table 2.7, 2) and double digested with Eco53KI/XbaI 
enzymes. The pRED1 plasmid was double digested with SwaI/XbaI enzymes (that 
allowed for the egfp replacement for further cloning of cmeB in the plasmid), and 
dephosphorylated. The digested cmeB and pRED1 products were ligated with T4 DNA 
ligase and the mixture was then transformed into E. coli, for further selection of non-
fluorescent clones. CloneChecker using ClaI enzyme was used to check the orientation of 
the cmeB-containing fragment in the pRRC plasmid, for further extraction and 
purification of this recombinant plasmid and transformation into C. jejuni cmeB mutant.  
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The insertion of the camr cassette into the rRNA clusters was confirmed by PCR using 
Ak233/234/235/237 primers (Table 2.7).  
 
Table 2.7. Primers used for generation of C. jejuni complementation derivatives 
 
2.2.8. Generation of G1/pTet derivatives 
To generate the C. jejuni G1/pTet strain, the pTet plasmid from C. jejuni 81-176 was 
transferred to C. jejuni G1 by conjugation. C. jejuni 81-176 and G1 bacteria were grown 
on CBA blood agar plates at 37°C for 24 hours suspended in MH broth and adjusted to an 
OD600nm of 1. A  mixture of 81-176 donor strain with  G1 recipient strain was plated on 
top of a 0.22μm sterile filter membrane (Millipore), placed on the surface of a CBA agar 
plate, and incubated overnight at 37ºC under microaerobic conditions. The bacterial 
culture was collected from the membrane and plated onto CBA agar supplemented with 
tetracycline (15μg/mL) and ampicillin (5μg/mL), the latter to prevent the growth of C. 
jejuni 81-176 strain. PCR was conducted to confirm the derivative strain using the pTet 
primers described in Table 2.4. 
 
 
Primer name Sequence (5’ – 3’) 
CmeB-compl-Fw-1 
AATATCTAGAAGGAGAATTCTCATGTTTTCTAAATTTTTTATAGAAAGACC 
 
CmeB-compl-Rv-1 
TATTTCTAGATTATTCATGAATCTTACCTCTTTTTTTATCTAGCCATTC 
 
CmeB-compl-Fw-2 GAGTAAATAGAGCTCATGTTTTCTAAATTTTTTATAGAAAGACC 
CmeB-compl-Rv-2 GAAATTATTTCTAGATTATTCATGAATCTTACCTCTTTTTTTATC 
AK233 GCAAGAGTTTTGCTTATGTTAGCAC 
AK234 GAAATGGGCAGAGTGTATTCTCCG 
AK235 GTGCGGATAATGTTGTTTCTG 
AK237 TCCTGAACTCTTCATGTCGATTG 
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2.3. Bioinformatics tools 
To verify that there were no mutations in the target genes and recombinant plasmids, 
these were sent for sequencing to Genewiz, the former Beckman Coulter Genomics. 
Nucleotide sequencing results from Sanger DNA Sequencing (Genewiz) were analysed 
as chromatograms and in FASTA format using the Chromas Lite program. Sequences of 
genes and genomes were obtained from the National Centre for Biotechnology (NCBI) 
database or from the CLC Genomics Workbench software (Qiagen bioinformatics). Gene 
and genome region analysis was conducted using BLAST and the cladogram was 
constructed using multiple sequence alignment in the Clustal Omega program (EMBL-
EBI). NEBcutter V2.0 tool was used for restriction mapping in order to ensure the correct 
orientation of the gene fragment in the vector. The NEB digest finder online tool was 
used to determine restriction digest reactions with two different enzymes that required 
different reaction conditions. Primers were designed using the OligoCalc online tool and 
were synthesised by Sigma Genosys, UK. It should be noted that, although I was 
involved in the project, Professor Karlyshev and his co-workers conducted the genome 
sequencing of the C. jejuni G1 strain (Lehri et al., 2015) and that is the reason why the 
genome-sequencing methodology is not referred to in this thesis. Professor Karlyshev 
also conducted the genome sequencing of the chimeric C. jejuni strain B7.  
  
2.4. Biofilm assays 
2.4.1. Non-attached aggregates in culture flasks 
The ability of C. jejuni to form non-attached aggregates in liquid culture (flocs) was 
performed as described previously (Joshua et al., 2006). Briefly, C. jejuni was grown in 
CBA blood agar plates at 37°C for 24h and suspended in MH broth at an OD600nm = 1. In 
25cm2 culture flasks, 100μl of the bacterial suspension was added to 5mL of MH broth 
and the flasks were incubated at 37°C under microaerobic conditions with 50 rpm 
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shaking for three days. Flasks were visualised using the upper light setting in a G:Box 
machine (Syngene). 
 
2.4.2. Attached biofilms in glass tubes  
Ability of C. jejuni to form attached biofilms was performed as described previously 
(Joshua et al., 2006). C. jejuni was grown in CBA blood agar plates at 37°C for 24h, 
suspended in BHI broth and adjusted to an OD600nm of 0.5. The bacterial suspension (1ml) 
was transferred to borosilicate glass tubes and incubated statically at 37°C for four days 
in microaerobic conditions, after which an attached pellicle in the gas-liquid interface was 
observed. For crystal violet staining, the glass tubes were washed twice with distilled 
water and let dry at 85°C for 30 minutes. Then, 1ml of 0.5% crystal-violet solution was 
added to the tubes and incubated at room temperature for 30 minutes with gentle shaking. 
Tubes were washed with distilled water and let dry at 85°C for 30 minutes. Lastly, 1ml of 
80% ethanol/20% acetone mixture was added for 15 minutes to dissolve the CV stain. 
Samples were transferred to 96-well plates in triplicate and the OD595nm was measured 
using an Infinite 200 PRO plate reader (Tecan). 
 
2.5.  Oxidative stress resistance assay 
C. jejuni was grown in CBA blood agar plates at 37°C for 24h, suspended in MH broth 
and adjusted to an OD600nm of 1. Aliquots of the bacterial suspension (100μl) were spread 
onto MH agar plates and a sterilised blank paper disc was placed at the centre of the 
plate. A 10μl aliquot of 100mM hydrogen peroxidase 30% solution (Sigma) was dropped 
onto the disc. The plates were incubated for 48h at 37°C microaerobically and the 
inhibition zone halos were posteriorly measured (mm). 
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2.6. Antibiotic susceptibility assays 
2.6.1. Antibiotic disc diffusion assay 
Antibiotic disc susceptibility of C. jejuni strains was determined according to the 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
recommendations (Sifre et al., 2015). C. jejuni was grown in CBA blood agar plates at 
37°C for 24h and suspended in 1ml of MH at an OD600nm of 0.5. The suspension (100μl) 
was spread onto MH agar supplemented with 5% lysed horse blood plates using a 
spreader. Antibiotic discs (Oxoid) were placed at the surface of the agar plates using 
sterile tweezers and plates were incubated for two days at 37°C under microaerobic 
conditions. Inhibition zone diameters were measured and interpreted accordingly to 
EUCAST zone diameter breakpoint (mm). For tetracycline 30μg disc sensitive (S) ≥30 
and resistant (R) <30 (Sifre et al., 2015).  
 
2.6.2. Microdilution broth assay 
The minimal inhibitory concentrations (MIC) were determined according to EUCAST 
recommendations (Sifre et al., 2015). The MIC of tetracycline (Sigma) for C. jejuni 81-
176 strains was determined by a micro dilution broth method, using MH-F broth (cation-
adjusted MH broth, 5% lysed blood, 20mg/L β-NAD). Briefly, 10μl of C. jejuni 
suspension in MH-F (OD600nm=0.5) was added to 90μl of two-fold dilutions of 
tetracycline in MH-F. Suspensions were transferred to a 96-well flat-bottomed microtiter 
plate (Corning) and incubated for two days at 37ºC under microaerobic conditions with 
shaking at 100rpm. The tetracycline concentration range tested was from 0.03μg/ml to 
500μg/ml, and control wells with no tetracycline were included. MICs were measured at 
OD600nm using an Infinite 200 PRO plate reader (Tecan). According to EUCAST, the 
tetracycline MIC breakpoint for C. jejuni is (S) for ≤2 and (R) >2 (Sifre et al., 2015).  
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2.7. In vitro co-culture assays 
2.7.1. Acanthamoeba polyphaga strain and culture conditions  
Acanthamoeba polyphaga (Linc Ap-1) was used in all experiments and was kindly 
provided by Dr. Bernard de La Scola, University de La Mediterranee in France. A. 
polyphaga was maintained in peptone yeast glucose (PYG) medium (1L: 20g protease 
peptone, 18g glucose, 1g yeast extract, 1g MgSO4 x 7H2O, 1g Na Citrate x 2H2O, 0.02g  
Fe(NH4)2(SO4)2 x 6H2O, 0.06g CaCl2, 0.14g  H2PO4, 0.35g  Na2HPO4 x 7H2O; 0.22μm 
filter sterilised; pH 6.8), aerobically at 25ºC in 75cm2 treated culture flasks (Thermo 
Scientific™). The concentration and viability of amoebae were determined by Trypan 
blue exclusion assay using 0.2% Trypan Blue (GE Hyclone) and haemocytometers 
(Immune Systems). To determine the viability of Acanthamoeba at different temperatures 
(25°C, 37°C and 42°C), Acanthamoeba was incubated in 50cm2 cell culture flasks 
(Thermo Scientific) in PYG medium for two, four and 24 hours. Amoebae cells were 
visualised by phase contrast microscopy with a 40x objective in an inverted cell culture 
microscope (Motic AE31).  
 
2.7.2. Intracellular survival and multiplication assay   
Co-culturing of C. jejuni with attached monolayers of A. polyphaga cells was conducted 
in 24-well plates. A. polyphaga cells were seeded at a density of 106 amoebae per ml in 
PYG medium and incubated at 25°C for two hours to allow the cells to settle and form a 
monolayer at the bottom of the well. Bacterial cells were harvested from overnight CBA 
blood agar plates, suspended in PYG medium and adjusted to OD600nm= 1. Then, 100μl of 
bacterial suspension was added to the wells with A. polyphaga achieving an MOI ranging 
from 100 to 400 bacteria per well. To allow for invasion to occur, co-cultures were 
incubated under aerobic conditions for two hours at 25ºC and 37ºC. Following co-
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incubation, wells were washed once with PYG medium and incubated aerobically with 
100μg/mL of gentamicin (Gibco) (this concentration was shown to be effective at fully 
eliminating extracellular bacterial cells in one hour). Following gentamicin treatment, the 
wells were washed three times with PBS and the amoebal cells were lysed with 0.1% 
(v/v) Triton X-100 (Sigma) for 10 minutes at room temperature, releasing the 
intracellular C. jejuni. Samples were serially diluted in PBS 1X (Fisher BioReagentTM) 
and plated onto CBA blood agar plates in duplicate, followed by two days incubation at 
37ºC in microaerobic conditions. For the longer incubation time-points (24, 48 and 72h), 
the wells were incubated with PYG medium without gentamicin. In the designated time-
points, prior to the addition of Triton 0.1%, the respective wells were re-incubated with 
gentamicin (100μg/ml) for one hour (modification of the standard gentamicin protection 
assay). Cells were washed three additional times with PBS 1X, lysed, diluted and plated 
in the same conditions as described above. To calculate the number of intracellular 
bacteria, the following formula was used: recovered C. jejuni (c.f.u) / total C. jejuni 
(c.f.u) x 100 = % of intracellular C. jejuni in A. polyphaga.  
 
2.7.3. Triton X-100 0.1% (v/v) resistance assay 
To test the sensitivity of C. jejuni 81-176 cmeB mutant strain to Triton X-100 0.1% (v/v), 
bacterial cells were harvested from overnight CBA blood agar plates suspended in BHI 
medium and adjusted to OD600nm=1 (initial inoculum). A 100μl aliquot of the initial 
suspensions of C. jejuni 81-176 wt, cmeB mutant and complement strains were serial 
diluted in PBS 1X and plated in CBA agar plates for the control c.f.u counts. The 
remaining initial suspension was then centrifuged for two minutes at 10.000xg speed and 
1ml of Triton X-100 0.1% (v/v) was added and cells were incubated for 15 minutes at 
RT. Bacterial suspensions in Triton detergent were serial diluted in PBS 1X and plated in 
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CBA blood agar plates. The c.f.u obtained after the detergent treatment were normalised 
with the c.f.u obtained in the initial inoculum plating. This assay was kindly conducted by 
my co-worker, Amiritha Ramesh. 
 
2.7.4. Extracellular survival assay  
To test extracellular survival of C. jejuni in the presence of amoebae, 100μl of bacterial 
inoculum prepared as described above was added to each of the 24 wells containing 1ml 
of 106 amoebae cells or 1ml of PYG medium only. The wells were incubated over a 
period of six days aerobically at 25°C. At each time-point, the culture medium was 
diluted in PBS, plated in CBA blood agar plates and incubated for 48 hours at 37ºC under 
microaerobic conditions for further bacterial c.f.u counts. 
 
2.8. Statistical analysis 
All experiments were repeated three times (biological replicates) with three technical 
replicates in each experiment, except where otherwise indicated, and the data were 
expressed as mean ± SD. Comparison of two groups was made with an unpaired, two-
tailed Student’s t-test. Mean differences were considered statistically non-significant (ns) 
when p values were above 0.05. For statistically significant differences: * for 
0.01<p≤0.05, ** for 0.001<p≤0.01 and *** for p≤0.001. ND stands for not detected. 
 
 
 
 
 
 57 
CHAPTER 3: Results 
 
Part I 
 
3.1. Identification and characterisation of Campylobacter jejuni strains 
 
3.1.1. Overview  
As noted earlier, different strains of Campylobacter jejuni display distinct structures of 
lipooligosaccharides (LOS), capsule and flagellum or the presence/absence of the 
virulence plasmid pVir, a result of high genetic variation, which leads to different 
capabilities to adhere/invade, survive or colonise various hosts (Young et al., 2007). In 
this part I of the results chapter the different C. jejuni strains used in this study are 
described along with how a chimeric strain of C. jejuni was created.    
 
3.1.2. Identification of C. jejuni strains 
The initial step in this study was to review the range of C. jejuni wild-type (wt) strains 
present in the laboratory -80°C bacterial collection to select the C. jejuni strain that was 
going to be used for the in vitro assays using Acanthamoeba polyphaga.  C. jejuni strains 
11168H, 81-176, G1 and X from the lab collection (as described in the methods section) 
were used throughout this study.  The Gram staining technique was used to check the 
purity of the different Campylobacter strains after 24h and 72h growth at 37°C in 
microaerobic conditions. The four wt strains were confirmed to be pure Gram-negative 
cells presenting a spiral shape at 24h (Fig. 3.1, A) and a coccoid form at 72h (Fig. 3.1, B), 
which is characteristic of Campylobacter bacteria.  
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Figure 3.1. Image of C. jejuni cells visualised using light microscopy. Spiral shaped 
cells can be seen at 24h (A) and coccoid cells at 72h (B). This figure is representative of 
the C. jejuni 11168H, 81-176, G1 and X strains tested. The strains were grown micro-
aerobically at 37°C for 24h and 72h and were prepared as described in Section 2.1.3. The 
samples were visualised under x100 magnification and images were taken with a Nikon 
80i microscope.  
 
To confirm the identity of the C. jejuni strains, PCR was conducted to amplify a unique 
gene present in each strain. To confirm the identity of the strains 11168H, 81-176, G1 
and X, the genes cj1435c, dmhA, tagF and moaA that encoded a putative phosphatase, a 
GDP-mannose 4, 6-dehydratase, a CDP-glycerol glycerophosphotransferase and a 
molybdenum cofactor biosynthesis protein A, respectively, were amplified by multiplex 
PCR using the respective primers described in Table 2.4. To detect the virulence and the 
tetracycline resistance plasmids pVir and pTet, respectively, in these strains a PCR with 
VirB11 and TetO primers was conducted in parallel. It was possible to distinguish 
different C. jejuni strains since each strain produced different size bands. Amplification 
of cj1435c, dmhA, tagF and moaA fragments were observed for strains 11168H, 81-176, 
G1 and X, respectively (Fig. 3.2, lanes 1-4).  The presence of plasmids pVir and pTet was 
observed for strains 81-176 and X, while they were absent in strains 11168H and G1 (Fig. 
B A 
   2μm    2μm 
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3.2, lanes 5-8 and lanes 9-12, respectively). Glycerol stocks of these C. jejuni strains in 
MH broth were stored in my personal -80°C bacterial collection.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.  Multiplex PCR for C. jejuni strain confirmation and for the detection of 
virulence and tetracycline resistance plasmids. PCR was conducted using DmhA, 
TagF, Cj1435c, TetO and VirB11 primers Lane L: 2-log DNA ladder; lane 1: 11168H - 
450bp; lane 2: 81-176 - 1021bp; lane 3: G1 A3 - 642bp; lane 4: X - 803bp; lane 5: 
11168H - no amplification; lane 6: 81-176 - 559bp; lane 7: G1 - no amplification; lane 8: 
X - 559bp; lane 9: 11168H - no amplification; lane 10: 81-176 - 708bp; lane 11: G1  - no 
amplification; lane 12: X - 708bp. 
 
3.1.3. Growth characteristics of C. jejuni strains   
Growth of four C. jejuni strains was assayed at 37°C in BHI broth for a period of 48 
hours microaerobically (Fig. 3.3). The strains tested were able to grow in BHI medium, 
but have different growth rates. Strains 81-176 and X were shown to have higher growth 
rates compared with both 11168H and G1 strains (Fig. 3.3). Strain G1 had a statistically 
significant lower growth rate than the other strains (24h: p=0.007; 30h: p=0.03 and 48h: 
p=0.01, in comparison with 11168H and p values<0.01 for these time-points in 
comparison with both 81-176 and X strains). C. jejuni strains 81-176 and X shared 
   L     1    2     3     4      L     5     6      7      8   L     9    10    11   12 
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similar growth rates with no statistically significant differences between these strains 
(24h, p=0.9; 30h; p=0.5 and 48h, p=0.09) (Fig. 3.3). Statistically significant differences 
of 81-176 and X strains in comparison with the reference strain 11168H were obtained 
for time-points 24h to 48h (81-176: 24h, p=0.01; 30h; p=0.007; 48h, p=0.01 and X: 24h, 
p=0.01; 30h; p=0.004; 48h, p=0.08). 
 
Figure 3.3. Growth of C. jejuni strains in BHI broth. C. jejuni strains 11168H, 81-176, 
G1 and X were grown in BHI broth at 37°C for 48h and are represented in blue, red, 
green and purple colours, respectively. Statistical analysis was conducted in relation to 
11168H strain. No statistically significant differences were observed for time-points 0 
and 6h among all strains tested. Values are mean ± SD from three independent 
experiments with one technical repeat each. 
 
As already mentioned, C. jejuni motility plays an important role in invasion of host cells 
(Lugert et al., 2015). In order to check the motility of the different C. jejuni wt strains, 
suspensions of these bacteria were transferred onto the surface of BHI soft-agar plates 
and incubated microaerobically for three days at 37°C. The average diameters of bacterial 
growth were compared visually (Fig. 3.4). It was observed that C. jejuni strains 11168H 
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and G1 shared similar growth in the motility plates (Fig. 3.4. A, C) whilst X was the least 
motile strain tested (Fig. 3.4, D). C. jejuni strain 81-176 was observed to be the most 
motile among these wt strains (Fig. 3.4, B).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Motility of C. jejuni strains in soft agar plates. BHI 0.4% soft agar plates 
were inoculated with the same amount of bacteria (A) 11168H, (B) 81-176, (C) G1 and 
(D) X for three days at 37°C. This figure is representative of three different assays with 
one technical repeat each and pictures were taken with the same magnification. 
 
As noted earlier, the ability to form biofilms is considered to be an important factor in the 
pathogenesis of C. jejuni, which helps in its survival in the environment (Bronowski et 
al., 2014). Biofilms are defined as matrix-enclosed bacterial population’s adherent to 
each other and/or to surfaces or interfaces (Costerton et al., 1995). C. jejuni is shown to 
produce three forms of biofilm in liquid culture: it may attach to a glass surface; form a 
pellicle at the liquid-gas interface in glass tubes and form non-attached and floating 
aggregates designated as flocs (Joshua et al., 2006).  
To check biofilm formation, the ability of the different C. jejuni wt strains to form flocs 
was tested using 25 cm2 tissue culture flasks containing bacterial suspensions in MH 
A B 
C D 
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broth which were incubated for three days at 37°C with slow speed shaking. Flocs were 
then visually observed and quantified according to those previously defined by Joshua et 
al. (2006) (Fig. 3.5).  All strains were able to form aggregates and, whilst C. jejuni strain 
11168H formed a large number of aggregates (Fig. 3.5, A), X strain exhibited one giant 
aggregate (Fig. 3.5, D). The G1 strain formed small sized aggregates (Fig. 3.5, C), whilst 
C. jejuni strain 81-176 presented normal size aggregates, but in a smaller amount than 
strain 11168H (Fig. 3.5, B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Flocs formation in C. jejuni strains. Quantification of non-attached 
aggregate formation (flocs) in BHI broth for C. jejuni strains was (A) 11168H, +++ (B) 
81-176, +++ (C) G1, + and (D) X, ++. Quantification of the aggregates was determined 
as previously reported, where +++ (extensive), ++ (intermediate) and + (small, just 
visible) (Joshua et al., 2006). This figure is representative of three different assays with 
one technical repeat.  
A B 
C D 
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One of the initial objectives was to infect amoebae cells with a C. jejuni GFP strain and 
visualise it using confocal microscopy to monitor the survival of C. jejuni within A. 
polyphaga. However, I failed to electroporate the GFP plasmid pMEK91 (Mixter et al., 
2003) into the C. jejuni strain 81-176 in our laboratory. Fortunately, Dr. Patricia Guerry 
(from the Naval Medical Research Centre) kindly provided us with a sample of the C. 
jejuni strain 81-146/GFP containing the plasmid pCPE111/28/GFP (Hickey et al., 2005). 
This C. jejuni strain 81-146/pCPE111/28/GFP was observed in a fluorescence 
microscope, and it showed a high level of fluorescence as expected (Fig. 3.6).  
 
 
 
 
 
Figure 3.6. Fluorescence microscopy of C. jejuni strains 81-176 and 81-176/ 
pCPE111/28/GFP. (A) 81-176 wt strain is non-fluorescent as opposite to the (B) 81-176/ 
pCPE111/28/GFP strain (provided by Dr, Patricia Guerry) which exhibits high 
fluorescence.  PCR was conducted to confirm the presence of both pTet and pVir plasmids 
in the fluorescent GFP strain (data not shown). Images were observed with 40x objective 
in a fluorescence microscope (Nikon Eclipse 80i). 
 
In summary, C. jejuni strain 81-176 contained both virulence and tetracycline plasmids, 
had a higher growth rate in BHI broth, was the most motile strain and was able to form 
biofilms. Furthermore, a fluorescent GFP derivative of this strain was available in the lab 
collection. Thus, C. jejuni 81-176 was selected as the best candidate strain for the 
amoebae experiments in this study. 
 
100 μm 
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3.1.4. Generation of the chimeric C. jejuni B7 strain 
A draft genome sequence of C. jejuni strain G1 was determined in our laboratory (Lehri 
et al., 2015). The gDNA from a strain located at the D6 position of the -80°C laboratory 
stock culture was collected after growth on a CBA plate supplemented with tetracycline 
(10μg/ml) at -80°C stock was used for genome sequencing. CLC genomics workbench 
software was used to assembly the genome of the assumed G1 strain, however, after 
analysis it was noticed that we actually sequenced the genome of strain 81-176 (Table 
2.4). Two distinct C. jejuni G1 bacterial stocks were used as controls (one located at 
position D6 and another located at A3 position in the laboratory collection) (Fig. 3.7). It 
was observed that the strain initially sequenced by my co-workers and myself was solely 
81-176 and not the intended G1 strain (Fig. 3.7, lane 1). In addition, it was observed that 
the strain G1 (D6) grown in Tet for further genome sequencing was contaminated with a 
high fraction of the 81-176 strain as it amplified both dmhA (1021bp) and tagF (642bp) 
size bands (Fig. 3.7, lane 2). The strain G1 (A3) was a pure culture (Fig. 3.7, lane 3).  
Because the initial G1 stock was contaminated with 81-176 and 10μg/ml of tetracycline 
was too high to allow for the former strain to grow, the strain that was initially sequenced 
was in fact pure 81-176 and not the intended G1 strain. The bacterial culture grown in 
tetracycline was kept in glycerol stock and was named B3. Eventually, my co-workers 
were able to use a pure stock of the G1 strain located in position A3 in the lab -80°C 
collection for genome sequencing (Lehri et al., 2015). 
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Figure 3.7.  Duplex PCR for confirmation of the C. jejuni G1 bacterial stock used for 
genome sequencing.  PCR was conducted using DmhA and TagF primers. Lane L: 2-log 
DNA ladder; lane 1: strain originally sequenced – 1021bp; lane 2: G1 D6 – 1021bp and 
642bp; lane 3: G1 A3 – 642bp.  
 
It should be noted that the -80°C stock of G1 from my personal bacterial collection was 
created from the G1 strain located at position A3 from the -80°C laboratory bacterial 
collection, which was shown to be pure G1 and was not contaminated with strain 81-176 
strain (Fig. 3.2, lane 3; Fig. 3.7, lane 3) and was used for the experimental work.  
 As previously mentioned, the concentration of Tet used was too high to support the 
growth of strain G1, which was, therefore, killed so that only strain 81-176 survived. As 
already noted, C. jejuni can easily acquire DNA from other strains (Parkhill et al., 2000). 
Since G1 and 81-176 strains were mixed-up in the G1 D6 bacterial stock and plated 
together on a tetracycline plate, which gave rise to the B3 culture. There was an interest 
in investigating if these strains exchanged genomic material during this stage. So, B3 
bacterial culture was plated onto CBA agar and a single clonal isolate was kept in 
glycerol stock. The latter was found to be a chimeric C. jejuni strain and named strain B7.  
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3.1.4.1. Comparison of the genome of B7 strain with other genomes   
The gDNA from strain B7 was isolated and Professor Karlyshev sequenced its genome.  
When the genome of C. jejuni strain B7 was compared with the reference strain 81-176 
using CLC genomic workbench software, a large number of mutations were observed in 
two specific parts of its genome, although there was still high similarity with strain 81-
176. From genome regions between CJJ81176_1102 to CJJ81-176_1117 and 
CJJ81176_1167 to CJJ81-176_1222 a higher number of mismatches was observed in the 
B7 strain in comparison with strain 81-176. The remaining part of the genome (from 
CJJ81176_0026 to CJJ81176_1223 and CJJ81176_1118 to CJJ81176_1166) was 
identical to strain 81-176, with the exception of the gene cjj81176_1449 (Fig. 3.8).  The 
genome regions presenting variation between the C. jejuni strains 81-176 and B7 (Fig. 
3.8) were identical between the latter strain and G1. Exceptionally, the B7 cjj81-
176_1449 gene presented a high number of mismatches when compared with both 81-
176 and G1 strains. Using NCBI nucleotide blast, the latter gene was shown to be 100% 
identical (100% query cover) to the cjj81176_pVir0048 gene from the C. jejuni strain 81-
176 virulence plasmid pVir (data not shown), possibly demonstrating that a plasmid gene 
was able to integrate itself into the chromosome of the respective bacterial strain. 
However, further evidence for this claim is still required. In summary, comparison of the 
genome of strain B7 with that of the strain G1 showed that the entire genome regions that 
were different between B7 and 81-176 strains were 100% identical with the G1 strain. 
Thus, it was concluded that strain B7 was a hybrid between strains G1 and 81-176 and 
that by growing together they were able to exchange part of their genome, confirming the 
ability of C. jejuni to acquire exogenous DNA. Examples of proteins in strain G1 that 
were encoded by the genes that were integrated intothe chromosome of the strain 81-176 
were the transcription-repair coupling factor Mfd and the S-ribosylhomocysteinase LuxS.
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Figure 3.8. Comparative analysis of the genome sequences of C. jejuni strains B7, 81-176 and G1. B7 sequencing reads were mapped onto the 
genome of 81-176 using CLC Genomics Workbench software. The yellow, red, blue or green vertical lines highlighted represent the mismatches 
between the G, A, C and T nucleotide bases, respectively, of a sequence region in B7 strain in comparison with strain 81-176.  
A  
B7
Cluster showing a high number of mismatches Cluster showing no mismatches 
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3.1.4.2. Origin and identification of strain B7  
LuxS is an enzyme that catalyses the production of the auto inducer signalling molecule 
AL-2 (Plummer et al., 2012). To distinguish between C. jejuni strains B7, G1 and 81-
176, primers for luxS gene amplification were designed using the OligoCalc online tool 
(Table 2.4). The luxS gene was selected since it is identical to that in the G1 strain and is 
found in the chromosome of strain B7.  PCR using the LuxS and the identification 
primers DmhA and TagF was conducted to distinguish between these strains. The primers 
were designed to identify the two versions of the luxS gene where LuxS-81-176, a 
forward primer that amplified a region for the C. jejuni 81-176 luxS gene and LuxS-G1, a 
forward primer that amplified a region of C. jejuni G1 luxS gene (Fig. 3.9). The reverse 
primer LuxS-rev amplified an identical downstream region identical in both C. jejuni 
strains G1 and 81-176.  
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Score Identities Gaps 
784 bits(424) 468/490(96%) 0/490(0%) 
Query  2    TGCCATTATTAGATAGTTTTAAAGTTAATCATACCAAAATGCCAGCGCCCGCTGTGCGTT  
61             ||||||||||||| || ||||||||| | ||||| ||||||||||| || 
|||||||||| Sbjct  
TGCCATTATTAGACAGCTTTAAAGTTGACCATACTAAAATGCCAGCTCCTGCTGTGCGTT  60  Query  
62   TAGCTAAAGTTATGAAAACACCTAAGGGTGATGATATTAGTGTATTTGATTTGCGTTTTT  121             
|||||||||||||||||||||||||||||||||||||||| || |||||||||||||||| Sbjct  
TAGCTAAAGTTATGAAAACACCTAAGGGTGATGATATTAGCGTGTTTGATTTGCGTTTTT  120  
Query  122  GCGTACCAAATAAAGACATTATGAGCGAAAAAGGTACACATACCTTAGAACATTTATTTG  
181             || |||||||||||||||||||||||||||||||||| 
|||||||||||||||||||||| Sbjct  
GCATACCAAATAAAGACATTATGAGCGAAAAAGGTACTCATACCTTAGAACATTTATTTG  180  Query  
182  CAGGATTTATGAGAGATCATCTTAATTCAGATTCGGTTGAAATCATTGATATTTCACCTA  241             
||||||||||||||||||||||||||||| |||| |||||||| |||||||||||||||| Sbjct  
CAGGATTTATGAGAGATCATCTTAATTCAAATTCAGTTGAAATTATTGATATTTCACCTA  240  Query  
242  TGGGCTGTCGTACGGGTTTTTATATGAGTTTAATTGGAACACCAGATGAAAAAAGTGTTG  301             
|||| ||||| |||||||||||||||||||||||||||||||| ||||| |||||| ||| Sbjct  
TGGGTTGTCGCACGGGTTTTTATATGAGTTTAATTGGAACACCTGATGAGAAAAGTATTG  300  Query  
302  CAAAAGCTTGGGAAGAAGCTATGAAAGATGTTTTAAGCGTAAGCGATCAAAGCAAAATTC  361             
||||||||||||||| ||| |||||||||||||||||||||||||||||||||||||||| Sbjct  
CAAAAGCTTGGGAAGCAGCCATGAAAGATGTTTTAAGCGTAAGCGATCAAAGCAAAATTC  360  Query  
362  CTGAACTTAATATCTATCAATGCGGAACTTGCGCAATGCATTCTTTAGATGAAGCCAAAC  421             
||||||||||||||||||||||||||||||| |||||||||||||||||||||||||||| Sbjct  
CTGAACTTAATATCTATCAATGCGGAACTTGTGCAATGCATTCTTTAGATGAAGCCAAAC  420  Query  
422  AAATTGCCCAAAAGGTTTTAAATCTAGGTATTAGCATAATGAATAACAAAGAATTAAAAC  481             
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Sbjct  
AAATTGCCCAAAAGGTTTTAAATCTAGGTATTAGCATAATGAATAACAAAGAATTAAAAC  480  Query  
482   
TCGAGAATGC  491              
|||||||||| Sbjct  481   
TCGAGAATGC  490  
Figure 3.9. BlastN result of the luxS gene from C. jejuni strains 81-176 and G1. To 
distinguish between the three C. jejuni strains B7, 81-176 and G1, primers for luxS gene 
amplification were designed. The forward primer LuxS-81-176 was used for 
amplification of the wt luxS version that is found in strain 81-176 (yellow). The primer 
LuxS-G1 was used for amplification of the allele version of the luxS gene found in both 
G1 and B7 strains (blue). The difference between both these forward primers is 
highlighted in red (T replaced by C).  
 
For the PCRs with the LuxS primers specific conditions were used: the gDNA from the 
samples was diluted 10 times, the denaturation step was performed with 20 cycles only 
and the annealing temperature was 60°C. As expected, in C. jejuni G1 strain there was 
amplification of a 642bp size band corresponding to tagF gene (Fig. 3.10, lane 1) and in 
both B7 and 81-176 strains amplification of a 1021bp corresponding to dmhA gene was 
observed (Fig. 3.10, lanes 2,3). Moreover, as expected, there was no amplification of the 
tetO and virB11 genes in this strain (Fig. 3.10, lane 4). On the contrary, in both B7 and 
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81-176 strains amplification of a 659bp and 748bp bands corresponding to the latter 
genes was observed, confirming the presence of the tetracycline and virulence plasmids 
(Fig. 3.10, lanes 5, 6). With the LuxS-G1 primer amplification of a 760bp size band in 
both 81-176 and B7 strains, corresponding to the allele version of the luxS gene was 
observed (Fig. 3.10, lanes 7, 8). As expected, no amplification of this luxS version was 
observed for 81-176 wt (Fig. 3.10, lane 9). However, it was expected to be the other way 
around when using the primer LuxS-81-176. Whilst in C. jejuni strain 81-176 the 
expected band for the luxS wt version was seen (Fig. 3.10, lane 12), in both strains B7 
and G1 there was also a 760bp band (Fig. 3.10, lanes 10-11). As this 760bp band was 
always observed in different C. jejuni strains with the luxS allele version when using the 
LuxS-81-176 primer (data not shown), it was assumed that the reason for the appearance 
of this unexpected band was likely caused by mis-priming during PCR. 
In summary, strain B7 could be distinguished from G1 and 81-176 wt strains by PCR if it 
amplifies a 1021bp size band using the DmhA primers and at the same time no 
amplification should be observed when using the LuxS-G1/LuxS-Rev primers.  
 
 
 
 
 
 
 
Figure 3.10. PCR analysis of C. jejuni strains G1, B7 and 81-176.  PCR was conducted 
using gDNA sample diluted 10 times; with 60°C annealing temperature; 20 denaturation 
cycles and the primers DmhA, TagF, pTet, pVir, LuxS-81-176 and LuxS-G1.  lane L: 2-
log DNA ladder; lane 1: G1 – 642bp; lane 2: B7 – 1021bp; lane 3: 81-176 – 1021bp; lane 
4: G1 – no amplification; lane 5: B7 – 559bp and 748bp; lane 6: 81-176– 559bp and 
748bp; lane 7: G1- 760bp; lane 8: B7 – 760bp; lane 9: 81-176 – no amplification; lane 10: 
G1 – 760bp; lane 11: B7 – 760bp; lane 12: 81-176 – 760bp.  
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To determine the origin of the C. jejuni chimeric B7 present the B3 culture, a PCR with 
the LuxS primers and identification primers was conducted with twelve single clonal 
isolates of B3 strain growing on CBA agar with no antibiotic supplementation. Control 
strains G1, B3, 81-176 and B7 were included (Fig. 3.11). Amplification of a 642bp size 
band corresponding to tagF was observed for strain G1, whilst a 1021bp size band 
correspondingto the dmhA gene was observed for the three latter strains (Fig. 3.11, A). To 
distinguish between the chimeric strain B7 and the 81-176 wt, a PCR was conducted 
using the LuxS-G1 primers (Fig. 3.11, B). 
As expected, in the control strains G1, B3 and B7 there was amplification of a 760bp 
band corresponding to the allele version of the luxS gene (Fig. 3.11B, lanes 17, 18, 20) 
and in the 81-176 wt strain no PCR product was observed (Fig. 3.11B, lane 19). Only in 
three B3 clonal isolates there was a 760bp band corresponding to the allele version of the 
luxS gene (Fig. 3.11B, lanes 22, 25 and 27), whilst in the other nine clones there was no 
PCR product (Fig. 3.11B, lanes 21, 23, 24, 26, 28-32). This shows that the fraction of C. 
jejuni strain B7 in the B3 stock culture was 25%. The same PCR analysis was conducted 
with some clonal isolates of G1 D6 original bacterial stock that was contaminated with 
81-176 and no chimeric strains were detected (data not shown). This suggests that the 
chimeric strains were created after plating G1 D6 culture (mixture of G1 + 81-176 
strains) onto CBA medium containing a high tetracycline concentration, which gave rise 
to the B3 heterogeneous culture (81-176 + B7 strains). The pure chimeric strain, named 
B7, was obtained by plating the B3 culture to single colonies onto CBA agar plates. In 
summary, the chimeric B7 strain was strain 81-176 containing parts of the genome from 
G1 (Fig. 3.12).   
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Figure 3.11. PCR analysis of C. jejuni B3 clonal isolates. The primers DmhA, TagF 
and LuxS-G1 primers were used and the G1, B7 and 81-176 strains were included as 
controls. (A) lane L: 2-log DNA ladder; lane 1: G1 – 642bp; lane 2: B3 – 1021bp; lane 3: 
81-176 – 1021bp; lane 4: B7 – 1021bp; lanes 5-16: B3 clonal isolates – 1021bp; (B) lane 
L: 2-log DNA ladder; lane 17: G1  – 760bp; lane 18: B3 – 760bp; lane 19: 81-176 – no 
amplification; lane 20: B7 – 760bp; lanes 22, 25, 27: B3 clonal isolates – 760bp; lanes 21, 
23, 24, 26, 28-32: B3 clonal isolates – no amplification.  
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Figure 3.12. Schematic representation of how the chimeric C. jejuni strain B7 was 
created.  
 
The growth of C. jejuni B7 strain was compared with that of C. jejuni 81-176 wt strain in 
BHI broth at 37°C for 48h, where the former strain was shown to grow somewhat better 
than the latter (Fig. 3.13). From time-point 24h onwards the growth differences among 
these strains were statistically significant (24h: p=0.0317; 48h: p=0.0008; p=0.0009) (Fig. 
3.13).  
Figure 3.13. Growth of C. jejuni strains 81-176 and B7. The growth of C. jejuni strains 
81-176 (dark purple) and B7 (light purple) was assessed in BHI broth for two days and 
OD600nm was measured in different time-points. Values are mean ± SD from three 
independent experiments with one technical replicate each. 
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3.1.4.3. Tetracycline resistance of strain B7 
Since B7 strain was created after growth of B3 on a tetracycline plate, it was assumed 
that the chimeric strain B7 was probably generated due to selective pressure and that this 
strain could be more resistant to tretacycline than 81-176. One clue for this hypothesis 
was the fact that one of the genes that was transferred from G1 to the strain 81-176 was 
the mutation frequency decline mfd gene (Fig. 3.14). This gene encodes for a 
transcription-repair coupling factor involved in strand-specific DNA repair. This gene 
was also shown to be important for antibiotic resistance (e.g. to tetracycline) in different 
foodborne pathogens (e.g. Helicobacter pylori) (Lee et al., 2009) and for fluoroquinolone 
resistance in C. jejuni (Han et al., 2008)  
It was presumed that, due to antibiotic pressure, the mfd gene was horizontally transferred 
from strain G1 to 81-176 creating a strain with a different antibiotic resistance profile.
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Figure 3.14. Comparative analysis of the mfd gene from C. jejuni strains G1, 81-176 and B7. Using CLC genomics workbench software, (A) B7 
sequencing reads were mapped onto the genome of 81-176 and (B) G1 sequencing reads were mapped onto the genome of B7 strain. The yellow, red, 
blue or green vertical lines highlighted represent the mismatches between the G, A, C and T nucleotide bases, respectively, of (A) B7 mdf sequence in 
comparison with 81-176 strain and (B) B7 mdf sequence in comparison with G1 strain. 
A B 
Cluster showing a high 
number of mismatches 
Cluster showing no 
mismatches 
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Tetracycline resistance of C. jejuni strain B7 was assessed and compared with that of wt 
strain 81-176 in both liquid and solid media. Antibiotic resistance was tested on CBA 
agar plates supplemented with increasing tetracycline concentrations (5 to 75μg/ml) and 
in BHI broth supplemented with doubling tetracycline concentrations (3.9 to 250μg/ml) 
(Fig. 3.15, A-B, respectively). No differences were observed in the growth of C. jejuni 
strains B7 and 81-176 in CBA plates supplemented with increasing concentrations of 
tetracycline, as both strains were able to grow in 50μg/ml of Tet, but failed to grow in 
agar plates supplemented with 75μg/ml of Tet (Fig. 3.15, A).  
In parallel, minimal inhibitory concentrations (MIC) of Tet were determined for these 
strains in BHI broth supplemented with 5% lysed blood and doubling concentrations of 
Tet and the bacterial strains were incubated at 37°C for 2 days. According to the 
EUCAST recommendations, the quality control ranges for tetracycline in Campylobacter 
were established for testing at both 37°C for 48h or 42°C for 24h (Ge et al., 2013; Sifré et 
al., 2015). In addition, it is recommended that if there is insufficient bacterial growth 
after 24h incubation period at 37°C, as observed in the experiments of this study, 
Campylobacter should be incubated for an extra 24 hours (Ge et al., 2013; Sifré et al., 
2015). It was observed that the Tet MIC for both 81-176 and B7 strain was 62.5μg/ml, 
showing that neither of these strains were able to grow above this Tet concentration and 
shared the same Tet resistance level (Fig. 3.15, B). Although the same starting OD600nm 
for both strains was used, B7 strain grew better than 81-176 when no antibiotic was 
present in the medium. This is in accordance with the results obtained in Fig. 3.13. This 
indicates that strain B7 is able to grow faster than the wt strain 81-176. 
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Figure 3.15. Tetracycline susceptibility of the chimeric C. jejuni strain B7.  
Tetracycline resistance of B7 strain (red) was compared with that of 81-176 strain (blue) 
and determined by (A) growth of these strains in CBA agar plates supplemented with 
increasing concentrations of Tet, ranging from 5 to 75μg/ml and (B) by the micro dilution 
broth method. The bacterial strains were incubated for 2 days at 37°C. Values are mean ± 
SD from three independent experiments. 
A 
B 
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Part II 
 
3.2. Molecular mechanisms of Campylobacter jejuni resistance to antibiotics  
 
3.2.1. Overview 
Knowledge of the association between virulence and antibiotic resistance is increasing, 
leading to prolonged survival of pathogenic bacteria (Beceiro et al., 2013). Bacterial 
virulence and antibiotic resistance share common characteristics, such as both processes 
are required for bacteria to survive under harsh conditions (virulence mechanisms are 
necessary to overcome host defence and development of AR is essential to enable 
pathogenic bacteria to surpass antimicrobial therapies and to adapt to and survive in 
competitive and demanding environments). In addition, bacterial factors involved in 
virulence are often involved in AR (e.g. multidrug efflux pumps) and AR is greatly 
associated with infections and is, therefore, related to virulence (Beceiro et al., 2013). In 
this section of the results, antibiotic resistance mechanisms of different C. jejuni strains 
were explored. Experimental work covered in the following section includes mainly 
different Tet resistance assays and construction of C. jejuni G1 cmeB mutant and 
derivative strains.  
 
3.2.2. Genome sequencing of C. jejuni strain G1  
As previously mentioned, C. jejuni G1 and 11168H strains do not contain pTet and pVir 
plasmids (Fig. 3.2). Despite the absence of the tetracycline resistance plasmid pTet in G1, 
it was previously observed that this strain was able to grow in the presence of tetracycline 
whilst strain 11168H could not, suggesting that other mechanisms may be associated with 
Tet resistance in the former strain (Lehri et al., 2015). 
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The genome of C. jejuni strain G1 (A3) was sequenced by co-workers in our laboratory 
and its genome was then compared with that of a reference strain NTCT 11168 using 
CLC genomics software. A remarkable difference between the CmeABC operons of 
these two strains, especially in the cmeB gene was revealed (Fig. 3.16), whilst the 
surrounding areas showed considerable conservation (Lehri et al., 2015). Protein blast 
showed 81% identity between the CmeB amino acid sequences of these two strains, 
whilst there was 99% similarity between the amino acid sequences of 11168H and 81-176 
strains.  
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Figure 3.16. Comparative analysis of the cmeABC operons of C. jejuni strains G1 and NTCT 11168. G1 sequencing reads were mapped onto the 
cmeABC operon of 11168 using CLC genomics Workbench software. The yellow, red, blue or green vertical lines highlighted represent the 
mismatches between the G, A, C and T nucleotide bases, respectively, of G1 cmeB in comparison with the cmeB from strain 11168. The white areas 
represent areas without similarity between the G1 cmeB and the cmeB from 11168 strain (Lehri et al., 2015).  
         Cluster showing a high number of mismatches 
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CmeB is already known to be involved in C. jejuni resistance to antibiotics and to act 
synergistically with other resistance mechanisms to increase AR (Iovine, 2013). This 
supports the observed increased resistance of C. jejuni strain G1 to tetracycline in 
comparison with 11168H, which was probably related with the cmeABC operon. 
Tetracycline resistance was tested for C. jejuni G1 wt and cmeB mutants in order to check 
if the contribution of this efflux pump to AR was dependent on the cmeB sequence 
variation. 
 
3.2.3. Generation of C. jejuni cmeB mutant and derivative strains 
To test sequence variation contribution of cmeB to tetracycline resistance, 11168H, G1 
and 81-176 cmeB mutants and complemented strains were generated. In this section, it is 
shown in detail how the G1 cmeB mutant strain was constructed. In addition, a derivative 
of G1 containing the pTet plasmid from strain 81-176 was generated. These constructs 
and the respective wt strains were further assayed to detect variation in antibiotic 
resistance.  
 
3.2.3.1. Generation of G1/cmeB::kanr mutant 
Construction of the G1/cmeB::kanr mutant strain was achieved by inactivation of the C. 
jejuni G1 gene cmeB through insertion of a kanamycin resistance (kanr) cassette, as 
described in the literature (Vieira et al., 2017). Briefly, the cmeB PCR product was 
purified and cloned into pGEM-T easy vector by ligation and transformed into E. coli 
cells. After transformation E. coli colonies were verified for the presence of cmeB gene 
by PCR and the orientation of the cmeB gene in the pGEM-T/cmeB plasmid was checked 
in several clones by restriction analysis, by which the clone in the forward orientation 
was used for the insertion of the kanr gene.  
 82 
The pJMK30 plasmid was digested with SmaI and the 1.5kb kanr fragment was extracted 
and purified before ligation to the pGEM-T/cmeB plasmid. The kanr was then ligated to 
the pGEM-T/cmeB recombinant plasmid and transformed into E. coli cells. To confirm 
the orientation of the kanr cassette in the recombinant plasmid, restriction maps were 
constructed using the SalI enzyme (Fig. 3.17). In the forward orientation of kanr cassette, 
the sizes of fragments were 6653bp and 1000bp (Fig. 3.17, A), whereas, in the reverse 
orientation of this cassette, the sizes of fragments were 5188bp and 2465bp (Fig. 3.17, B).  
The ligation mixture was transformed into E. coli cells producing colonies on LB 
supplemented with kanamycin (50μg/ml). The CloneChecker kit was used to confirm the 
orientation of the kanr in the clones transformed with pGEM-T/cmeB/kanr plasmid. The 
clone with the cassette in the forward orientation was confirmed by restriction digestion 
with SalI (Fig. 3.17, C) and was then selected for further transformation of C. jejuni G1 
wt via electroporation. It is important to select the clone in the forward orientation to 
avoid a polar mutation that would affect the expression of the downstream genes in the 
operon (cmeA and cmeC).   
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Figure 3.17. Restriction analysis of pGEM-T/cmeB/kanr recombinant plasmid with 
SalI. Restriction digestion maps using NEBcutter online tool of pGEM-T/cmeB/kanr 
digested with SalI, showing the kanr in the (A) forward orientation and (B) reverse 
orientation. (C) Restriction digestion analyse with SalI. Lane L: 2-log DNA ladder; lane 
1: uncut pGEM-T/cmeB/kanr; lane 2: pGEM-T/cmeB/kanr digested with SalI – 6653bp + 
1000bp (forward orientation).  
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Lysates of three C. jejuni clones were tested to confirm the presence of kanr by PCR 
using the CmeB primers. The expected size of the PCR product in the G1/cmeB::kanr 
should be 4.6kb (3.1kb size of cmeB  + 1.5kb size of the kanr cassette). The difference of 
the 1.5kb among the cmeB gene bands of wt and mutants indicates the presence of kanr in 
the mutant strains. Confirmation that the mutants were the G1 strain was conducted by 
PCR using the TagF primers (Fig. 3.18). 
As mentioned previously, a similar procedure was used for construction of the cmeB 
mutant strains in C. jejuni strains 11168H and 81-176.  
 
 
 
 
 
 
 
 
Figure 3.18. Confirmation of C. jejuni G1/cmeB::kanr mutant. Gel electrophoresis 
analysis of the lysates of three C. jejuni G1/cmeB::kanr clonal isolates. Lane L: 2-log 
DNA ladder; lane 1: G1 – 642bp; lanes 2-4: G1/cmeB::kanr– 642bp; lane 5: G1 – 3.1kb; 
lanes 6-8: G1/cmeB::kanr– 4.6kb.  
 
3.2.3.2. Generation of G1/cmeB::kanr/cmeB derivative 
Complementation of C. jejuni G1/cmeB::kanr was attempted using pRRC plasmid as the 
gene delivery vector, a technique that has previously been  shown to be successful 
tagF 
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(Karlyshev & Wren 2005). Complementation CmeB primers were designed (Table 2.7, 1) 
and the cmeB gene was amplified by a high fidelity PCR, digested with XbaI and cloned 
into pRRC, a plasmid containing a camr cassette. After transformation of the recombinant 
plasmid pRRC/cmeB/camr into C. jejuni G1/cmeB::kanr cells  for further integration of 
the camr cassette into one of the three rRNA clusters where cmeB would be under the 
control of the constitutive camr gene promoter. After transformation of the recombinant 
plasmid in E. coli cells, the CloneChecker kit was used for restriction analysis with ClaI 
enzyme to check the orientation of the cmeB gene in the pRRC plasmid. It was 
considered important that the cmeB was cloned in the forward orientation so that the camr 
promoter could express this gene. Unfortunately, all clones tested either had the cmeB 
fragment cloned in the reverse (incorrect) orientation (Fig. 3.19, lanes 2, 4, 7) or did not 
have this fragment cloned in the pRRC (Fig. 3.19, lanes 1, 3, 5, 6), which could be due to 
inefficient ligation reaction.  
 
 
 
 
 
 
 
Figure 3.19. Using CloneChecker for selection of a pRRC/cmeB plasmid 
with camr cassette insert. Lane L: 2-log DNA ladder; lane 1: pRRC – 5115bp and 730bp; 
lanes 2, 4, 7: pRRC/cmeB/camr in the reverse orientation – 7156bp + 730bp + 1136bp; 
lanes 3, 5, 6: empty pRRC – 5115bp and 730bp.  
1.2k
3kb 
    L                  1                 2               3                4                5               6               
6kb 
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Further to the failure using the pRRC plasmid, complementation via the same gene 
delivery system technique was attempted, but this time using another plasmid. The 
plasmid pRED1 containing the egfp gene was used to select recombinant clones via 
fluorescence. New complementation primers were used (Table 2.7, 2) to amplify the 
cmeB gene from C. jejuni G1. The PCR product was then purified and digested with 
Eco53KI and XbaI enzymes and ligated to the pRED1 plasmid digested with SwaI and 
XbaI and dephosphorylated. The ligation mixture was then transformed into E. coli cells 
and the CloneChecker kit was used for restriction analysis using ClaI to check for the 
clones lacking fluorescence (egfp was cut out after digestion and replaced by cmeB 
fragment, so these clones were no longer fluorescent). The clones with the cmeB in the 
correct orientation (Fig. 3.20) were further sent for sequencing to check for the presence 
of mutations.  
 
 
 
 
 
 
 
Figure 3.20. Using CloneChecker for selection of a pRED1/cmeB plasmid 
with camr cassette insert. Lane L: 2-log DNA ladder; lane 1: pRED1 – 5901bp + 730bp; 
lanes 2-4: E. coli clones with pRED1/cmeB/camr in the forward orientation – 5901bp + 
730bp + 2384bp.  
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The recombinant plasmid pRED1/cmeB/camr was electroporated into C. jejuni 
G1/cmeB::kanr strain and plated onto CBA supplemented with Cm (10μg/ml). To confirm 
the insertion of the camr cassette into the three rRNA clusters, primers 
Ak233/234/235/237 were used (Table 2.7). PCR using these latter primers and the TagF 
and CmeB primers was conducted with transformants of G1/cmeB::kanr with the 
recombinant plasmid pRED1/cmeB/camr (Fig. 3.21). The control pRRC plasmid was 
successfully transformed in the G1/cmeB::kanr as demonstrated by the 2.8kb size band 
when using the primer pair Ak233/Ak237 insertion primers for the camr cassette (Fig. 
3.21, lane 8). Another control condition was the successful transformation of the 
recombinant plasmid pRED1/cmeB/camr in the G1 wt, which was demonstrated by the 
2.8kb band using the Ak233/Ak237 primer pair (Fig. 3.21, lane 3). However, no 
transformants were obtained when the recombinant pRED1/cmeB/camr was 
electroporated into the C. jejuni G1/cmeB::kanr, demonstrated by the absence of a band 
when using the Ak primers (Fig. 3.21, lanes 13-15), which could be due to low 
transformation efficiency of the G1/cmeB::kanr competent cells. In addition, for an 
unexplained reason, the G1/cmeB::kanr strain might not accept the foreign DNA used, 
which might be degraded by the nucleases inside the bacterial cells. Different stocks of C. 
jejuni cmeB mutant strain competent cells were prepared; however, no positive results for 
transformation with the recombinant plasmid were observed. This complementation 
strategy was attempted with another C. jejuni strain, 11168H, but, again, without success. 
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Figure 3.21. PCR analysis of C. jejuni G1/cmeB::kanr/cmeB insertion derivatives. 
PCR was conducted with TagF, CmeB and Ak233/234/235/237 primers Lane L: 2-log 
DNA ladder; lane 1: G1+pRED1/cmeB/camr – 642bp; lane 2: G1+pRED1/cmeB/camr – 
3.1kb; lanes3-5: G1+pRED1/cmeB/camr – no amplification; lane 6: 
G1/cmeB::kanr+pRRC – 642bp; lane 7: G1/cmeB::kanr+ pRRC – 4.6kb; lane 8: 
G1/cmeB::kanr+pRRC – 2.8kb; lanes 9-10: G1/cmeB::kanr+ pRRC no amplification; 
lane 11: G1/cmeB::kanr +pRED1/cmeB/camr – 642bp; lane 12: 
G1/cmeB::kanr+pRED1/cmeB/camr – 4.6kb; lanes 13-15: 
G1/cmeB::kanr+pRED1/cmeB/camr  no amplification. 
 
Since complementation of the C. jejuni G1/cmeB::kanr mutant using the pRRC gene 
delivery system failed, another approach was attempted. 
The cmeB gene is required for AR in C. jejuni and thus, it could act as an antibiotic 
resistance marker. The strain C. jejuni G1/cmeB::kanr/cmeB was constructed via 
homologous recombination and considered a repair strain as this is a strain in which the 
mutant allele was replaced by the wt allele. The genomic DNA from the C. jejuni G1 wt 
strain was transformed into G1/cmeB::kanr/cmeB mutant via electroporation and 
transformants were selected in CBA agar supplemented with 10μg/mL of 
chloramphenicol, a concentration which did not support the growth of G1/cmeB::kanr, but 
allowed the growth of G1 wt strain. Due to the selective pressure, this bacterial strain was 
forced to replace the kanr cassette from its genome so that it would re-integrate the cmeB 
gene by homologous recombination and restore the AR required for its survival. A 
similar procedure was used for construction of the derivative of C. jejuni 81-176 strain, 
but these transformants were selected on CBA agar supplemented with 10μg/mL of 
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tetracycline, a concentration which did not support the growth of the 81-176/cmeB::kanr 
mutant strain, but allowed for the 81-176 wt strain to grow. PCR using the respective 
TagF and CmeB primers was conducted to confirm the complementation derivatives of 
C. jejuni G1/cmeB::kanr (Fig. 3.22).  The repaired strain derivatives were confirmed by 
amplification of a 3.1kb size band corresponding to the wt version of the cmeB gene (Fig. 
3.22, lane 5). The G1 wt and G1/cmeB::kanr mutants were used as positive and negative 
controls, respectively (Fig. 3.22, lanes 2-3). The repaired strains were designated C. 
jejuni G1/cmeB::kanr/cmeB and C. jejuni 81-176/cmeB::kanr/cmeB. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22. PCR analysis of C. jejuni G1/cmeB::kanr/cmeB repair strain obtained 
by homologous recombination. PCR was conducted using TagF and CmeB primers. 
Lane L: 2-log DNA ladder; lane 1: G1 – 642bp; lane 2: G1 – 3.1kb; lane 3: 
G1/cmeB::kanr – 4.6kb; lane 4: G1/cmeB::kanr/cmeB – 642bp; lane 5: 
G1/cmeB::kanr/cmeB – 3.1kb. 
 
 
The objective of this part of the work was to construct a complementation derivative of 
C. jejuni G1/cmeB::kanr mutant with the cmeB genes from both G1 and 11168H strains. 
These strains were selected as the pTet plasmid was absent and they presented different 
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tetracycline resistance levels, a possible result of a large difference in their cmeB 
nucleotide sequences. The idea was to complement the C. jejuni G1/cmeB::kanr mutant 
with both G1 and 11168H cmeB genes using the same method so that the two different 
cmeBs would be under the control of the same promoter and expressed at the same level 
in C. jejuni strain G1. Thus, if the tetracycline resistance levels were different between C. 
jejuni G1 strains with the different cmeBs, this would confirm that nucleotide sequence of 
the cmeB gene was very important in determining the AR levels in C. jejuni. However, it 
was not possible to ligate the 11168H cmeB gene in the pRED1 plasmid, as the E. coli 
transformants tested by restriction analysis were empty pRED1 vectors and this was most 
likely due to technical errors (data not shown).  
 
3.2.3.3. Generation of C. jejuni G1/pTet derivative 
C. jejuni strains G1 and 81-176 present large differences in their cmeB nucleotide 
sequences. As already mentioned, CmeB is known to act together with pTet to confer 
high antibiotic resistance (Iovine, 2013). It was hypothesised that if C. jejuni strain G1 
received the pTet plasmid from C. jejuni strain 81-176, G1 would probably become more 
resistant to Tet than the latter strain. To test this hypothesis, conjugation was conducted 
between strains 81-176 and G1. It was first necessary to find an antibiotic that allowed 
growth of C. jejuni strain G1, but not strain 81-176. An antibiotic disc assay was 
conducted where bacterial suspensions of these strains were plated onto MH blood agar 
plates topped with several different random antibiotics and plates were incubated for 
three days to measure the zones of inhibition (Fig. 3.23). The higher the inhibition zone, 
the more susceptible was the strain to the antibiotic. It was observed that both C. jejuni 
strains G1 and 81-176 were fully resistant to ceftazidime, cefoxitin, linezolid, methicillin, 
penicillin G, rifampicin and trimethoprim antibiotics in the concentrations used (Fig. 
3.23).  Although C. jejuni strain 81-76 was slightly more resistant to amikacin, 
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erythromycin and gentamicin than G1, these differences were not statistically significant. 
Overall, C. jejuni strain G1 was significantly more resistant to the vast majority of the 
antibiotics tested (amoxicillin, ampicillin, chloramphenicol, cefquinome, clarithromycin, 
clindamycin and mupirocin) than strain 81-176.  
Since G1 was fully resistant to ampicillin (10μg/ml) as opposed to strain 81-176, this 
antibiotic was selected for the conjugation experiment (Fig. 3.23).
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Figure 3.23. Antibiotic susceptibility of C. jejuni strains G1 and 81-176. The susceptibility of C. jejuni strains G1 (black bars) and 81-176 (beige 
bars) to different antibiotics was tested by disc diffusion assay over a 48h incubation period at 37°C, according to EUCAST recommendations. 
Absence of bars indicates full resistance of the C. jejuni strains. Amikacyn (AK), amoxicillin (AML), ampicillin (AMP), chloramphenicol (C), 
ceftazidime (CAZ), cefquinome (CEQ), ciprofloxacin (CIP); clarithromycin (CLR), gentamycin (CN), clindamycin (DA), erythromycin (E), cefoxitin 
(FOX), linezolid (LZD), methicillin (MET), mupirocin (MUP), penicillin G (P), rifampicin (RD) and trimethoprim (W). The antibiotic concentration 
used (μg/ml) is presented in brackets. Values are mean ± SD from three independent experiments with three technical replicates each.
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For conjugation, the bacterial mixture was then plated onto CBA supplemented with both 
15μg/mL of tetracycline that forced G1 strain to receive the pTet plasmid as without it, it 
would not be able to survive in this high Tet concentration and 10μg/mL of ampicillin, 
the latter did not support the growth of C. jejuni strain 81-176, but allowed strain G1 to 
grow (Fig. 3.23). PCR of the conjugation transformants with the primers TagF, DmhA, 
pTet and pVir was conducted to confirm the G1/pTet derivatives (Fig. 3.24). C. jejuni G1 
and 81-176 wt strains were used as controls (Fig. 3.24, lanes 1-2, 11-12).  Eight G1/pTet 
transformants were shown to be G1, as expected, since a 642bp size band corresponding 
to G1 tagF fragment was obtained (Fig. 3.24, lanes 3-10). Except for one of the 
transformants (Fig. 3. 24, lane 14) the other seven amplified the tetO gene (Fig. 3.24, 
lanes 12, 13, 15-20), confirming that pTet plasmid was successfully transferred from C. 
jejuni 81-176 to G1 strain. In addition, and as expected, no pVir plasmid was present in 
the G1/pTet derivatives (Fig. 3.24, lanes 13-20).  
 
 
 
        
Figure 3.24. Duplex PCR analysis for confirmation of the C. jejuni G1/pTet 
derivatives. PCR was conducted with lysates of the conjugation transformants. Lane L: 
2-log DNA ladder; lane 1: 81-176 – 1021bp; lane 2: G1 – 642bp; lanes 3-10: G1/pTet 
isolates - 642bp; lane 11: 81-176 – 708bp + 559bp; lane 12: G1 – no amplification; lanes 
13, 15-20: G1/pTet transformants - 559bp; lanelane 14: negative G1/pTet transformants – 
no amplification.  
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3.2.4. Tetracycline resistance levels of C. jejuni wt, mutant and derivative strains 
The minimal inhibitory concentrations to Tet of C. jejuni strains 81-176, G1 and 11168H 
and the respective cmeB mutants as well as the derivative strain G1/pTet were determined 
by the micro dilution broth method in MH broth supplemented with 5% lysed blood over 
a 48h incubation period at 37°C, according to the EUCAST recommendations (Sifre et 
al., 2015). The MIC values obtained for the different C. jejuni strains, as well as the fold-
change difference in Tet resistance between the wt strains and the respective cmeB 
mutants, (three clonal isolates were tested for each strain) are shown in Table 3.1. 
Complementation of C. jejuni G1 and 81-176 cmeB mutants restored the level of Tet 
resistance (data not shown). As expected, in comparison with the other strains tested 81-
176 exhibited a higher level of Tet resistance due to the presence of the pTet plasmid. 
Mutation of the cmeB gene in this strain, led to a 8-fold decrease in the Tet resistance 
levels. Importantly, a 16-fold difference in the Tet resistance levels was observed 
between G1 and 11168H with G1 strain having higher resistance to this antibiotic. In 
addition mutation of cmeB in 11168H and G1 strains resulted in 2-fold and 32.5-fold 
reduction in tetracycline resistance, respectively. The latter results were confirmed by 
growth of C. jejuni 81-176, G1 and 11168H wt strains and three clonal isolates of the 
G1/cmeB::kanr in CBA plates supplemented with 2μg/ml of tetracycline. It was observed 
that strains 81-176 and G1 were able to grow at this Tet concentration, whilst 11168H 
and G1/cmeB::kanr clonal isolates could not (Fig. 3.25, A). Strikingly, transfer of pTet 
plasmid from C. jejuni 81-176 to G1 strain by conjugation made the latter eight times 
more resistant to Tet than the donor C. jejuni strain 81-176 carrying this plasmid (Table 
3.1). Due to the large 250-fold increase in the Tet resistance of G1/pTet compared with 
the wt strain, three clonal isolates of this derivative and the control 81-176 and G1 strains 
were plated onto CBA medium supplemented with 250μg/ml of tetracycline to confirm 
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these results. It was observed that indeed the three G1/pTet derivatives were able to grow 
in a high Tet concentration, whilst the wt strains could not (Fig. 3.25, B).  
These findings possibly suggest that the CmeB of C. jejuni strain G1 has a higher activity 
to excrete this drug than its homologues in C. jejuni strains 11168H and 81-176.  
 
 
 
Table 3.1. Tetracycline susceptibility of C. jejuni wt, mutant and derivative strains  
   -, absence or disruption of the gene; +, presence or integrity of the gene. MIC values 
were determined by the microdilution broth method over an incubation period of 48h 
at 37°C. Values are mean ± SD from three independent experiments with three 
technical replicates each 
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Fig. 3.25. Growth of C. jejuni wt, mutant and derivative strains on CBA plates 
supplemented with different tetracycline concentrations. (A) C. jejuni strains (1) 81-
176; (2) G1; (3) 11168H; (4) G1/cmeB::kanr clone 1; (5) G1/cmeB::kanr clone 2; (6) 
G1/cmeB::kanr clone 3 plated onto CBA supplemented with 2μg/ml of tetracycline. (B) 
C. jejuni strains (1) 81-176; (2) G1; (7) G1/pTet clone 1; (8) G1/pTet clone 2; (9) 
G1/pTet clone 3 plated onto CBA supplemented with 250μg/ml of tetracycline.  
 
3.2.5. Antibiotic susceptibility of different C. jejuni strains  
Resistance to other antibiotics, such as aminoglicosides, amphenicols, β-lactams, 
fluoroquinolones, lincosamides, macrolides and rifamycins of different C. jejuni strains was 
also tested. As previously shown in Figure 3.23, C. jejuni strain G1 was significantly more 
resistant to the majority of the antibiotics tested than strain 81-176. An antibiotic disc 
diffusion assay was also conducted to test resistance of C. jejuni strains G1 and 11168H 
strains (Fig. 3.26, A). It was observed that strain G1 was significantly more resistant to 
amoxicillin, ampicillin, chloramphenicol, cefquinome, ciprofloxacin, clarithromycin, 
clindamycin, mupirocin, oxytretracycline and tetracycline antibiotics. No statistically 
significant differences between these two strains were observed in AR to the other 
antibiotics tested (amikacyn, gentamicin and erythromicin) (Fig. 3.26, A). Interestingly, AR 
resistance levels of C. jejuni strains 11168H and 81-176 were very similar, except for 
tetracycline due to the presence of the pTet plasmid in strain 81-176 (Fig. 3.26, B).  In 
addition, strain 11168H was significantly more resistant to the β-lactams, amoxicillin and 
ampicillin (Fig. 3.26, B).  
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Figure 3.26. Antibiotic susceptibility of C. jejuni G1, 11168H and 81-176 strains. (A) 
The susceptibility of C. jejuni strains G1 (black bars) and 11168H (grey bars) and (B) C. 
jejuni strains 11168H (grey bars) and 81-176 (beige bars) to different antibiotics was tested 
by disc diffusion assay over a 48h incubation period at 37°C, according to EUCAST 
recommendations. Absence of bars indicates full resistance of the C. jejuni strains. 
Amikacyn (AK), amoxicillin (AML), ampicillin (AMP), chloramphenicol (C), ceftazidime 
(CAZ), cefquinome (CEQ), ciprofloxacin (CIP); clarithromycin (CLR), gentamycin (CN), 
clindamycin (DA), erythromycin (E), cefoxitin (FOX), linezolid (LZD), methicillin (MET), 
mupirocin (MUP), oxytetracycline (OT), penicillin G (P), rifampicin (RD), tetracycline (TE) 
and trimethoprim (W). The antibiotic concentration used (μg/ml) is presented in brackets. 
Values are mean ± SD from three independent experiments with three technical replicates 
each. 
A
B
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In summary, these findings show that strain G1 is much more resistant to various 
categories of antibiotics than the two other wt strains 11168H and 81-176.  
To determine if the cmeB sequence variation in G1 was also responsible for the resistance 
to other antibiotics rather than only Tet, an antibiotic disc diffusion assay was conducted 
on C. jejuni G1 wt and cmeB mutants (three clonal isolates) (Fig. 3.27). It was observed 
that the G1 wt and the three G1/cmeB/kanr mutants were fully resistant to the antibiotics 
penicillin, rifampicin and trimethoprim most likely because the concentrations of these 
antibiotics tested (1, 2 and 5μg/ml, respectively) were too low (Fig. 3.27). On the other 
hand, when cmeB was mutated in G1 strain, resistance to the other antibiotics tested was 
greatly decreased. The antibiotic resistance differences obtained between the wt and 
G1/cmeB/kanr clonal isolates were statistically significant (p<0.01) (Fig. 3.27). C. 
jejuni/cmeB::kanr mutants were highly susceptible to the antibiotics tested, confirming 
what was described in the literature that cmeB is required for AR. In addition, it suggests 
that the difference in the nucleotide sequence of the cmeB gene in these C. jejuni wt 
strains may be the cause of the different levels of AR observed.  
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Figure 3.27. Antibiotic susceptibility of C. jejuni strains G1 and G1/cmeB/kanr. The susceptibility of C. jejuni strains G1 (black bars) and 
G1/cmeB::kanr mutants (clonal isolate 1, blue bars; clonal isolate 2, green bars; clonal isolate 3, purple bars) to different antibiotics was tested by disc 
diffusion assay over a 48h incubation period at 37°C, according to EUCAST recommendations. Absence of bars indicates full resistant of the C. jejuni 
strains. Amikacyn (AK), amoxicillin (AML), ampicillin (AMP), chloramphenicol (C), ceftazidime (CAZ), cefquinome (CEQ), ciprofloxacin (CIP); 
clarithromycin (CLR), gentamycin (CN), clindamycin (DA), erythromycin (E), cefoxitin (FOX), linezolid (LZD), methicillin (MET), mupirocin 
(MUP), oxytetracycline (OT), penicillin G (P), rifampicin (RD), tetracycline (TE) and trimethoprim (W). The antibiotic concentration used (μg/ml) is 
in brackets. Except for P, RN and W antibiotics differences of p<0.01 were obtained between C. jejuni G1 wt strain and the three G1/cmeB/kanr 
mutants. Values are mean ± SD from three independent experiments with three technical replicates each. 
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Additionally, to check if the C. jejuni cmeB could work with other efflux systems as a 
membrane component and confer resistance to tetracycline in other bacterial species, an 
E. coli strain susceptible to Tet was used. As previousely mentioned, cmeA, cmeB and 
cmeC are homologues of the E. coli acrA, acrB and tolC genes, respectively. According 
to the manufacturer (NEB) of this E. coli strain there is no evidence that the AcrAB-TolC 
efflux system was deleted. MIC values were determined for E. coli NEB transformed 
with pRED1/cmeB plasmid (cmeB from C. jejuni G1) (Fig. 3.28). E. coli wt and E. coli 
transformed with an empty pRED1 plasmid were used as controls. The plasmid pRED1 
was selected since it does not require an inducer to express the gene and the former is 
constitutively expressed. It was observed that expression of cmeB in E. coli did not alter 
the tetracycline resistance levels of this strain since the Tet MIC values for E. coli wt, E. 
coli/pGEM-T and E. coli/pGEM-T/cmeB was the same (0.5μg/ml) (Fig. 3.28).  
Figure 3.28. Tetracycline susceptibility of E. coli expressing the C. jejuni G1 cmeB 
gene. Serial dilutions of tetracycline were tested for E. coli NEB wt strain (blue bars), E. 
coli/pRED1 plasmid (red bars) and E. coli/pRED1/cmeB (green bars) by the 
microdilution broth method over a 24h incubation period at 37°C, according with the 
EUCAST reccommendations. The Tet MIC value for the three E. coli strains was 
0.5μg/ml. Values are mean ± SD from three independent experiments with three technical 
replicates each. 
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Overall, it was demonstrated that the contribution of CmeABC MDR pump to antibiotic 
resistance was not only dependent on the different levels of regulation of this gene operon 
(Lin et al., 2005; Cagliero et al., 2007; Guo et al., 2008; Perez-Boto et al., 2015), but 
may also be due to its sequence variation observed in this study, which is in accordance 
with what was previously observed (Cagliero et al., 2006; Yao et al., 2016). Since 
nucleotide sequence differences were predominantly limited to cmeB, the variation in the 
efficiency of this pump may be primarily associated with the product of this gene, 
although other contributors, such as other components of the CmeABC multidrug efflux 
pump as well as the cmeR transcriptional repressor cannot be excluded (Tables 3.2-3.4). 
In addition, secondary efflux pumps might also be responsible for these antibiotic 
resistance differences. Further studies are therefore required to check the main role of 
CmeB.  
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Table 3.2. Sequence identities between C. jejuni G1 cmeA, cmeB, cmeC and cmeR genes 
and their respective proteins in comparison with those of strain 11168H. 
 C. jejuni G1  
C. jejuni 11168H 
CmeABC/R  
Amino acid sequence 
identity 
Nucleotide sequence 
identity 
CmeA 97% (100%)* 96% (100%) 
CmeB 81% (100%) 80% (99%) 
CmeC 99% (98%) 98% (100%) 
CmeR 94% (100%) 93% (100%) 
**The numbers between brackets represent the coverage %.   
 
Table 3.3. Sequence identities between C. jejuni G1 cmeA, cmeB, cmeC and cmeR genes 
and their respective proteins in comparison with those of strain 81-176. 
 C. jejuni G1  
C. jejuni 11168H 
CmeABC/R  
Amino acid sequence 
identity 
Nucleotide sequence 
identity 
CmeA 97% (100%)* 96% (100%) 
CmeB 82% (100%) 80% (100%) 
CmeC 99% (98%) 98% (100%) 
CmeR 95% (100%) 94% (100%) 
**The numbers between brackets represent the coverage %.   
 
Table 3.4. Sequence identities between C. jejuni 81-176 cmeA, cmeB, cmeC and cmeR 
genes and their respective proteins in comparison with those of strain 11168H. 
 C. jejuni 81-176  
C. jejuni 11168H 
CmeABC/R 
Amino acid sequence 
identity 
Nucleotide sequence 
identity 
CmeA  98% (100%)*  98% (100%) 
CmeB 98% (100%)  99% (100%) 
CmeC 99% (100%) 99% (100%) 
CmeR 99% (100%) 99% (100%)  
**The numbers between brackets represent the coverage %.   
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Part III 
 
3.3. Molecular mechanisms of Campylobacter jejuni survival in Acanthamoebae  
 
3.3.1. Overview 
As already noted, in addition to a role in multidrug resistance, the Campylobacter 
CmeABC RND-type multidrug efflux pump may also be involved in virulence. The 
protozoan Acanthamoeba may act as a vector for various pathogenic bacteria and is 
considered to be a good model for investigation of bacterial survival in the environment. 
In part III of the results section the relation between Campylobacter jejuni and the 
protozoa, Acanthamoeba polyhaga, and two possible factors involved in this interaction, 
CmeB and capsule production were investigated. In addition, the role of CmeB in 
biofilm, oxidative stress and motility was explored.  
 
3.3.2. Setup of the in vitro co-culture assays 
         Although A. polyphaga is considered to be easy to handle experimentally, a few initial 
trial experiments were conducted. Due to its lifestyle, Campylobacter is likely to 
encounter a wide range of environmental conditions including different temperatures 
(Stintzi, 2003). So, firstly A. polyphaga viability was tested at distinct temperatures (25, 
37 and 42°C) and at different time-points (2h, 4h and 24h). The temperatures 25°C and 
37°C were selected for this study to mimic environmental and human host temperatures 
respectively. The temperature 42°C was selected since it is the body temperature of 
chickens. It was observed that at both 25ºC and 37ºC, A. polyphaga was able to replicate 
since the number of throphozoite cells increased with time (Fig. 3.29). In contrast, at 
42ºC A. polyphaga was not able to replicate, and although it was still viable, it changed to 
the dormant cyst form; however, this process was reversible when shifted back to 37ºC 
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(Fig. 3.29). Overall, these eukaryotic organisms could be maintained in PYG medium for 
long periods of time, especially at environmental temperatures such as 25°C.  
 
 
 
 
Figure 3.29. Phase-contrast microscopy of A. polyphaga cultured at different 
temperatures. These cells were grown at 25°C, 37°C and 42°C for 2, 4 and 24 hours. 
Cells grown at 42°C overnight were shifted back to 37°C for one week. Throphozoite 
form and replication of the amoebic cells were observed at both 25°C and 37°C but not at 
42°C. 
 
The multiplicity of infection (MOI) is important for the outcome of infection (Dasti et al., 
2010). So, to determine the MOI, the bacterial numbers of C. jejuni cells OD600nm=1 was 
quantified. A loop of bacterial cells was inoculated in PYG broth and adjusted to 
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OD600nm=1. Then, the bacterial suspensions were serially diluted 10-fold in PBS and 50μl 
aliquots were plated in duplicates onto a CBA blood agar plate (triplicate assay). It was 
observed that, although the number of colonies varied slightly between the different 
assays, these were always seen in dilution -6 (data not shown). The c.f.u/ml was 
calculated by dividing the number of colonies that were multiplied by the dilution factor 
with the volume of culture plated. C. jejuni at an OD600nm=1 was equivalent to 2-4 x 10
9 
c.f.u/ml, as this depends on growth conditions, especially growth time.  
Although 100μg/ml of gentamicin is widely used to kill extracellular bacteria in the co-
culture experiments, this concentration was tested during the outset of this experimental 
work. For that, C. jejuni suspension in PYG medium was inoculated with amoebae cells 
and further incubated at 25ºC for two hours. Then, the co-culture was incubated for one 
hour with 100μg/ml of gentamicin, after which the supernatant (co-culture medium) was 
collected and plated onto a CBA blood plate (Fig. 3.30). As a control C. jejuni in co-
culture medium without gentamicin was also plated in parallel (Fig. 3.30, A). As 
expected, it was observed that 100μg/ml of gentamicin was sufficient to kill all bacterial 
cells (Fig. 3.30, B). In addition, the viability of the amoebae cells incubated with 
gentamicin was not affected (data not shown). So, for all the co-culture experiments in 
this study, 100μg/ml of gentamicin was used to kill the extracellular bacteria for 
quantification of intracellular bacteria.  
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Figure 3.30. Extracellular C. jejuni 81-176 before and after gentamicin treatment. 
The co-culture medium (A) without gentamicin and (B) with 100μg/ml of gentamicin was 
plated onto CBA agar plates.  
 
3.3.3. Quantification of C. jejuni 81-176 in co-culture assays 
During co-culture of C. jejuni with A. polyphaga, the former can be quantified 
extracellularly or intracellularly. To quantify extracellular bacteria, the supernatant was 
diluted and plated onto CBA agar plates. To detect the intracellular bacteria, amoeba cells 
were treated with gentamicin, lysed and plated onto CBA blood agar. For bacteria 
quantification in medium alone, C. jejuni was incubated in the same conditions, but in 
PYG with no amoebae (Fig. 3.31). It was observed that there was 1-log decrease in the 
bacterial numbers of extracellular bacteria in medium alone as compared with bacteria in 
the initial inoculum. In addition, the number of C. jejuni inside the amoebae cells was 
significantly lower (105 c.f.u/ml) as compared with the initial inoculum and the 
extracellular bacteria (108 c.f.u/ml) (Fig. 3.31).  
 
A B 
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Figure 3.31. Quantification of C. jejuni strain 81-176 in co-culture with A. polyphaga. 
The quantity of bacterial cells in the initial inoculum (dark blue); in the medium alone 
(dots); extracellularly (horizontal strips) and intracellularly (diagonal stripes) is 
represented. Values are mean ± SD from three independent experiments with three 
technical replicates each. 
 
3.3.4. Quantification of C. jejuni within A. polyphaga 
To evaluate the numbers of different C. jejuni wt strains inside A. polyphaga, the MOI 
used ranged between 200-400 bacteria per cell depending on the initial c.f.u/ml of the 
bacterial inoculum. To normalise the numbers of the intracellular bacteria recovered in 
each assay, the initial bacterial inoculum was always plated. The intracellular bacterial 
numbers were determined at time-point 0h. This was defined as the time-point 
immediately after the first gentamicin. A statistically significant increase in the 
intracellular bacterial numbers for C. jejuni strain 81-176 in comparison with strains 
11168H, G1 and X was observed (p=0.003; p=0.007; p=0.0016, respectively), indicating 
that the former strain invaded and/ or survived better inside this amoebic host (Fig. 3.32).  
Although it was expected that lower numbers of C. jejuni strains 11168H and G1 would 
be found inside amoebae due to the absence of the virulence plasmid, this was not 
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expected for C. jejuni X, a strain that contains the virulence plasmid (Fig. 3.32). One 
explanation could be the fact that different C. jejuni strains present high variability in 
their capsular polysaccharides structure, and that capsule was shown to be involved in 
bacterial invasion of host cells and virulence (Bacon et al., 2000).  
Overall, C. jejuni strain 81-176 was selected for the co-culture in vitro experiments since 
this strain survived better in the amoebae host.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.32. Quantification of C. jejuni strains within A.  polyphaga. Quantification 
of intracellular bacteria was determined by viable counts at 0h post-gentamicin 
treatment at 25°C in aerobic conditions. Values are mean ± SD from three independent 
experiments with three technical replicates each. 
 
 
3.3.4.1. Quantification of C. jejuni 81-176/pCPE111/28/GFP within A. polyphaga 
Since one objective of this study was to perform microscopy of amoebae cells infected 
with C. jejuni strain 81-176/pCPE111/21GFP, the intracellular bacterial numbers within 
amoebae was determined as previously described. This was done to confirm that survival 
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of the GFP strain was the same as the wt strain, so that the microscopy observations could 
be extrapolated to the C. jejuni 81-176 strain. It was observed that although the 81-
176/pCPE111/21GFP strain survived reasonably well compared to the wt strain in A. 
polyphaga, this difference was not statistically significant (p=0.3) and thus, 81-
176/pCPE111/21GFP strain could be used in the microscopy experiments (Fig. 3.33), 
which unfortunatly was not performed.  
 
 
Figure 3.33. Quantification of intracellular 81-176 wt and 81-176/pCPE111/28/GFP 
strains within A.  polyphaga. Quantification of intracellular bacteria was determined by 
viable counts at 0h post-gentamicin treatment at 25°C in aerobic conditions.  Values are 
mean ± SD from three independent experiments with three technical replicates each. 
 
 
 
3.3.5. Extracellular survival of C. jejuni in the presence of A. polyphaga  
The number of viable extracellular bacteria in co-culture with A. polyphaga was 
monitored for a 6-day period and compared with C. jejuni in medium alone at 25°C. At 
96h post-infection a statistically significant increase in the bacterial counts (p=0.044) was 
observed when compared with bacteria incubated in medium alone. Moreover, after six 
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days of incubation the presence of amoebae still allowed the isolation of viable bacteria 
whilst none could be detected in their absence (Fig. 3.34). After 72h incubation one 
would expect the Campylobacter in the absence of amoebae to be coccoid (viable but not 
cultural cells) however, it was observed viable bacterial counts. As it is highly doubtful 
that these are not Campylobacter cells, it could mean that Campylobacter cells are 
culturable under the conditions used in this experiment. It would be relevant to repeat this 
experiment to check its reproducibility and investigate further this issue. These results 
also indicate that amoebae can prolong survival of extracellular C. jejuni in the 
environment.   
 
Figure 3.34. Extracellular survival of C. jejuni 81-176 in the presence of A. 
polyphaga at 25°C. Extracellular survival was determined by viable counts at 0, 5, 24, 
48, 72, 96 and 144 hours post-infection at 25°C in aerobic conditions. Grey bars represent 
bacterial numbers for C. jejuni 81-176 in co-culture with A. polyphaga and white bars 
correspond to when in PYG medium alone. Values are mean ± SD from three 
independent experiments with three technical replicates each. 
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3.3.6. Interaction between C. jejuni 81-176 and A. polyphaga 
To elucidate the interaction between C. jejuni and amoebae, at this stage of the project, 
it was decided to optimise the standard gentamicin protection method.          
 
3.3.6.1. Strain 81-176 is able to survive and multiply within A. polyphaga 
The standard gentamicin protection method was modified by adding an extra hour of 
gentamicin treatment at longer incubation time-points (from 24h after gentamicin 
treatment up to 72h) before lysing the cells to make sure only internal bacteria were 
quantified. This avoided quantification of bacteria that were attached, or which had 
escaped to the extracellular medium and were potentially capable of re-invasion. By 
using the modified version of this method a substantial difference in the numbers of 
intracellular bacteria when compared with the standard version at both 25°C (Fig. 
3.35, A) and 37°C (Fig. 3.35, B) temperatures was observed.   
As expected, at time-point 0h, no significant difference was observed in bacterial 
counts between both standard and modified methods. On the other hand, at 25°C a 
significant difference was detected at 5h and 24h time-points (90%, p=0.031 and 80%, 
p=0.000027, respectively) (Fig. 3.35, A). This data indicated that C. jejuni was able to 
invade and survive inside amoebae at 25°C for a certain period of time. At 37°C the 
decrease in intracellular bacterial numbers at 24h post-gentamicin treatment was even 
more pronounced when using the modified gentamicin method, and a highly 
significant difference was also observed for the later time-points (24h, p=0.03; 48h, 
p=0.0.0011; 72h, p=0.0003) (Fig. 3.35, B). With both methods, an initial reduction in 
the viable counts was followed by increase after prolonged incubation, suggesting 
bacterial multiplication (Fig. 3.35, B).   
In summary, these data support both the extra- and intracellular mode of survival of C. 
jejuni when co-cultured with A. polyphaga under different temperatures.  
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Figure 3.35. C. jejuni 81-176 is able to survive and multiply within A. polyphaga. (A) 
Intracellular survival of strain 81-176 was determined by viable counts at 0, 5 and 24h 
post-gentamicin treatment at 25°C and (B) intracellular multiplication at 0, 24, 48 and 
72h post-gentamicin treatment at 37°C in aerobic conditions. Black bars represent 
bacterial counts for 81-176 obtained by the standard gentamicin protection assay and grey 
bars represents bacterial counts for 81-176 obtained by a modified version developed in 
this study. Values are mean ± SD from three independent experiments with three 
technical replicates each. 
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A modified gentamicin protection method, in which a lower concentration of gentamicin 
was constantly maintained, has been employed previously (Chu et al., 2010). However, 
using this method we observed that C. jejuni was not able to survive and/or multiply 
intracellularly and was not detected after 48h post-infection (Fig. 3.36), probably because 
this antibiotic was able to enter the amoebae cells during prolonged incubation periods. 
This observation is in accordance with the previous studies reporting the ability of 
gentamicin to enter the host cells during prolonged incubation and to kill intracellular 
bacteria (Drevets et al., 1994; Elsinghorst, 1994).  
 
Figure 3.36. Continuous incubation with low concentrations of gentamicin kills 
intracellular C. jejuni 81-176. Intracellular multiplication of strain 81-176 (black bars) 
was determined by viable counts at 0, 5, 24 and 48h after the secondary gentamicin 
treatment at 37°C in aerobic conditions. For the time-points 5 to 48h the co-culture wells 
were incubated continuously with 10μg/ml gentamicin before lysis of the amoebae cells. 
ND (not detected). Values are mean ± SD from three independent experiments with three 
technical replicates each. Statistically significant differences were observed for 5h 
(p=0.041) and 24h (p=0.037).  
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3.3.7. CmeB is beneficial for survival and multiplication of C. jejuni within A. 
polyphaga 
As previously mentioned, different CmeB homologues have been shown to be required 
for bacterial virulence and host cell invasion and so, it was decided to check whether 
CmeB was involved in the interaction between C. jejuni strain 81-176 and A. polyhaga. 
 
3.3.7.1. Confirmation of 81-176 cmeB mutant and complement strains 
To investigate the role of C. jejuni CmeB transporter in survival and multiplication within 
amoebae, the cmeB gene of C. jejuni strain 81-176 was inactivated by insertional 
mutagenesis to create the 81-176/cmeB::kanr mutant, in similar way to that described 
previously (see Section 3.2.3.1).  Complementation was achieved by replacement of the 
mutated gene with its wild type copy and the the repaired strain derivative was selected 
by using a tetracycline concentration that did not support growth of the mutant strain 
(Section 3.2.3.2). Construction of the mutant strain and its complementation derivative 
was confirmed by PCR using the DmhA and CmeB primers (Fig. 3.37, A). Increased 
fragment size with the latter indicates insertion of the kanr cassette. Except for time-point 
30h (p=0.02), the mutation had no impact on the overall bacterial growth rate (Fig. 3.37, 
B).  
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Figure 3.37. Growth of C. jejuni 81-176 is not affected by cmeB mutation (A) PCR 
results: Lane L: 2-log DNA ladder; lane 1: 81-176 – 1021bp; lane 2: 81-176/cmeB::kanr – 
1021bp;  Lane 3: 81-176/cmeB::kanr/cmeB – 1021bp; lane 4: 81-176 – 3.1kb; lane 5: 81-
176/cmeB::kanr – 4.6kb;  Lane 6: 81-176/cmeB::kanr/cmeB – 3.1kb. (B) Growth rates of 
81-176 wt (black), 81-176/cmeB::kanr mutant (light grey) and 81-176/cmeB::kanr/cmeB 
derivative (dark grey). Values are mean ± SD from three independent experiments with 
one technical replicate each. 
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3.3.7.2. Involvement of CmeB in the interaction between C. jejuni and A. polyphaga  
 Using the modified gentamicin assay, it was observed that at 25°C the 81-
176/cmeB::kanr mutant strain was less able to survive intracellularly compared with the 
wt 81-176  (time-point 0h, a 10-fold reduction compared to wt, p=0.018) (Fig. 3.38, A). 
The difference between the wt strain and its isogenic cmeB mutant was even more 
profound at 5h and 24h (Fig. 3.38, A). At 37°C the intracellular bacterial numbers of the 
81-176/cmeB::kanr mutant strain were also significantly lower (time-point 0h, 6-fold 
lower than the wt, p=0.0021) (Fig. 3.38, A). At 24, 48 and 72h there was more than a 47, 
36 and 1263-fold reduction (p=0.031, p=0.027 and p=0.0000039, respectively) in the 
intracellular numbers of the cmeB mutant strain compared with the wt (Fig. 3.38, B). 
Although there was a small increase in internal bacterial numbers for 81-176/cmeB::kanr 
at 48 and 72h post-gentamicin treatment, the difference between these time-points in this 
strain was not statistically significant (p=0.24 and p=0.09)  (Fig. 3.38, B). 
Complementation of the C. jejuni 81-176 cmeB mutant strain restored the phenotype in 
all experiments.  
 In summary, these results indicate that C. jejuni CmeB is required for the interaction 
between this pathogen and the host amoebae.  
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Figure 3.38. CmeB is required for survival and multiplication of C. jejuni 81-176 
within A. polyphaga. (A) Intracellular survival was determined by viable counts at 0, 5 
and 24h post-gentamicin treatment at 25°C and (B) intracellular multiplication at 0, 24, 
48 and 72h post-gentamicin treatment at 37°C, in aerobic conditions. Colour coding: 
black, 81-176 wt; white, 81-176/cmeB::kanr mutant; grey, 81-176/cmeB::kanr/cmeB 
complementation derivative. Values are mean ± SD from three independent experiments 
with three technical replicates each.  
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The tissue culture experiments involved lysis of eukaryotic cells with 0,1% of Triton X-
100 for 15 minutes at RT. As C. jejuni cmeB mutant strain was shown to be susceptible to 
this detergent by minimum inhibitory concentration testing (Lin et al., 2003), 
experiments were performed to ensure that any data obtained were genuine and not 
experimental artefacts. The effect of Triton X-100 0.1% (v/v) was investigated by 
simulating its use in cell culture experiments, where this detergent was added to the 
bacteria during a short exposure time. Under these conditions bacterial counts for C. 
jejuni 81-176/cmeB::kanr mutant were similar to the wt and complement strains after 
exposure to Triton X-100 0.1% (v/v) (Fig. 3.39). Also, the bacterial counts were similar 
before and after addition of this detergent for the three strains tested. These data indicate 
that Triton X-100 0.1% (v/v) had no detrimental effect on cell viability during the time-
span of the experiments. 
 
 
Figure 3.39. CmeB mutation had no effect on the resistance to Triton X-100 0.1% 
(v/v) of strain 81-176. Bacteria were in the exponential phase of growth (OD600nm=1) 
for this experiment and the initial inoculum was plated as control and to normalise the 
viable counts after exposure to this detergent. Colour coding: blue, C. jejuni 81-176 wt; 
green, C. jejuni 81-176/cmeB::kanr mutant; red, 81-176/cmeB::kanr /cmeB 
complementation derivative. Values are mean ± SD from one independent experiment 
with three technical replicates. 
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3.3.8. Capsule production is beneficial for survival of C. jejuni within A. polyphaga 
As previously mentioned, the capsular kpsM gene was shown to be required for C. jejuni 
virulence and invasion of INT407 (Bacon et al., 2000). So, it was decided to mutate the 
kpsM gene to check if capsule production was required for the intracellular survival of C. 
jejuni strains G1 and 81-176 in A. polyphaga.  
 
3.3.8.1. Confirmation of G1 and 81-176 kpsM mutants 
A non-polar kpsM mutant of C. jejuni 11168H strain (Karlyshev & Wren, 2001) present 
in the laboratory bacterial collection was used to create the C. jejuni G1 and 81-176 kpsM 
mutant strains, denominated C. jejuni G1/kpsM::kanr and C. jejuni 81-176/kpsM::kanr, 
respectively. Briefly, the gDNA of C. jejuni 11168H/ kpsM::kanr was extracted using the 
Gentra Puregene Yeast/bacteria Kit from Qiagen and transformed individually into G1 
and 81-176 via electroporation. Transformants of C. jejuni G1/kpsM::kanr and C. jejuni 
81-176/kpsM::kanr were selected on CBA blood agar plates supplemented with 
kanamycin (50μg/ml) and confirmed by PCR using the ak54-fw and ak59-rev primers 
(Fig. 3.40 and 3.41, A, respectively).  A 600bp size band corresponding to the kpsM gene 
was observed for both G1 and 81-176 strains (Fig. 3.40 and 3.41, A, lane 1). On the other 
hand, a 2100bp size band was observed for both G1/kpsM::kanr and 81-176/kpsM::kanr 
mutant strains. This confirmed the disruption of the kpsM gene by integration of the 
1.5kb kanr cassette (Fig. 3.40 and 3.41, A, lanes 2-4). dmhA and tagF identification 
primers were used to confirm the identity of the strains. A 642bp and 1021bp size bands 
were observed for wt strains G1 and 81-176 (Fig. 3.40 and 3.41, A, lane 5) and for the 
three clonal kpsM isolates of each strain (Fig. 3.40 and 3.41, A, lanes 6-8).  
The growth of the G1/kpsM::kanr and 81-176/kpsM::kanr mutant strains (three clonal 
isolates) was assessed in BHI broth at 37°C for two days and compared with the G1 and 
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81-176 wt strains, respectively (Fig. 3.40 and 3.41, B). The kpsM mutation had no effect 
on growth of G1 (Fig. 3.40, B), but did, however, slightly affect the growth of strain 81-
176 although no statistically significant differences were obtained (Fig. 3.41, B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.40. Growth of C. jejuni G1 is not affected by kpsM mutation. (A) PCR 
results: Lane L: 2-log DNA ladder; lane 1: G1 – 600bp; lanes 2-4: G1/kpsM::kanr clonal 
isolates – 2100bp; lane 5: G1– 642bp; lanes 6-8: G1/kpsM::kanr  clonal isolates – 642bp. 
(B) Growth rates of G1 wt (blue), G1/kpsM::kanr mutants (1, red; 2, green; 3, purple). 
Values are mean ± SD from three independent experiments with one technical replicate 
each. No statistically significant differences were obtained between the wt and the kpsM 
mutant strains.  
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Figure 3.41. Growth of C. jejuni 81-176 is slightly affected by kpsM mutation. (A) 
PCR results: Lane L: 2-log DNA ladder; lane 1: 81-176 – 600bp; lanes 2-4: 81-
176/kpsM::kanr clonal isolates – 2100bp; lane 5: 81-176 – 1021bp; lanes 6-8: 81-
176/kpsM::kanr  clonal isolates – 1021bp (B) Growth rates of 81-176 wt (blue), 
G1/kpsM::kanr mutants (1, red; 2, green; 3, purple). Values are mean ± SD from three 
independent experiments with one technical replicate each. No statistically significant 
differences were obtained between the wt and the kpsM mutant strains.  
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3.3.8.2. Involvement of capsule production in the interaction between C. jejuni and 
A. polyphaga  
To investigate if capsule production was involved in the interaction between C. jejuni and 
A. polyphaga, co-culture assays at 25°C were conducted for G1/kpsM::kanr and 81-
176/kpsM::kanr mutant strains (three clonal isolates) and the respective wt strains (Fig. 
3.42). Mutation of kpsM resulted in a reduction of intracellular bacteria in both strains 
(Fig. 3.42). There was a 49%, 59% and 39% reduction in the bacterial counts of the three 
G1/kpsM::kanr clonal isolates as compared with the wt. These differences were 
statistically significant (1, p=0.0046; 2, 0.0050; 3, p=0.0038) (Fig. 3.42, A). The same 
results were observed for the three clonal isolates 81-176/kpsM::kanr which showed 
statistically significant lower intracellular bacterial counts (42, 23 and 39%) when 
compared with the wt strain (1, p=0.006; 2, 0.005; 3, p=0.0046) (Fig. 3.42, B). Overall, 
these results suggest a possible role for the capsule in the survival of C. jejuni within 
amoebae. Whether this capsular gene is involved in C. jejuni multiplication inside A. 
polyphaga is still unknown and remains to be elucidated.  
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  Figure 3.42. Capsule production is required for C. jejuni intracellular survival 
within A. polyphaga. Quantification of intracellular bacteria was determined by viable 
counts at 0h post-gentamicin treatment at 25°C in aerobic conditions (A) Intracellular 
numbers of G1 wt  (dark red) and respective G1/kpsM::kanr clonal isolates (light red); 
(B) Intracellular numbers of C. jejuni 81-176 wt strain (dark blue) and respective 81-
176/kpsM::kanr clonal isolates (light blue). Values are mean ± SD from three 
independent experiments with three technical replicates each. 
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3.3.9. CmeB is not required for C. jejuni strain 81-176 motility, biofilm formation 
and oxidative stress response 
As noted earlier, C. jejuni motility is considerd to play an important role in the invasion 
of host cells (Lugert et al., 2015). In order to check whether the observed phenotypic 
changes in the cmeB mutant (Section 3.3.7) were attributed to defects in motility, the 
latter was compared among the C. jejuni 81-176 wt, mutant and complemented 
derivatives (Fig. 3.43, A). It was observed that cmeB mutation did not impair bacterial 
motility as the average diameters of bacterial growth were 34.2 ± 6.37, 26.7 ± 3.33 and 
32.2 ± 4.54 for the wt, cmeB mutant and complement strain, respectively. No statistically 
significant difference in growth zones (p=0.15) was observed between the wt and cmeB 
mutant strain (Fig. 3.43, A). The ability to form biofilms is also considered to be an 
important factor in the pathogenesis of C. jejuni (Bronowski et al., 2014). Some studies 
showed that inactivation of the multidrug efflux pumps can prevent biofilm formation 
(Baugh et al., 2014). To assess the ability of 81-176/cmeB::kanr mutant to develop 
biofilms, glass test tubes were used to quantify the pellicle formation in the air-liquid 
interface (Joshua et al., 2006). The cmeB mutation was found to have no effect on the 
bacterial ability to form a biofilm (Fig. 3.43, B-C). The OD600nm measured for the 81-176 
wt, cmeB mutant and complement strains were 0.179 ± 0.06, 0.151 ± 0.01 and 0.145 ± 
0.02, respectively. No statistically difference (p=0.443) in biofilm formation was 
observed between the wt and cmeB mutant strain (Fig. 3.43, B). In Figure 3.43, the 
biofilm halo formed in the glass tube was present in the three strains tested and, as 
expected, there was an absence of the halo when the glass tube was incubated with BHI 
broth only (Fig. 3.43, C). 
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Figure 3.43. CmeB mutation has no effect on the motility and biofilm formation of 
strain 81-176. (A) Quantification of bacterial growth in BHI soft-agar motility plates 
inoculated with 81-176wt, cmeB mutant and complement strains. (B) Biofilm 
quantification in the air-liquid interface of the glass tubes and (C) visualisation of the 
biofilm halos in the glass tubes produced these strains. Values are mean ± SD from three 
independent experiments with three technical replicates each. 
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Increased oxygen tension in the atmosphere is the most threatening stress for C. jejuni 
viability during environmental transmission (Kim et al., 2015). The efflux pump 
component CmeG was demonstrated to be required for oxidative stress response of C. 
jejuni (Jeon et al., 2011). So, the role of CmeB in oxidative stress resistance to hydrogen 
peroxidase (H2O2) was investigated for C. jejuni strain 81-176. It was observed that cmeB 
mutation did not impair oxidative stress resistance to H2O2 as the average diameters of 
inhibition zones were 33 ± 3.21, 35 ± 2.21 and 34 ± 1.03 for the C. jejuni 81-176 wt, 
cmeB mutant and complement strain, respectively (Fig. 3.44, A). No statistically 
significant difference in the growth zones (p=0.34) was observed between the wt and 
cmeB mutant strain (Fig. 3.44, B).  
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Figure 3.44. CmeB mutation has no effect on the oxidative stress response of strain 
81-176.  (A) Quantification of 81-176wt, cmeB mutant and complementation derivative 
inhibition zones in MH plates topped with a 100mM H2O2 disc; (B) Visualisation of the 
inhibition zones produced by these strains. Values are mean ± SD from three independent 
experiments with three technical replicates each. 
 
Overall, CmeB was shown to be beneficial for intracellular survival and multiplication of 
C. jejuni 81-176 within A. polyphaga, but not for this pathogen´s motility, biofilm 
formation or oxidative stress response.  
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CHAPTER 4: Discussion 
 
4.1. Selection of a strain to investigate the interaction between C. jejuni and A. 
polyphaga  
As previously mentioned, Campylobacter possesses several pathogenicity-associated 
factors involved in important bacterial processes, such as motility, antibiotic resistance, 
adhesion/invasion, toxin production, stress response and chemotaxis (Dasti et al., 2010). 
An essential aim of the on-going C. jejuni research is to clarify the precise role of these 
factors in bacterial pathogenesis and survival in different hosts so that possible drugs 
could be developed to combat infections by this pathogen (Backert & Hofreuter, 2013). 
In this study the A. polyphaga in vitro model was used to identify possible factors 
involved in C. jejuni pathogenesis. This is considered to be important because the 
association between free-living amoebae and pathogenic bacteria is concerning as it may 
have significant implications for human health (Goni et al., 2014). In addition, as 
Campylobacter may encounter specific antibiotics during commensal carriage in food 
animals or during infection in humans (Bolton, 2015), antibiotic resistance mechanisms 
of this pathogen were explored.   
The efficiency with which C. jejuni interacts with cultured host cells depends on the 
specific properties of C. jejuni strains and the cultured cell lines and, consequently, the 
outcomes of the in vitro assays varies considerably (Backert & Hofreuter, 2013). As there 
is significant C. jejuni strain-to-strain variation, this is considered important in 
determining the outcomes in terms of virulence and survival of this pathogen. The range 
of C. jejuni strains present in our laboratory collection was, therefore, characterised in 
respect of their virulence and survival attributes. A common characteristic of C. jejuni 
cells is their ability to change the natural spiral cell shape to coccoid form when in 
stressed conditions (Ikeda & Karlyshev, 2012) and, so C. jejuni cells cultured for 24h 
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were used for the experimental work as after two days of growth it was possible to 
observe only a few coccoid cells in the bacterial population. C. jejuni strains 11168H, 81-
176, G1 and X were present in our laboratory culture collection. In order to identify and 
distinguish between the different strains, primers for amplification of unique genes in 
these strains were designed. Amplification of cj1435, dmhA, tagF and moaA genes 
identified the 11168H, 81-176, G1 and X strains respectively. In addition, multiplex PCR 
using these primers helped in determining whether there was any contamination between 
these bacterial strains. In order to detect the virulence pVir and tetracycline resistance 
pTet plasmids, primers for amplification of the virB11 and tetO were also designed. To 
determine which of these strains had a higher growth rate in vitro, growth curves in BHI 
broth were conducted for two days and it was possible to determine that C. jejuni 81-176 
strain was able to grow better than the other wt strains. 
As referred to previously, motility is a crucial factor for C. jejuni pathogenesis (Backert 
& Hofreuter, 2013) and, so, motility of these wt strains was determined in BHI soft agar 
plates. It was observed that C. jejuni strain 81-176 was the most motile, followed by 
11168H, G1 and the least motile X strain. This may confer an advantage for strain 81-176 
to survive better inside a host, and was, therefore, another reason why this strain was 
considered to be the best candidate for the co-culture experiments with amoebae. Biofilm 
formation is another common strategy for bacterial survival in the environment, 
especially when they are under harsh environmental conditions (Bronowski et al., 2014). 
Biofilm formation in distinct wt strains was determined by quantification of aggregates 
(flocs) in MH broth. Strains 11168H and 81-176 produced extensive floc formation in the 
broth medium, as opposed to both G1 and X strains. Overall, as C. jejuni strain 81-176 
contains the virulence plasmid pVir, had the highest growth rate in BHI broth, was highly 
motile and formed extensive biofilm aggregates, it seemed one of the most promising 
candidate strains to study the interaction between C. jejuni and amoebae. Moreover this 
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invasive strain has been widely used for a number of studies in the Campylobacter 
research field (Hofreuter et al., 2006). 
 
4.2. Generation of a chimeric C. jejuni strain 
During the course of this study and as referred to previously, laboratory co-workers 
sequenced for the first time the G1 strain isolated from a Guillan-Barré patient (Lehri et 
al., 2015). However, further to the initial sequencing, analysis of the genome of this strain 
using CLC genomics software revealed that the strain sequenced was not C. jejuni G1, 
but that of the 81-176 strain. It was discovered that the mixture between these two strains 
during the -80°C storage and subsequent plating on CBA medium with tetracycline 
concentration allowing growth of strain 81-176, but not G1, lead to the creation of a 
chimeric strain, which was named strain B7.  This chimeric strain presented two large 
genome regions of the strain G1 integrated in the genome of 81-176.  To distinguish 
between G1, 81-176 and chimeric B7 strains, primers for the luxS gene amplification (81-
176 wt and G1-allele version) were designed and PCR together with the identification 
primers was conducted with these strains. This PCR also helped in determining the 
fraction of the chimeric strains in the culture mixture, which was approximately 25%. 
Although it was hypothesised that antibiotic selection pressure might have been the 
reason for the creation of this chimeric strain there was no difference in the tetracycline 
resistance levels between both the chimeric B7 and 81-176 strains. Examples of selective 
pressure that might possibly lead to the DNA exchange between these strains could be 
microbial competition for food and energy source. It would be interesting to unravel the 
mechanism by which this strain was naturally created as this might reveal an effective 
strategy utilised by bacteria for adaptation to selection from the surrounding environment. 
Nonetheless, the creation of this chimeric strain demonstrated how easily Campylobacter 
can exchange DNA. Since horizontal genetic exchange strongly influences the evolution 
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of many bacteria (Sheppard et al., 2011) it would be relevant to explore these results 
more deeply. 
 
4.3. Contribution of CmeABC pump and sequence variation of CmeB protein to 
tetracycline resistance  
The emergence and spread of bacterial resistance to antibiotics is an increasing problem 
that is becoming a major public health concern (O´Neill, 2014). Understanding antibiotic 
resistance mechanisms in Campylobacter may open a new direction in comprehending 
how bacteria adapt to antibiotic treatment and thus, in this study the tetracycline 
resistance mechanism in C. jejuni G1 strain was explored. Further to genome sequencing 
of strain G1, it was observed that this strain presented a large difference in the sequence 
of the cmeB gene when compared with the cmeBs from the reference strains 11168 and 
81-176 (Lehri et al., 2015). Protein blast analysis revealed that the CmeB from strain G1 
shared only 81% identity (100% query cover) with both 11168H and 81-176 strains, 
whilst the CmeBs from the latter strains shared 99% identity. In addition, despite the fact 
that both G1 and 11168H strains do not contain the tetracycline resistance plasmid pTet, 
the former strain was more resistance to tetracycline. So, it was hypothesised that the 
difference in the cmeB sequence might be the cause for the different levels in Tet 
resistance between these C. jejuni strains.  
To test this hypothesis, G1, 81-176 and 11168H cmeB mutants were constructed. In 
addition, to test the effect of cmeB and pTet in AR, this plasmid was transferred from C. 
jejuni 81-176 to G1 strain. Tetracycline susceptibility assays revealed that the G1 strain 
was not only more resistant to tetracycline, but also to several other antibiotics than 
strains 11168H and 81-176 and that its cmeB may be the principal factor responsible for 
the differences in AR. Also, when the pTet plasmid was present in G1 strain, a huge 
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increase in Tet resistance of G1 was observed. This suggests a role of cmeB and pTet in 
antibiotic resistance (Iovine, 2013).  
As demonstrated in this study, genetic exchange of elements involved in antibiotic 
resistance can result in a dramatic increase in C. jejuni antibiotic resistance levels. This is 
in accordance with other studies that found CmeB sequence variants presented a greater 
and more powerful efflux of antibiotics (Cagliero et al., 2006; Yao et al., 2016). 
Consequently these variants also displayed enhanced antibiotic resistance (Cagliero et al., 
2006; Yao et al., 2016). The CmeB from C. jejuni G1 strain shared a high similarity with 
two “super” efflux pumps variants previously discovered, the 154KU CmeB (Cagliero et 
al., 2006) and the RE-CmeB variants (Yao et al., 2016), indicating that CmeB from the 
G1 strain could also be a super efflux variant. In particular, in this study it was possible to 
generate bacteria with tetracycline resistance levels, which significantly exceeded those 
of all parental strains. Such exchanges are likely to occur in the environment, not only via 
conjugation e.g. involving a transfer of the pTet plasmid, but also via transformation, as 
many strains of C. jejuni, as previously mentioned, are naturally competent and can easily 
acquire DNA released due to lysis of the cells carrying antibiotic resistance genes (Young 
et al., 2007). In addition, the studies showing that regulation of the expression of the 
cmeABC efflux pump potentiates the differences in Campylobacter antibiotic resistance 
(Lin et al., 2005; Cagliero et al., 2007; Perez-Boto et al., 2015), we and others  (Cagliero 
et al., 2006; Yao et al., 2016) suggest that cmeB sequence variation may also be 
responsible for these differences.  However, other contributors (e.g. CmeR; CmeA/C; 
second efflux pump, etc.) cannot be excluded and further evidence is required to claim 
that antibiotic resistance is mainly due to the CmeB transporter. 
This data confirms that originally sensitive C. jejuni strains might easily become more 
resistant to antibiotics, and that this is an effective strategy, which may be utilised by 
bacteria for adaptation to selective pressure, which poses a serious threat to public health.  
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4.4. C. jejuni is able to survive and multiply within the Acanthamoebae host 
The association of bacteria with free-living amoebae may have significant implications 
for human health (Goni et al., 2014). Also, there are conflicting accounts in the literature 
regarding the interaction between C. jejuni and A. polyphaga which may be explained by 
different methodologies used or different strains of C. jejuni and Acanthamoebae species 
(Vieira et al., 2015). In this present study therefore, the interaction between these 
microorganisms was investigated for a clear knowledge regarding the Campylobacter-
Acanthamoebae interaction.  Luckily, A. polyphaga is very easy to handle 
experimentally, shares similarities with macrophages and has been widely used to unravel 
bacterial virulence factors (Sandstrom et al., 2011; Tosetti et al., 2014; Guimaraes et al., 
2016).  
The efficiency by which C. jejuni strains interact with cultured cells depends on the 
specific properties of the strain (Young et al., 2007; Backert & Hofreuter, 2013). 
Selection of the C. jejuni strain to be used in this study was, therefore, very important, 
because it could determine the outcome of the infection.  C. jejuni strain 81-176 was 
selected for this study after careful consideration because it was a highly virulent strain 
(Bacon et al., 2000; Hofreuter et al., 2006) and it was shown to have a higher potential to 
invade amoebic cells than the other strains tested (G1, 11168H and X). Nonetheless, it 
would be interesting to test the capability of survival within amoebae of other C. jejuni 
strains to check if the positive interaction between strain 81-176 and A. polyphaga may 
be also extended to other strains.   
 In order to survive, Campylobacter must be able to sense, adapt, and respond to 
temperature fluctuations (Stintzi, 2003). To study survival of C. jejuni inside amoebae, 
the temperatures of 25°C and 37°C were selected. At 37°C during longer incubation 
periods with A. polyphaga, C. jejuni may escape to the environment and begin to 
multiply. Further, re-infection of other amoebae cells by a high number of bacterial cells 
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may occur, resulting in toxicity to the amoebae and lysis and thus, this may be confused 
with intracellular multiplication of C. jejuni within A. polyphaga. If gentamicin is not 
applied before the lysis of amoebae with Triton during these times (standard gentamicin 
protection assay) (Mavri & Mozina, 2012), the extracellular bacterial numbers may also 
be included and intracellular numbers might be a result of re-infection. So, to avoid this it 
was decided to add an extra gentamicin step from the 24h time-point onwards (modified 
version). Compared with the standard gentamicin assay, a much more significant 
reduction in the intracellular bacterial numbers was observed at both 25oC and 37oC. This 
modified method allowed for quantification of intracellular bacteria only leading to more 
reliable results. In future, it would be noteworthy to investigate the interaction between C. 
jejuni and A. polyphaga at 42°C as this is the chicken body temperature and it was 
previously observed that at, this temperature, amoebic cells changed to the cyst shape. 
This could be considered relevant to human health as it is known that amoebic cysts may 
play a role in the contamination and persistence of pathogenic bacteria in food-related 
environments, because they allow for internalised foodborne pathogens to survive the 
physical and chemical disinfection methods used in the food industry (Lambrecht et al., 
2015). 
At 25°C a decline in the intracellular bacteria was detected 5h after gentamicin treatment. 
However, it should be noted that even if strain 81-176 was able to reside within an 
amoeba for a short time period, this might be sufficient time to increase the risk of 
infection by this pathogen.  The data presented here also demonstrated prolonged survival 
of C. jejuni 81-176 in the presence of amoebae, which is in accordance with previous 
results (Bui et al., 2012b). These results confirm that the presence of amoebae enhances 
the survival of C. jejuni in the environment. According to Bui et al., this is likely due to 
the depletion of dissolved oxygen by amoeba, thus creating the microaerophilic 
environment optimal for C. jejuni growth (Bui et al., 2012b). Additionally, it was 
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observed viable C. jejuni after 4 days incubation in PYG medium aerobically without 
amoebae. Because coccoid cells are viable but not culturable and coccoid cell formation 
in C. jejuni is stimulated by stress conditions, such as, starvation and oxidative stress, it 
would be expected no viable counts. Although in some bacteria viable but non culturable 
forms are able to resuscitate and convert to culturable and fully infective forms, in 
Campylobacter whether they can resuscitate or not is a controversial issue (Ikeda & 
Karlyshev, 2012). The confliting results may be due to variation in the stress conditions 
used, leading to different types of coccoid cell formation. There are reports of reversion 
of coccoid forms into culturable forms after acid treatment (Chaveerach et al., 2003) and 
also, according to some studies using animal models of infection, the coccoid forms of C. 
jejuni are be able to convert to fully infectious forms (Jones et al., 1991; Saha et al., 
1991). However, it was noticed that some of these results were also controversial due to 
irreproducibility of the data and that this process deserves further investigation (Medema 
et al., 1992; Van de Giessen et al., 1996).  
At 37°C, the initial decrease in the number of viable bacteria was followed by a 
remarkable increase in the bacterial numbers after 48h of incubation. A similar trend was 
already reported for S. enterica and L. monocytogenes (Anacarso et al., 2012).  The 
authors named this first phase of viability decrease as the eclipse phase, which occurs 
probably due to an initial use of the bacteria as food source, or just due to a prolonged lag 
or adaptation phase, followed by an active intracellular growth (Anacarso et al., 2012). 
Intracellular growth was confirmed by phase-contrast microscopy where C. jejuni cells 
were seen bursting out of the amoeba cells to the extracellular medium, a result of 
intracellular bacterial multiplication.  
The results obtained in this study are in agreement with the studies supporting C. jejuni 
intracellular survival or multiplication inside A. polyphaga (Axelsson-Olsson et al., 2005, 
2007, 2010a,b; Snealling et al 2005, 2008; Baré et al., 2010; Olofsson et al., 2013; 
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Grieskspoor et al., 2013), thus contradicting with the studies from Bui et al., that support 
an extracellular mode of survival only (Bui et al., 2012a,b). 
Based on the information available in the literature and in the data presented here, we 
suggest a hypothetical model describing the mechanism of interaction between C. jejuni 
and its amoeba host (Fig. 4.1). According to this model, the intracellular bacteria acquired 
from the environment (at 25°C in our experiments) multiply at 37°C (conditions 
simulating host temperature). Upon ingestion of a product (e.g. water or milk) 
contaminated with amoebae, the latter are lysed releasing large amounts of bacteria 
causing the disease.  A global search for other bacterial factors involved in the interaction 
between C. jejuni and amoebae could be based on differential expression studies 
(transcriptomics and proteomics).   
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Figure 4.1. Hypothetical model of the interaction between C. jejuni 81-176 and A. 
polyphaga. The following possible stages of bacterial entry are depicted: 1, adhesion to 
and invasion of amoebic cells via phagocytosis; 2, gathering within amoebic vacuoles 
(Baré et al., 2010; Olofsson et al., 2013); 3a, bacteria degradation and/or coccoid 
formation; 3b), intracellular survival  (ICS) followed by intracellular multiplication 
(ICM) and 3c, release of C. jejuni into the EC medium (Grieskspoor et al., 2013); 4), C. 
jejuni is able to multiply and re-infect other amoebic cells.  Stages 1, 3a-b and 4 are based 
on the observations reported in this study.  
3c. C. jejuni escapes to the EC medium  
4. Multiplication of C. jejuni in 
the EC medium  
1. Adhesion 
and invasion 
of C. jejuni 
2. Entering in 
amoebic vacuoles  
 ICM of C. jejuni
3a. Lysis of C. jejuni and/or coccoid formation 
3b. ICS of C. jejuni 
 Reinfection 
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4.5. Role of CmeB transporter and capsule production in the interaction between C. 
jejuni and A. polyphaga  
As several CmeB homologues in other bacterial species were shown to have a role in 
virulence (Hirakata et al., 2002; Jerse et al., 2003; Chan & Chua, 2005; Buckley et al., 
2006; Bina et al., 2008a; 2008b; Padilla et al., 2010), the concept that efflux pumps may 
indeed act as virulence determinants has increased and could be expanded to C. jejuni. 
Although the CmeABC of C. jejuni was previously reported to be required for 
colonisation of the intestinal tract of the chicken (Lin et al., 2003) its role in host cell 
interaction had not previously been determined. In this study, the role of CmeB in C. 
jejuni pathogenesis was explored using Acanthamoeba polyphaga as an in vitro host 
model.  
The results presented here show that CmeB is required for survival and replication of C. 
jejuni 81-176 within amoebae and that this phenomenon was not an artefact of the 
detergent used in the co-culture experiments. These observations support the theory that 
efflux pumps may indeed act as virulence determinants. CmeB contribution to survival 
within amoebae might be related to the efflux pumps capability to pump out and confer 
resistance to host-derived antimicrobial agents (such as toxins or antimicrobial peptides) 
or because these pumps are able to export virulence determinants (Piddock, 2006).  
As previously mentioned, different C. jejuni strains display wide differences in the 
sequence of their cmeB genes affecting the function of this efflux transporter (Cagliero et 
al., 2006). For this reason the role of strain-dependency of cmeB in survival and 
multiplication of C. jejuni in A. polyphaga cannot be excluded. In the future it would be 
interesting to include other C. jejuni strains in a similar study to check whether CmeB 
contributes to survival of other strains in amoebae. 
Capsule was found to be implicated in the interaction between E. coli and Streptococcus 
suis with amoebae (Jung et al., 2007; Bonifait et al., 2011). So, the role of capsule in the 
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interaction between C. jejuni and this eukaryotic organism was explored in this study. 
Interestingly, it was found that capsule production is also required for survival of C. 
jejuni 81-176 and G1 strains inside amoeba, but whether it is also implicated in 
multiplication still needs further confirmation. Because different C. jejuni strains have 
different capsular polysaccharide structures (CPS) and this might also have an impact on 
the outcome of infection, it would be interesting to identify the role of various types of 
CPS in survival of C. jejuni within amoebae.  
Since motility was shown to be a crucial factor in C. jejuni host cell invasion and biofilm 
formation and contributes to pathogenesis (Bolton, 2015), the involvement of CmeB in 
these processes was tested. No statistically significant difference in the motility halo 
formed by the mutant strain compared with the wt was detected. No statistically 
significant differences were also observed for biofilm formation between these strains. As 
opposed to other studies that showed the involvement of an efflux pump in both flagellar 
motility and biofilm (Kvist et al., 2008; Webber et al., 2009) these data demonstrated that 
neither of these processes were responsible for the decrease of the cmeB mutant strain 
survival within the A. polyphaga host. The C. jejuni CmeG, a putative efflux transporter, 
was shown to be involved in oxidative stress response (Jeon et al., 2011), and so, it was 
hypothesised that CmeB could also contribute towards the oxidative defence in 
Campylobacter. This is of particular relevance since reactive oxygen species (ROS) are 
produced by the immune system of hosts (such as phagocytes), and are toxic, or deadly 
for bacterial cells (Paiva & Bozza, 2014). Unexpectedly, mutation of cmeB did not affect 
resistance to hydrogen peroxide of both C. jejuni strains 81-176 (Fig. 3. 47) and G1 (data 
not shown). The reason why CmeB was not involved in oxidative defence is not known, 
but it may be that the CmeDEF and CmeG are the major contributors for the 
detoxification process of ROS.  
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In summary, this study is the first to report that a C. jejuni 81-176 efflux pump was 
advantageous for its survival in amoebae and, by using an accurate gentamicin protection 
method, it was demonstrated that the interaction with A. polyphaga was beneficial for this 
foodborne pathogen.  
 
 
4.6. Conclusion 
This study provides up to date experimental data regarding the interaction between 
Campylobacter and Acanthamoebae. The results presented here help to clarify the 
conflicting accounts in the literature as to whether C. jejuni was able to survive and/or 
multiply inside the A. polyphaga host. This is considered to be a clinically relevant 
interaction since both these microorganisms can co-exist in poultry farms and are 
resistant to the existing biosecurity measures, thus increasing the risk of infection with C. 
jejuni. So, deciphering the type of interaction between C. jejuni and A. polyphaga and the 
molecular mechanisms involved it is considered that this has improved our knowledge 
regarding the Campylobacter lifestyle and thus will help in the development of drugs 
against this foodborne pathogen. Because CmeABC is required for C. jejuni antibiotic 
resistance and virulence, this efflux pump is a promising target for interventions to 
combat C. jejuni infections. 
Additionally, it was demonstrated how easily C. jejuni can acquire DNA from other 
strains, and thus display an extensive genetic variation. This proves how relevant this 
organism is to human health (e.g. increased AR) and that rigorous care is needed when 
working with this pathogen so that it does not accumulate unwanted mutations.   
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4.7. Future work 
C. jejuni fluorescent strain 81-176/pCPE11/28/GFP strain is available in the laboratory 
collection. This strain was able to invade A. polyphaga as efficiently as the 81-176 wt 
strain and so, it would be interesting to conduct confocal microscopy on A. polyphaga 
cells infected with this GFP strain. This would allow visualisation of the location of this 
pathogen within amoebae as C. jejuni bacteria will appear green due to GFP and amoebae 
will appear in both blue (due the 4', 6-diamidino-2-phenylindole that stains the nuclei) 
and red (due to phalloidin that will stain the actin cytoskeleton).  
Although it is suggested that CmeB and capsule production are involved in the interaction 
between Campylobacter and Acanthamoeba, many bacterial factors that might participate 
in this interaction remain unknown. A promising approach in this direction would be a 
gene expression study (transcriptomics analysis) aimed at the identification of the 
bacterial genes differentially regulated during invasion. Despite the low intracellular 
concentration obtained for C. jejuni inside the amoebae cells, there may be improved 
techniques to be able to obtain a higher intracellular bacterial concentration and thus, be 
able to extract sufficient RNA for RNA-seq analysis. In addition, since capsule was found 
to be involved in survival of C. jejuni inside A. polyphaga, it would be interesting to 
know whether it is also implicated in multiplication of this pathogen inside this host and 
whether it is involved in the different outcomes of amoebae infection by the different C. 
jejuni strains.   
 As previously mentioned, amoebae and macrophages share similarities in their cellular 
structure, motility, physiology and in their ability to capture their prey (Ruqaiyyah & 
Naveed, 2011).  It would be interesting to know whether the KpsM and CmeB are 
involved in survival of C. jejuni in macrophages, because it would appear likely given the 
results obtained in this study with A. polyphaga. This would be clinically relevant since 
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only few bacterial factors have been found to be involved in survival of this pathogen in 
macrophages (Backert & Hofreuter, 2013).  
As previousely discussed, it is important to explore whether Campylobacter cells are 
culturable under the growth conditions used in the experiment investigating extracellular 
survival in the presence of amoebae.  As there is controversial data in the literature this 
should help clarifying if C. jejuni coccoid cell formation can be a reversible process or 
not.  
 It was noted that there was a large difference in the sequence of cmeB from strain G1 
when it was compared with the cmeB from strains 11168H and 81-176. In order to prove 
that amino acid sequence contributes to the enhanced antibiotic efflux function it was 
attempted to transform the cmeB gene from strains G1 and 11168H in the G1/cmeB::kanr 
mutant so that  the former could be under the regulation of the same promoter in G1 
strain. This would allow for further analysis of the tetracycline resistance of these strains. 
Although a similar strategy confirming this hypothesis was recently demonstrated by Yao 
et al., (2016), it would still be relevant to try to conclude this part of the work especially 
since it used a different strategy than the one published.  
The chimeric B7 strain was naturally constructed via horizontal gene transfer during the 
in vitro growth of two different C. jejuni strains. It would be interesting to explore the 
reason behind this genetic material exchange and if this mechanism is reproducible both 
in vitro and in vivo. For the in vivo growth, as amoebae was shown to support C. jejuni 
growth at 37°C, the former microorganism would be infected by both 81-176 and G1 
strains for a determined period of time after which, amoebae will be lysed and the 
bacterial genomic DNA would be extracted and further sequenced to check for mutations.  
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